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1.1 G Protein-Coupled Receptors 
G protein-coupled receptors (GPCRs) comprise the largest family of cell surface receptors 
and share the characteristics of seven transmembrane helices (TM1-7) linked by three 
extracellular loops and three intracellular loops.
1 An additional short helix (H8), directly 
linked to TM7, is located parallel to the cytoplasmic surface of the membrane.
2 It is worth 
mentioning, that the bovine rhodopsin GPCR has been the only crystallized structure 
solved.
2 The human genome project has revealed more than 800 GPCR genes, and only 
approximately 30 genes are targets of drugs presently on the market, while 50% of all 
launched drugs exert their actions on them.
3,4 Conclusively, GPCRs represent one of the 
most important families as pharmaceutical targets in the drug discovery process.
3,5 
GPCRs communicate extracellular signals into the cell to give an intracellular response. 
The nature of the signals is highly diverse and includes extracellular signal molecules, such 
as biogenic amines, peptide and protein hormones, nucleosides and nucleotides, sensory 
signals such as light signals and even more (glutamate, ions, eicosanoids).
4 The binding of 
these signal ligands to the extracellular site or transmembrane region induces a 
conformational change of the receptor which triggers the heterotrimeric guanine nucleotide 
binding proteins, consequently promoting the intracellular response.
1 Generally, activation 
of the receptor induces the exchange of guanosine-5’-triphosphate (GTP) for guanosine-5’-
diphoshate (GDP) bound to the Gα unit, following the dissociation of the heterotrimeric G 
protein into GTPα and βγ.
1 Both subunits regulate the activity of the effector systems, 
mainly adenylyl cyclase, phospholipase or ion channels.
1,6,7 The production of second 
messengers strongly depends on the distinct G protein. The G protein becomes inactivated 
by hydrolysis of the Gα bound GTP to GDP.
1,8 
GPCRs are classified into different families according to their structural and genetic 
characteristics: family A (rhodopsin-like), family B (glucagon-receptor-like), and family C 
(metabotropic glutamate receptors).
4 The rhodopsin-like family is by fare the largest 
subgroup and is characterized by various highly conserved amino acids and a disulphide 
bridge that connects the first and second extracellular loops.
4 As an example of a 
rhodopsin-like GPCR a homology model of the human dopamine D3 receptor is shown in 
Figure 1.1. 
Among the family A, the subfamily of biogenic amine binding GPCRs is of particular 
interest due to its interaction with predominant neurotransmitters such as acetylcholine, 
serotonin, histamine, and the catecholamines dopamine, epinephrine, and norepinephrine. 
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Figure 1.1 Homology model of the human dopamine D3 receptor with ligand BP 897 interacting 
with Asp 110 (distance of basic nitrogen to carboxylic acid of Asp 110: 2.45 Å). The homology 
model was obtained by Byvatov et al., 2005.
9 The dopamine binding pocket was defined by Asp 
110. BP 897 was docked into the binding pocket using GOLD (version 2.2) with default parameter 
settings. Results were visualized using PyMOL (version 0.99).  
 
A phylogenetic dendrogram of biogenic amine receptors is shown in Figure 1.2 (human 
sequences of the aminergic GPCRs were extracted from GPCRDB;
10,11 multiple sequence 
alignment and dendrogram display were performed with ClustalW
12,13). The class of 
biogenic amine receptors has displayed a tremendous drug target for the treatment of 
several diseases, such as schizophrenia, Parkinson’s disease, depression, and allergies.
4,14 
Recently, increasing evidence has been suggested that the rhodopsin-like GPCRs, but also 
other members of the GPCR family form dimers or high-order oligomers.
15 Studies on the 
formation of oligomers have been based on results received by a variety of biophysical 
techniques.
16 Arrangements of homo-oligomers with identical GPCRs or hetero-oligomers 
by forming complexes with different GPCRs have been identified.
17 There is still a 
requirement of investigations in the influence on ligand binding and the functional 
relevance of oligomerized GPCRs.  
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Figure 1.2 Phylogenetic dendrogram of biogenic amine receptors. Dopamine D1- and D2-like 
receptors as well as the histamine H1 receptor are indicated by gray shaded circles. 
 
1.2 Dopamine  
The biogenic monoamine dopamine (DA) (2-(3,4-dihydroxyphenyl)ethanamine) is one of 
the most important neurotransmitter in the central nervous system (CNS) and firstly 
identified by Arvid Carlsson in 1958, who was awarded for the Nobel Prize for his 
pioneering work on dopamine systems in 2000.
18 Dopamine belongs to the group of 
catecholamine neurotransmitters, structurally characterized by a catechol nucleus (a 
benzene ring with two adjacent hydroxyl groups), and is also the biogenic precursor of 
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norepinephrine and epinephrine. Dopamine agitates through interaction with G protein-
coupled membrane bound receptors, and functions as a major regulator for processes of 
emotion, motivated behavior, cognition, voluntary movements, positive reinforcement, and 
hormone production in the mammalian brain.
19,20 Imbalance in dopaminergic 
neurotransmission is associated with pathological disorders linked to neurological 
movement dysfunctions like Parkinson’s disease (PD), Huntington’s disease, attention 
deficit hyperactivity disorder (ADHD), Tourette syndrome, but also neuropsychiatric 
disorders, like schizophrenia, and drug addiction.
21-23 In the periphery dopamine modulates 
cardiovascular and renal functions; hormone secretion, vascular tone and gastrointestinal 
motility.
24  
Dopamine is mainly biosynthesized in the central nervous system by mesencephalic 
neurons of the substantia nigra and ventral tegmental area, and by hypothalamic neurons. 
Therefore, the aromatic amino acid L-tyrosine is hydroxylated by the enzyme tyrosine 3-
hydroxylase (TH) in a rate-limiting step to form levodopa, L-3,4-dihydroxyphenylalanine 
(L-DOPA). Subsequently, L-3,4-dihydroxyphenylalanine is decarboxylated by the 
cytoplasmic enzyme aromatic L-amino acid decarboxylase (AADC, L-DOPA 
decarboxylase) to give dopamine (Figures 1.3 and 1.4).
25 TH is activated by the 
calcium/calmodulin-dependent protein kinase and this enzyme is consequently activated by 
calcium-bound calmodulin.
25 
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Figure 1.3 Biosynthesis and metabolism of dopamine.  
 
The synthesized dopamine is stored in vesicles and is released into the synaptic cleft by 
depolarization of the presynaptic neuron due to Ca
2+ influx. In the synaptic cleft it 
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stimulates postsynaptic D1-like and D2-like receptors and/or negatively modulates the 
release of dopamine and dopamine synthesis by stimulating presynaptic dopamine D2 or D3 
autoreceptors via inhibition of tyrosine hydroxylase (negative feedback mechanism). The 
reuptake of synaptic dopamine into presynaptic neurons is regulated by dopamine 
transporter (DAT). Hence, dopamine is metabolized by monoamine oxidase (MAO-A, 
mainly MAO-B) to form 3,4-dihydroxyphenylacetaldehyde (DOPAL), following oxidation 
to give 3,4-dihydroxyphenylacetat (DOPAC). DA and DOPAC are also metabolized by 
catechol-O-methyltransferase (COMT) to form homovanilic acid (HVA). Synaptic 
dopamine is metabolized by COMT via 3-methoxytyramin to give HVA (Figures 1.3 and 
1.4).
26 
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Figure 1.4 Schematic synaptically dopaminergic transmission. 
 
Recently, the neuroprotective and neurotoxic effects of dopamine, which may forms 
autotoxic metabolites, on distinct areas of neurons have been the focus of research.
27 
Additionally, there is some evidence, that levodopa itself is a neurotransmitter candidate, 
but further investigation is required.
28,29  
In the central nervous system the dopaminergic neuron system primarily originates from 
three major groups of neurons located in the midbrain (mesencephalon) and from neurons 
presented in the hypothalamus (nuclei arcuate and periventricular) (Figure 1.5).  
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Figure 1.5 Schematic dopaminergic pathway. 
 
The midbrain dopaminergic neurons are nominated as the A8 group in the retrorubral area 
(RRA), A9 group designates the substantia nigra pars compacta (SNc), and A10 group 
corresponds to the ventral tegmental area (VTA). The nigrostriatal dopaminergic system 
arises from dopaminergic cell groups in RRA (A8) and SNc (A9), and projects their axons 
to the dorsal striatum (nucleus caudatus, putamen).
30 This pathway is primarily associated 
with the control of movement and involved in Parkinson’s disease. The dopaminergic 
neurons located in the ventral tegmental area (A10) project to limbic area (ventral striatum 
(nucleus accumbens), corpus amygdaloideum, and hippocampus). This innervation is 
referred as mesolimbic pathway, while projection to cortical areas (medial, prefrontal, 
cingulate and entorhinal cortex) represents the mesocortical pathway. The former pathway 
is implicated in motivated behavior, while the later is linked to aspects of learning and 
memory. Both dopaminergic pathways are associated with reward and schizophrenia. The 
arcuate and periventricular nuclei (nucleus infundibularis, A12) of the hypothalamus 
project to the eminentia mediana and to the intermediate lobe of the pituitary via the 
tuberoinfundibular pathway. This dopaminergic system plays an important role in the 
inhibitory control of prolactin. A short overview of dopaminergic pathways is given in 
Table 1.1.  
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Table 1.1 Overview of dopaminergic pathways. 
Dopaminergic 
Pathway 
Dopaminergic 
Neurons 
Projection 
to 
Disease 
nigrostriatal  substantia nigra  caudate/putamen 
(dorsal striatum) 
•Parkinson’s disease 
•drug abuse 
mesolimbic  ventral tegmental 
area 
limbic areas 
(nucleus accumbens, 
ventral striatum, 
amygdale) 
•schizophrenia (positive 
symptoms) 
•drug abuse 
mesocortical  ventral tegmental 
area 
cortex 
(medial, prefrontal, 
cingulate, entorhinal 
cortex) 
•schizophrenia (negative 
& cognitive symptoms) 
•drug abuse 
tuberoinfundibular  hypothalamus pituitary, 
median eminence 
•hyperprolactinaemia 
 
1.2.1 Dopamine Receptors 
Dopamine receptors belong to the rhodopsin-like G protein-coupled receptor family A. In 
1972, the first evidence for the existence of dopamine receptors in brain was confirmed by 
demonstrating the modulation of adenylyl cyclase (AC) activity by dopamine.
31 Soon after 
and on the basis of pharmacological and biochemical investigations, the assumption of 
diverse dopamine receptors was proposed. At that time, two receptor populations or 
subtypes were suggested to nominate dopamine D1 the receptor population that was 
capable to stimulate adenylyl cyclase, and dopamine D2 the receptor population, that was 
independent of AC or not coupled to this effector.
32 This dual classification system was 
established by further pharmacological, physiological, biochemical and anatomic 
investigations and remained for more than a decade. In the following years novel gene 
cloning techniques were introduced, and as a result, three new dopamine receptor subtypes 
have been identified, namely dopamine D3, D 4 and D5.
33,34,35 Although some differences 
among subtypes within a family have been recognized, dopamine receptors are classified 
into two subtype receptor families according to homology in their transmembrane 
sequences and signaling pathways. Dopamine D1-like receptors comprise dopamine D1 and 
D5 receptors; and dopamine D2-like receptors consist of dopamine D2, D3 and D4 receptors 
(see Figure 1.2).
24 The dopamine D1-like receptors are coupled to Gαs/Gαolf and activate 
adenylyl cyclase type, consequently increasing the production of the second messenger 
cyclic adenosine-3´,5´-monophosphate (cAMP), activate the cAMP-dependent protein 
kinase A (PKA) and protein phosphatase-1-inhibitor DARPP-32 (dopamine and cyclic 
AMP-regulated phosphoprotein, 32kDa).
24,36 Both mechanisms are involved in the 
following regulation of enzymes, ion channels, receptors and transcription factors. By 
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coupling to Gαq a phospholipase C-dependent (PLC), but cAMP-independent mechanism 
modulates the intracellular Ca
2+ concentration and protein kinase C (PKC). Dopamine D2-
like receptors signal via pertussis-toxin sensitive Gαi/Gαo protein.
36,37 The Gαi/o subunit 
induces inhibition of adenylyl cyclase type 5, as a result downregulating the concentration 
of cAMP and activation of PKA, while the Gβγ subunit is involved in activating adenylyl 
cyclase type 2 (AC2) and the modulation of ion channels, phospholipases, proteinkinases, 
and receptor tyrosine kinases.
24,36 Besides interaction between dopamine receptors and G 
proteins, dopamine receptors couple to a complex signaling cascade including calcium 
channels, potassium channels, phospholipase C, arachidonic acid release (AA), Na
+/H
+ 
exchangers, Na
+-H
+-ATPase, and mediate with further signal-modulating proteins.
24,36,38  
Structure of Dopamine Receptors 
Dopamine receptors as GPCRs contain the putative characteristic of seven transmembrane 
domains (see Figure 1.1). The N-terminus of the receptor protein is located on the 
extracellular side of the membrane and contains N-linked glycosylation sites. The protein 
forms seven helical regions (I-VII) that span the membrane and ends with the short helix 
(H8) and the C-terminal tail on the cytoplasmic side of the membrane. Three extracellular 
loops (E-1, E-2, and E-3) connect the helices on the extracellular surface, and three 
intracellular loops (C-1, C-2, and C-3) bond the helices on the intracellular side. 
Phosphorylation sites are located on the third intracellular loop and on the C-terminus.
39 
Dopamine D2-like receptors display a shorter C-terminal tail and an increased third 
intracellular loop compared to D1-like receptors. This increase in length is found in 
receptors coupling with Gi proteins and inhibiting AC, while D1-like receptors, coupling to 
Gs proteins and activating AC, present a short third intracellular loop.
24 Within the same 
dopamine subtype family, receptors share considerable homology of amino acid sequences. 
The dopamine D2 and D3 receptors demonstrate 75% similarity in the TM domains, while 
its signal-transduction pathway, pharmacological profile and brain distribution is 
dissimilar.
33 The dopamine D2 and D4 receptors share 53% identity in the TM domains.
34 
For the D1-like family, there is 80% identity in the TM domain between dopamine D1 and 
D5 receptors. The genomic structure of dopamine receptors is based on two gene families 
that principally diverge in the absence and the presence of introns in the coding regions.
40 
Dopamine D1 and D5 receptor genes do not possess introns in their coding region, while 
dopamine D2-like receptor genes contain introns.  
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Receptor-receptor interactions and dimerization/oligomerization have been recognized for 
all five dopamine receptor subtypes in in vitro heterologous expression systems.
41 It has 
been demonstrated that dopamine D1 and D2 receptors each generate homo-oligomers 
and/or together form robust hetero-oligomers.
42,43 Within a homo-oligomer or hetero-
oligomer complex the ligand binding properties and signaling pathways have changed, but 
a functional synergism between dopamine D1 and D2 receptors has been proposed. A co-
activation of co-expressed dopamine D1 and D2 receptors results in an increase in Ca
2+ 
signaling mediated by phospholipase C and is unlike to the signaling cascade of dopamine 
D1 and D2 receptor homo-oligomers.
43 Besides the oligomerization of dopamine D1 and D2 
receptors, further hetero-dimerization has been reported of dopamine D2 and D3 
receptors,
44,45 but also adenosine A1/dopamine D1 receptors, adenosine A2A/dopamine D2 
receptors, adenosine A2A/dopamine D3 receptors, and somatostatin SSTR5/dopamine D2 
receptors.
17,46,47  
Dopamine Receptor Subtypes 
The rat dopamine D2 receptor was cloned and isolated for the first time in 1988.
48 Due to 
the sixth exon within the coding region of dopamine D2 receptors, two alternative spliced 
isoforms, a short variant named D2short (D2S, D2(414) or D2B) and a long isoform known as 
D2long (D2L, D2(443) or D2A) was revealed, which differ by 29 amino acids in the third 
cytoplasmic loop.
48,49 As known so far the isoforms demonstrate minor differences in 
regional brain distribution, response of signaling pathways
50 and sequestration rate, but 
display the same pharmacological profile concerning binding affinities.
51 The distribution 
of dopamine D2 receptor mRNA has been localized by in situ hybridization with high 
density in the caudate putamen, substantia nigra, olfactory tubercle and low density in 
nucleus accumbens.  
The dopamine D3 receptor was identified by screening rat brain cDNA library using the D2 
receptor sequence by Sokoloff et al.
33 Alternative splice variants have been identified,
52 but 
only mouse spliced isoforms display a pharmacological profile. The dopamine D3 receptor 
is predominantly localized in the ventral striatum, specifically in the islands of Calleja and 
shell of nucleus accumbens, but exists in lower levels in substantia nigra pars compacta 
and caudate putamen.
53,54 Figure 1.6 shows dopamine D3 receptor mRNA expression in 
human horizontal cryosection from the right hemisphere of the brain at the level of the 
anterior commissure using in situ hybridization.
54 Highest densities of dopamine D3 
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receptor mRNA were found in the islands of Calleja (left panel) and within the nucleus 
accumbens (right panel).  
 
Figure 1.6 Dopamine D3 receptor mRNA expression in the human brain using in situ 
hybridization. Left panel: islands of Calleja, IC; caudate nucleus, CN; right panel: nucleus 
accumbens (adapted from Suzuki et al., 1998).
54 
 
In 1991, the dopamine D4 receptor was first cloned by van Tol et al. by screening a library 
from the human neuroblastoma cell line SK-N-MC.
34 Investigation in the gene revealed the 
presence of polymorphic variations within the coding sequence. The major form in human 
with 60% is the D4.4 variation; the D4.7 is present in 14%, while D4.2 exists in 10% of the 
population.
55 The dopamine D4 mRNA is localized in frontal cortex, amygdale, olfactory 
bulb, hippocampus, hypothalamus and mesencephalon.  
The dopamine D1 receptor was cloned by using screening of libraries and polymerase 
chain reaction based on the sequence of the dopamine D2 receptor in 1990.
56 High levels of 
dopamine D1 receptor mRNA have been discovered in the striatum, nucleus accumbens, 
and olfactory tubercle. In 1991, the dopamine D5 receptor was isolated using the sequence 
of the D1 receptor.
35 Pseudogenes of the dopamine D5 receptor have been identified on 
chromosome 1 and 2, being 98% alike, and 95% identical to the human D5 receptor. 
Dopamine D5 mRNA is of abundant density in the thalamus, hippocampus, and 
mammillary nucleus. A summary of dopamine receptor subtypes is given in Table 1.2. 
The endogen neurotransmitter dopamine discriminates between the five dopamine receptor 
subtypes. Dopamine has a higher affinity for the dopamine D3 receptor than for the 
dopamine D2 receptor that is explained by the sequence differences in the third 
intracellular loop.
33 The affinity binding for dopamine D5 is 10 times higher than for the D1 
receptor (Table 1.2).
57  
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Table 1.2 Summary of properties of the dopamine receptor subtypes. 
  D1-like Receptor Family  D2-like Receptor Family 
  D1 D 5 D 2(short)/(long) D 3 D 4 
Alternative 
name 
D1, D1A  D5, D1B  D2 D3  D4 
Amino acids  446 (h, r)  477 (h) 
475 (r) 
414/443 (h) 
415/445 (r) 
400 (h) 
446 (r) 
387 (h, r) 
Major 
transduction 
Gαs, Gαolf, 
Gαq 
Gαs, Gαolf    Gαi2, Gαi3, 
Gαo, Gβγ 
Gαo, Gβγ G αi2, Gαi3, 
Gαo, Gβγ 
Response   AC5↑ AC5↑ AC5↓, AC2↑ AC5↓, (AC2↑) AC5↓, 
AC2↑ 
Effector/ 
second 
messenger 
cAMP↑, 
PKA↑, 
DARPP-32↑, 
PLC↑, 
Ca
2+↑, 
PKC↑ 
cAMP↑, 
PKA↑, 
DARPP-32↑, 
PLC↑, 
Ca
2+↑, 
PKC↑ 
cAMP↓, 
PKA↓, 
AA↑, 
 
cAMP↓, 
PKA↓, 
 
cAMP↓, 
PKA↓, 
AA↑, 
 
Dopamine 
low affinity 
state  
(Ki) [nM]  
2,000
58 228
58 1,705
33 27
33 148
57 
Major 
receptor 
distribution 
caudate/ 
putamen, 
nucleus 
accumbens, 
olfactory 
tubercle, 
(hypo) 
thalamus, 
frontal cortex 
hippocampus, 
thalamus, 
lateral 
mammillary 
nucleus, 
striatum, 
cerebral 
cortex 
caudate/ 
putamen, 
olfactory 
tubercle, 
nucleus 
accumbens, 
cerebral 
cortex 
Islands of 
Calleja, 
olfactory 
tubercle, 
nucleus 
accumbens, 
cerebral cortex 
frontal 
cortex, 
midbrain, 
amygdalae, 
hippo-
campus, 
hypo-
thalamus, 
medulla, 
retina 
The human and rat forms of the receptors are indicated by (h) and (r), respectively. ↑, stimulation; 
↓, inhibition.  
1.2.2 Signal Transduction of Dopamine D2 and D3 Receptors 
The G protein-coupled dopamine D2 and D3 receptors belong to the dopamine D2-like 
family. The dopamine D2 receptors are coupled to a pertussis-toxin sensitive Gαi/Gαo, and 
being activated, they release Gαi/o and βγ subunits. The Gαi/o subunit inhibits adenylyl 
cyclase 5, consequently reduces the concentration of cAMP and thereby the activation of 
protein kinase A. The Gβγ subunit activates adenylyl cyclase type 2 and regulates 
intracellular signaling by direct interaction with numerous types of ion channels and 
additionally, assists Ca
2+ release from intracellular Ca
2+ stores. Furthermore, it is able to 
activate MAP (mitogen-activated protein) kinase system via different pathways, involving 
phosphoinositide 3-kinase, Ras, and transactivation of a growth factor receptor.
36 Recently, 
additional and new insights into the signaling pathways of dopamine D2 receptors and its 
regulation by intracellular binding partners have been discovered. Park et al. have 
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introduced prostate apoptosis response 4 (Par-4), a proapoptotic protein, which interacts 
through its leucin zipper motif at the calmodulin binding domain in the third cytoplasmic 
loop of the dopamine D2 receptor.
59 This association induces the coupling of the dopamine 
D2 receptor to Gαi and consequently the inhibition of cAMP activity. Increasing 
concentrations of intracellular Ca
2+ activate calmodulin, which competes with Par-4 at the 
calmodulin binding domain. Displacement of Par-4 by calmodulin results in an uncoupling 
of the receptor from the Gαi and gives a negative feedback on D2-mediated cAMP 
reduction. It has been observed, that mutant mouse with a deletion in the leucin zipper 
domain of Par-4 (Par-4ΔLZ) display a depression-like syndrome, but further investigations 
have to be done to clearly interpret these results. A new role of β-arrestin in the signaling 
pathway of dopamine D2 receptors, in addition to its role in receptor internalization, has 
been proclaimed recently.
60 Activation of the dopamine receptor induces the arrangement 
of a signaling complex containing the intracellular proteins β-arrestin 2, serine threonine 
kinase Akt, and protein phosphatase PP2A, that mediates the effects independently of 
Gαi/o-coupled mechanisms. Dopamine D2 receptors regulate Akt by dopamine: prolonged 
dopamine stimulation inactivates Akt via dephosphorylation and activates its substrate 
glycogen synthase kinase 3 (GSK3), while a loss of stimulation activates Akt through 
phosphorylation and inhibits GSK3. The signaling pathways of dopamine D2 receptors 
have been illustrated in Figure 1.7. 
Although the dopamine D3 receptor has been extensively characterized, the main second 
messenger signaling pathways still remain to be elusive. So far, the signaling pathways 
highly depend on the expression system of recombinant D3 receptors. Stimulation as well 
as inhibition of adenylyl cyclase has been demonstrated, highly depending on host cells. 
Nevertheless, it has been reported, that inhibition of AC seems less efficiently than for D2 
receptors.
24 Inhibition of forskolin-stimulated adenylyl cyclase was found in CHO cells.
61 
The dopamine D3 receptor modulates activity of potassium and calcium channels, protein 
kinase cascades and transcription factor c-fos expression in several expression systems. 
Additionally, an increased extracellular acidification and mitogenesis has been reported.
62 
Signaling mechanisms in brain remain to be determined. An additional function is the 
modulation of intracellular Ca²
+ concentrations, inducing changes in the activity of Ca²
+- 
regulated signaling proteins like protein phosphatase calcineurin (PP2B).
63  
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Figure 1.7 Signaling pathways of dopamine D2 receptors (adapted from Kottke & Stark, 2005).
64  
1.2.3 Distribution and Function of Dopamine D2 and D3 Receptors 
Since the identification of the dopamine D3 receptor in 1990 by Sokoloff et al.,
33 
considerable effort has been undertaken in this prospective target for antipsychotic and 
antiparkinsonian drugs due to its restricted distribution in limbic regions of the brain.
22,65 
The dopamine D3 receptor also plays a major role in drug addiction and strong evidence 
has been accumulated that it is implicated in the motivation to self-administer drugs and in 
influencing environmental stimuli on drug-seeking behavior.
21,66 Dopamine D3 receptors 
are present in a 10 - 100-fold lower density in brain regions as compared to that of 
dopamine D2 receptors.
67 In rat brain, dopamine D3 mRNA and receptors are expressed in 
a restricted distribution pattern with highest abundance in granule cells of islands of 
Calleja and moderate levels in medium-sized spiny neurons of the rostral and ventromedial 
shell of nucleus accumbens.
65 The neurons co-express the dopamine D1 receptor, substance 
P, dynorphin and/or neurotensin and induce in an interactive influence on diverse effector 
systems.
68,69 These limbic regions of the striatum are implicated in the dopaminergic 
mesolimbic pathway and control emotion, motivation, reward and behavior, and are 
consequently involved in schizophrenia and drug addiction.
65 Dopamine D3 receptors are 
also localized in the cerebral cortex, ventral tegmental area, amygdalae, ventral pallidum 
and mediodorsal thalamus in rodents. In human brain, the distribution is alike with highest 
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levels in islands of Calleja and nucleus accumbens, but an extended distribution in the 
caudate putamen and the cerebral cortex.
65,70 The existence of the dopamine D3 
autoreceptor and consequently its influence on dopamine release and synthesis is still 
questioned, but recent studies using a selective dopamine D3 antibody have supported its 
presynaptic localization on dopaminergic neurons of the ventral tegmental area and 
substantia nigra.
69,71-73 It has been reported that dopamine D3 receptor mRNA and D2 
receptor mRNA are co-expressed in dopaminergic neurons and projection areas, assuming 
a functional interaction between both subreceptors.
22,45  
The dopamine D2 receptor is predominantly expressed in brain regions, such as the caudate 
nucleus, putamen and olfactory tubercle, lower levels are found in the nucleus accumbens, 
where the receptor is expressed by GABAergic neurons co-expressing enkephalins.
24,70 In 
these areas, the receptor is mainly expressed postsynaptically (D2L).
70 Additionally, it is 
distributed in the substantia nigra pars compacta and in the ventral tegmental area and is 
mostly presynaptic generated (D2S), capable of regulating dopamine synthesize and 
release.
70 Dopamine D2 receptors are involved in functions related to the nigrostriatal 
dopaminergic system. Its cell degeneration results in an imbalance of the two output 
pathways, namely the direct projection neurons, regulate via dopamine D1 receptors, and 
indirect projection neurons, controlled by dopamine D2 receptors, both generated in the 
striatum. Consequently, disproportion causes movement disorders associated with 
Parkinson’s disease.
24,70  
1.2.4 Therapeutic Relevance of Selective Dopamine D3 Receptor Ligands 
Alterations in the dopaminergic pathways are involved in a variety of neurological and 
psychiatric disorders, like Parkinson’s disease, schizophrenia and drug abuse. 
Degeneration of dopaminergic neurons in the substantia nigra causes striatal dopamine 
depletion in Parkinson’s disease. Imbalance of the mesolimbic dopaminergic pathway is 
involved in schizophrenia and addictive types of behavior. Further diseases associated with 
dysfunction of the dopaminergic system are restless legs syndrome, depression, 
Huntington’s disease, epilepsy, attention deficit hyperactivity disorder, and ischaemia. The 
extended improvement in immunocytochemical methods, like polyclonal antibodies, in situ 
hybridization, recombinant receptors and knock-out animals, and the availability of highly 
affine and selective receptors allow the scientist to enlighten the role of each dopamine 
receptor subtype and its function in various pathological processes.  
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Parkinson’s Disease 
Parkinson’s disease (PD), firstly described by James Parkinson in 1817,
74 is a progressive 
neurodegenerative movement disorder, characterized by rigidity, tremor, bradykinesia or 
akinesia, additionally allied with concomitant syndromes, such as anxiety and depression, 
and affects about 1% of the general population. The loss of dopaminergic cells in the 
substantia nigra pars compacta results in a deficiency of dopamine in the striatum, causing 
the major motor symptoms of the disease. Further progression of cell death involves areas 
of the origin of the mesolimbic dopamine system and is associated with deficits in 
cognitive functions and goal-directed behavior. The neuropathology of PD is well 
characterized, but etiology still remains unknown. Environmental and endogenous 
neurotoxicants, such as neurotoxicity of levodopa
75 or dopamine-induced autotoxicity,
27 
finally leading to oxidative stress, as well as mitochondrial dysfunction, infection
76, or 
genes, such as α-synuclein and parkin, are considered to be implicated.  
The symptomatic treatment of Parkinson’s disease involves the stimulation of remaining 
dopamine receptors in order to balance dopamine transmission. Levodopa and dopamine 
agonists are highly effective for the treatment of the motor symptoms.
77 Since dopamine 
does not cross the blood-brain barrier, the precursor levodopa in combination with the 
peripheral decarboxylase inhibitors carbidopa (Nacom
®) or benserazide (Madopar
®) is 
administered. Levodopa penetrates into the central nervous system and is subsequently 
converted to dopamine by enzymatic decarboxylation. Levodopa treatment results in 
instant motor benefits, but long-term levodopa therapy consequences a significant loss of 
efficacy, motor fluctuations (on-off, wearing off, freezing) and dyskinesia (hyperkinetic 
movements) after 3 – 5 years.
78 In recent times, administration of dopamine receptor 
agonists, used in early monotherapy or adjunctive therapy with levodopa, has become 
common.
79 Dopamine agonists can be categorized in ergot and non-ergot derivatives. Ergot 
dopamine agonists comprise bromocriptine (Pravidel
®), α-dihydroergocriptine (Almirid
®), 
cabergoline (Cabaseril
®), lisuride (Dopergin
®), and pergolide (Parkotil
®), and non-ergot 
dopamine agonists include ropinirole (Requip
®), pramipexole (Sifrol
®), rotigotine 
(Neuropro
®), and apomorphine (Apomorphine-Woelm
®) (cf. 1.2.6). All dopamine receptor 
agonists have proved to be effective in clinical practice but display considerable 
differences in their binding profiles at dopaminergic receptor subtypes and other 
neurotransmitter receptors as well as in their pharmacokinetic properties.
80 Cardiac side 
effects, in particular fibrotic valvular heart disease, have been associated with ergot 
derivatives but further studies are still under investigation; consequently they are used 
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more cautiously.
81 The recently launched drug rotigotine is the first transdermally 
delivered dopamine receptor agonist for the treatment of early PD and allows a continuous 
administration and dopaminergic stimulation.
82 Ropinirole and pramipexole have 
demonstrated clinical benefits over levodopa, reduce motor deficits, minimize the risk of 
dyskinesia and additionally, they possess neuroprotective effects. Although stimulation of 
the dopamine D2 receptor has been mainly considered for antiparkinsonian effects, the 
majority of the dopamine agonists used in the treatment of PD have high or higher affinity 
at the dopamine D3 receptor than at the dopamine D2 receptor. Consequently, it is assumed 
that the D3 receptor, which is located in high abundance located in the limbic striatum, 
plays an important role in PD and might contribute to movement dysregulation.
78,83  
Studies with a primate model of PD have revealed that levodopa-induced dyskinesia (LID) 
was associated with over expression of dopamine D3 receptors. Administration of 
dopamine D3 receptor partial agonists has relieved LID, without influencing the therapeutic 
success of levodopa, while dopamine D3 receptor antagonists increased PD-like 
symptoms.
51 It has been suggested that an additional diagnosis of dementia or non-
responder to parkinsonian medication was correlated with a lower number of dopamine D3 
receptor.
22 The D3 receptor-preferring non-ergot dopamine agonist pramipexole has shown 
effectively to reduce the risk of motor complications.
84 Furthermore, pramipexole has been 
shown to be neuroprotective against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
toxicity in non-human primates.
85 The MPTP administration produces parkinsonian-like 
symptoms and can also used as a model to study neuroprotection. MPTP is metabolized by 
monoamine oxidase B to the active metabolite N-methyl-4-phenylpyridinium (MPP+) and 
causes loss of dopaminergic neurons of the substantia nigra. Some evidence has been 
accumulated that the neuroprotective effect of pramipexole is due to its biological effect on 
dopaminergic neuron-associated genes, including dopamine transporter, vesicular 
monoamine transporter 2, and transcription factor Nurr1, but further studies need to 
confirm the assumption.
86 A positive influence on depression symptoms relieved by 
pramipexole has also be reported.
87 It has been shown that activation of dopamine D1 
receptors results in a relief of Parkinson symptoms and additionally, stimulation of 
dopamine D1 and D2 produces synergistic effects, but clear evidence is still lacking. 
Functional interaction of the dopamine D1/D3 receptors has been assumed due to its co-
expression and similarities in reply to rodent Parkinson model.
68  
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Restless Legs Syndrome 
The restless legs syndrome (RLS), firstly described by Karl-Axel Ekbom in 1945,
88 is a 
neurological sensorimotor disorder characterized by abnormal leg sensations (paresthesias) 
that occur mainly at rest and during the evening and night, leading to severe insomnia and 
daytime tiredness.
89 The paresthesias induce an irresistible urge to move the limbs 
following a temporal relieve of the symptoms. In the majority of RLS patients periodic 
limb movements (PLMs), a disorder with repetitive movements of the lower limbs during 
sleep, have been observed. RLS affects 3% to 15% of the general population, women twice 
as often as men, but many patients go undiagnosed because the syndrome has only recently 
recognized, its pathophysiology is rarely understood and standardizes diagnostic criteria 
were first developed in 1995 and recently updated guidelines on management of RLS were 
published.
90 The pathophysiology of primary (idiopathic) RLS includes changes in central 
dopaminergic transmitter systems, which may result in alteration of the spinal cord 
function, and abnormal brain iron metabolism. The hypothesis of the hypofunction in brain 
dopamine signaling is supported by the first-line treatment of RLS with dopamine D2-like 
receptor agonist, predominantly the non-ergot derived, D3 receptor-preferring compounds 
such as pramipexole (Sifrol
®),
91 ropinirole (Requip
®),
92 rotigotine (Neuropro
®),
93 which 
alleviate sensory and motor symptoms in 70 - 100% of patients (cf. 1.2.6).
89 A decreased 
dopamine D2 receptor binding and hypofunction of the dopaminergic nigrostriatal system 
has been obtained in PET and SPECT investigations in RLS patients.
89 Studies on 
experimental lesions of hypothalamic A11 nucleus and in D3 receptor knockout mice by 
Clemens et al. led to the hypothesis of a dysfunction of a supraspinal located dopaminergic 
region in the dorsal-posterior hypothalamus and subsequent alterations in spinal network, 
finally contributing to RLS.
94 Future experimental investigations need to confirm the 
hypothesis, but these results and the effective treatment of RLS with dopamine D3 
receptor-preferring agonists reflect the potential relevance of dopamine D3 receptors in 
mechanisms of primary RLS pathophysiology. 
Schizophrenia  
Schizophrenia is a devastating mental disorder and affects about 1% of the world’s 
population. The incidence is similar throughout diverse economical limits or cultures. The 
clinical symptoms of schizophrenia comprise several clinical features and are generally 
occurring at ages of 15 – 45. The psychiatric disorder is characterized by the appearance of 
positive symptoms, such as hallucinations, delusions, disorganization of thought, bizarre 
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behavior, and negative symptoms, including diminished affect, loss of motivation and the 
inability to experience pleasure. In same cases, cognitive impairments are also noticed, for 
example deficits in verbal fluency and memory recall. The etiology still remains elusive, 
although several environmental risk factors have been recognized, including maternal 
malnutrition, prenatal and perinatal birth complications. But also viral infections and 
genetic factors might be implicated.
95,96 For over forty years the neurochemical 
pathophysiology has based on the “hyperdopaminergic hypothesis” of schizophrenia, 
which is revisited and not singly valid anymore.
97,98 This theory is explained by the 
observation that direct or indirect dopamine agonists induce paranoia, while antagonists at 
the dopamine D2 receptor relief psychosis.
99 An augment of dopamine release increases the 
positive psychotic symptoms, but do not influence the negative symptoms. Brain imaging 
studies have demonstrated that the imbalance of the dopaminergic system results from a 
hyperstimulation of striatal dopamine D2 receptors, which is related to positive symptoms, 
and hypostimulation of cortical dopamine D1 receptors, causing negative symptoms.
100 It is 
assumed that the origin of the synaptic dysconnectivity is a consequence of changes in N-
methyl-D-aspartate (NMDA) and glutamatergic action, finally leading to NMDA 
hypoactivity in the prefrontal cortex.
101 The “glutamate hypofunction hypothesis” of 
schizophrenia is based on studies of the noncompetitive NMDA receptor antagonist 
phencyclidine which has shown to induce positive, negative and cognitive symptoms of 
schizophrenia in healthy patients and exacerbate these symptoms in schizophrenics.
102 
Conclusively, drugs with enhanced activity at prefrontal dopamine D1 transmission and 
NMDA transmission are assumed to contribute to schizophrenia.
103 The limbic areas of the 
striatum play a key role in schizophrenia. This region is associated by high abundance of 
the dopamine D3 receptor. Post-mortem studies demonstrated an enhanced expression of 
dopamine D3 receptors in the ventral striatum of untreated schizophrenia patients, but a 
reduction in antipsychotic-treated patients.
104 It has been supposed that antipsychotic drugs 
normalize the dopamine D3 expression and stable the ventral striatal activity. 
Consequently, dopamine D3 receptor antagonists are assumed to have antipsychotic 
effects.
105 It has also been shown that dopamine D3 receptor antagonists improve cognitive 
functions in models of rodents due to enhancing frontocortical cholinergic transmission.
106 
In summary, selective antagonism of dopamine D3 receptors, which are mostly located in 
the limbic regions, may reduce negative and cognitive symptoms of schizophrenia and 
prevent undesirable extrapyramidal side-effects (EPS). 
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Antipsychotic drugs of the first generation (cf. 1.2.6) demonstrate some preference for 
dopamine D2 receptors, but although exhibit affinity for dopamine D3 receptors. Their 
interaction with dopamine D2 receptors in limbic brain regions releases positive symptoms, 
while antagonism in the dorsal striatum causes EPS.
78 Second generation, so-called 
atypical antipsychotics (cf. 1.2.6), have a low incidence of EPS, display moderate 
dopamine D2 and D3 receptor antagonism and have additional effects on other 
neurotransmitter systems including histamine H1 receptors, serotonin 5-HT1a, 5-HT2a , 5-
HT2c  receptors, adrenergic α1/α2 receptors and muscarinic acetylcholine M1 receptors 
(multireceptor targeting), which has been assumed to advance the therapeutic profile.
107 
Atypical antipsychotics have demonstrated to improve in particular negative symptoms, 
cognitive impairment and have shown a lower prevalence of tardive dyskinesia.
108 
Additionally, this class of drugs has also provided neuroprotective effects in animal 
model.
109 Since the atypical antipsychotic clozapine (Clozaril
®) has demonstrated a higher 
affinity for the dopamine D4 receptor than for the dopamine D2 receptor and additionally 
interacts with various neurotransmitter receptors, this former observation suggested that 
the dopamine D4 antagonism might contribute to its unique clinical profile (cf. 1.2.6).
34 
Supported by additional post-mortem neuropathological and pharmacological studies 
selective and high affine dopamine D4 receptor antagonists were developed for the 
treatment of schizophrenia.
110 However, clinical trials of dopamine D4-selective ligands, 
among them sonepiprazole, have demonstrated to be ineffective against psychotic 
symptoms.
111 Likely, the promiscuous binding behavior of atypical antipsychotic 
contributes to the clinical efficacy. 
Depression 
Major depression is a severe disorder with a prevalence of 10-15% and genetic, 
developmental, and environmental factors are involved in its etiology. The cardinal 
symptoms include depressed mood (sadness) and the inability to experience pleasure 
(melancholy or anhedonia), but depression is also characterized by various other features 
such as insomnia, hypersomnia, pain or lethargy. Depression often co-occurs with co-
morbid disorders, for example Parkinson’s disease.
112 For decades, the neuropathology of 
depression is based on the serotonergic and noradrenergic hypothesis, but latest 
investigations implicate an important role of the dopaminergic system and a deficit in 
dopaminergic transmission might contribute to depression.
112 Recently, dopamine D3 
receptor agonists have demonstrated antidepressant effects and mood enhancement in 
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depressive patients but also in depressed Parkinson’s patients. Ropinirole has been used 
effectively in combination with antidepressants in treatment-resistant depression.
113 
Antidepressant properties of rotigotine (Neuropro
®) have been reported in experimental rat 
models of depression at low doses (cf. 1.2.6).
114 Pramipexole (Sifrol
®) has been effective 
in the treatment of depression in Parkinson’s disease and bipolar depression (cf. 
1.2.6).
115,116 These results reveal the beneficial effect of agonists at dopamine D3 receptors 
for the treatment of depression, but additional studies are of absolute necessity.  
Drug Addiction 
Drug abuse and addiction are long-lasting conditions and are associated with drug-induced 
neuroadaptions in the brain. Drugs of abuse, such as opiates, nicotine, cannabis, cocaine, 
produce reward and are involved in reinforcement and drug dependence. This chronic 
relapsing disease is not only of scientific interest, but also socially important due to its 
enormous and rising economic cost.
117 The mesocorticolimbic system, projecting from the 
ventral tegmental area to the nucleus accumbens and frontal cortex, is implicated in reward 
and reinforcement effects of abused drugs (alcohol, heroin, cocaine, tetrahydrocannabinol 
and nicotine) and it is well evidenced that drugs of abuse increase dopamine levels in the 
shell of nucleus accumbens.
21,118 Cocaine and amphetamine inhibit the uptake of dopamine 
by the dopamine transporter (DAT), leading to an increased synaptically dopamine 
concentration, a mechanism which is responsible for their rewarding and reinforcing 
properties.
117,119 Post-mortem studies of human brains from cocaine addicts have 
demonstrated that dopamine D3 mRNA and binding are increased in the nucleus 
accumbens, but there is no alteration in dopamine D1 and D2 receptor expression.
120 The 
dopamine D3 receptor is highly expressed and co-localized with dopamine D1 receptors, 
dynorphin and substance P in brain regions involved in drug dependence. Current 
investigations using highly selective dopamine D3 receptor ligands, either partial agonists 
or antagonists, and dopamine D3-deficient mice have revealed that dopamine D3 receptors 
participate in the motivation to self-administer drugs and in the control of environmental 
stimuli on drug-seeking behavior. Consequently, the therapeutic concept in the treatment 
of drug addiction and prevention of relapse includes the inhibition of dopamine D3 
receptors using partial agonists or antagonists. The expression of dopamine D3 receptors is 
regulated by brain-derived neurotrophic factor (BDNF).
104 Administration of drugs of 
abuse results in a transient increase in BDNF expression, inducing an increase in D3 
receptors.
104 So both dopamine D3 receptors and BDNF are involved in drug conditioning. 
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1.2.5 Ligand Binding Mode at Dopamine D2 and D3 Receptors 
The three dimensional (3D) crystal structure of the G protein-coupled receptor bovine 
rhodopsin has been identified in 2000.
2 Since that time the high-resolution structure has 
been used as a template to generate homology models in order to design novel ligands for 
GPCRs, including the human dopamine D3 receptor.
9,121 The computer-assisted method to 
receive a 3D model of dopamine D3 elucidates the function of highly conserved GPCR 
residues, ligand binding mode and enables structure-based drug design. However, it is 
worth mentioning that the rhodopsin template corresponds to the inactive conformation of 
the receptor with an inverse agonist as an endogenous ligand, consequently models have to 
be interpreted with caution. 
The predicted binding site of dopamine D2 receptors for dopamine and other agonists 
involves TM domains 3, 4, 5, and 6. Aspartate residue Asp-114 in TM3 forms a tight salt 
bridge with the basic amino group of the ligand. The Asp is highly conserved among 
human biogenic amine receptors.
122 Two serine residues Ser-193 and Ser-197 in TM5 
contribute to hydrogen bond via binding hydroxyl groups of the catechol moiety and are 
essential for activation of the receptor.
123 Agonists interact with both conserved serine 
residues. Ser-194 serves as an option to Ser-193 for hydrogen-bonding. Agonists hold tight 
binding of TM3 and TM6. Additional residues such as His-394 (TM6), Trp-386 (TM6) and 
Phe-390 (TM6) form hydrophobic interactions with aromatic moieties. Antagonist binding 
mode mainly includes TM helices 2, 3, 4, 6, and 7. Prominently, Asp-114 (TM3) binds via 
salt bridge to the cationic moiety, Ser-193 (TM5) or Ser-197 (TM5) gives one hydrogen 
bond, and Trp-386 (TM6) is important for a hydrophobic pocket. His-393 (TM6) stabilizes 
the inactive form of the receptor. Especially TM3 and TM6 involve tight antagonist 
binding.  
The predicted binding mode for dopamine D3 focuses on Ser-192 (TM5) as a hydrogen-
bond donor and Asp-110 (TM3) that forms an interaction with a positively charged group 
of the ligand.
124 Phenylalanine Phe-345 and Phe-346 have demonstrated to be implicated in 
aromatic and hydrophobic interactions, respectively.
121 For the dopamine D3 receptor, 
more evidence to confirm the prediction, for example site-directed mutagenesis, is 
requested. 
Basically, agonists for dopamine D2 and D3 receptors comprise the structural feature of a 
basic amine group in a defined distance to an aromatic moiety with the characteristic of a 
hydrogen-bond acceptor. Intensive investigation has been done on the pharmacophore 
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model of dopamine D2 and D3 receptors for antagonists or partial agonists.
9,125,126 
Fundamental structural features for ligands with antagonist properties require an aryl 
moiety, a hydrogen acceptor pharmacophore at the position of the oxygen amide, a 
hydrophobic or aromatic pharmacophore in the spacer region and a cationic and an 
aromatic pharmacophore in the basic amine aryl residue. The aryl residue can be 
represented by extended bi- and tricyclic aryl rings, additionally substituted with 
heteroatoms, or by a conjugated olefinic phenyl ring system.
127 A general structural 
scheme exampled by the structure of BP 897 is shown in Figure 1.8. Dopamine D3 receptor 
ligands prefer an extended and more linear conformation, while dopamine D2 receptor 
ligands adopt a more bent conformation. Consequently the distance between hydrogen 
acceptor and positively charged nitrogen for dopamine D3 spans about 6.5 Å and for 
dopamine D2 stretches 5.5 Å.
126 
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Figure 1.8 General structural scheme of dopamine D2 and D3 receptor ligands with antagonist or 
partial agonist properties. 
1.2.6 Ligands for Dopamine D2 and D3 Receptors  
Classical pharmacological receptor studies, the introduction of molecular cloning 
techniques and development of radioligand competition binding studies using recombinant 
dopamine receptor subtypes allow determining affinity binding of novel ligands. 
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Dopamine D2-like Receptor Ligands 
The development of dopamine D2-like receptor agonists was based on the rigidification of 
the neurotransmitter dopamine and itemization of the dopamine agonist apomorphine 
(Apomorphin-Woelm
®). This effort resulted in the 2-aminotetralin derivative 7-hydroxy-
N,N-dipropyl-2-aminotetralin (7-OH-DPAT) and its related modification PD128907 (Chart 
1.1).
67,128 Both compounds have demonstrated high affinity and moderate dopamine D3 
receptor-preference. Due to metabolic instability the ligands are only used as 
pharmacological tools. The antiparkinsonian drug ropinirole (Requip
®), which is also used 
for the treatment of restless legs syndrome, has demonstrated low affinity for dopamine 
D1-like and D4 receptors, but has bound with slightly higher affinity for dopamine D2 than 
for D3 receptors.
129 The pyrimidine derivative piribedil (Trivastal
®, France) is a dopamine 
D2/D3 agonist with additional α2-noradrenergic properties. It is used for the treatment of 
Parkinson’s disease and it has additional pro-cognitive effects.
130 Compounds are shown in 
Chart 1.1.  
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Chart 1.1 Dopamine D2-like receptor agonists. 
 
The butyrophenone derivative and antagonist haloperidol (Haldol
®) demonstrates 10 to 20-
fold higher affinity for dopamine D2 versus D3 receptors.
131 Since 1958, haloperidol has 
been an important representative of “classical” antipsychotic drugs and its pharmacological 
effects, but also extrapyramidal side effects are mediated by interacting with other central 
nervous system neurotransmitter receptors. Its neuroleptic activity depends on the tertiary 
amino group linked to the butyrophenone structure. Variation in the piperazine ring to give 
a spiro analogue of haloperidol resulted in spiperone (spiroperidol), just as haloperidol 
slightly preferring dopamine D2 over D3 receptors.
132 The 2-methoxybenzamide derivatives 
sulpiride (Dolmatil
®) and raclopride comprise an aminomethylpyrrolidine residue and are 
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antipsychotics with high affinities for both dopamine D2 and D3 receptors.
132 The 
dibenzazepine derivative and atypical antipsychotic clozapine (Clozaril
®) has a unique 
pharmacological behavior due to its low affinities for dopamine D1, D2, and D3, but 
moderate affinity for dopamine D4 receptors. It is assumed that its therapeutic effect results 
from interaction with several of neurotransmitter receptors, such as histaminergic, 
serotoninergic, muscarinic receptor. Typical (haloperidol, spiperone, raclopride) and 
atypical antipsychotics (sulpiride, clozapine) are shown in Chart 1.2. 
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Chart 1.2 Dopamine D2-like receptor antagonists. 
Selective Dopamine D3 Receptor Ligands 
Pramipexole (Sifrol
®, Mirapex
®) is an analogue of (R)-(+)-7-OH-DPAT revealed by 
bioisosteric replacement of the phenol residue with a metabolically more stable 2-
aminothiazole moiety.
133,134 Pramipexole is a full dopamine receptor agonist and binds at 
presynaptic and postsynaptic dopamine D2-like receptors with highest affinity for 
dopamine D3 receptors and has shown only low affinities at adrenoceptors and serotonin 
receptors.
135 It has been effective in the treatment of Parkinson’s disease. Recently, it has 
been introduced for the treatment of restless legs syndrome (Chart 1.3).
91 The aminotetralin 
derivative rotigotine (Neuropro
®) is a dopamine receptor agonist used in a transdermal 
delivery system and for the treatment of Parkinson’s disease (Chart 1.3).
82,136 Rotigotine 
demonstrated agonist activity with 20-fold preference for the dopamine D3 over the D2 and 
about 100-fold over the D1 receptor. FAUC 88 has been introduced as a novel class of 
nonaromatic dopamine D3 receptor agonist (Chart 1.3).
137 The conjugated enyne residue 
represents a bioisosteric replacement of the catechol structure. 
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Chart 1.3 Dopamine D3 receptor agonists.  
 
A set of dopamine D3 receptor selective antagonists and partial agonists is shown in Chart 
1.4. Among the first dopamine D3 receptor antagonists with significant selectivity for D3 
versus D2 was U99194A.
138 Development of analogues of the dopamine D2-like receptor 
antagonist sulpiride (see Chart 1.2) resulted in the benzamide derivative nafadotride. Its 
levoisomer has subnanomolar affinity and a 20-fold preference for dopamine D3 
receptors.
138 The 1,2,3,4-tetrahydroisoquinoline antagonist SB 277011 has nanomolar 
affinity and 100-fold selectivity for dopamine D3.
139 It has been used as a pharmacological 
agent in animal models of drug abuse and reduces cocaine-, nicotine-, ethanol-, and heroin-
seeking behaviors.
21,127 BP 897 was identified as a selective dopamine D3 receptor partial 
agonist with high affinity binding at human dopamine D3 receptors and a 70-fold 
selectivity over human D2, which behaves as an antagonist at this subtyp.
66,140  
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Chart 1.4 Dopamine D3 receptor antagonists and partial agonists. 
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Further evaluation of in vitro models showed, that BP 897 has demonstrated antagonist 
dopamine D3 receptor profile in addition to its partial agonist properties.
141,142 BP 897 has 
attenuated the behavioral and reinforcing effects of cocaine, showing a promising property 
for the treatment of drug abuse. Considering further interactions of BP 897 with multiple 
classes of monoaminergic receptors, the only pivotal role of dopamine D3 receptors in the 
mechanism of reduced cocaine-seeking behavior is not confirmed yet.
21,143 To date BP 897 
is ongoing phase II of clinical studies as a therapeutic target for the treatment of cocaine 
abuse and related central nervous disorders.
144 Another related development in this lead 
structure is FAUC 365, an antagonist bearing a heteroatome substituted bicyclic ring 
system and a (2,3-dichlorophenyl)piperazine substructure. The compound demonstrated 
high affinity for hD3, while the affinity for hD2 was depending on different assay 
conditions, but provided an impressive high selectivity for hD3 over hD2
125 although this 
could not be confirmed by other groups.
145 Further development is represented by the 
1,2,3,4-tetrahydroisoquinoline compound ST 198. It has been reported that the antagonist 
normalizes dopamine D3 receptor function and subsequently attenuates levodopa-induced 
dyskinesia.
83 The benzopyranopyrrole derivative S 33084 behaves also as an antagonist 
and has displayed high dopamine D3 binding affinity and >100-fold selectivity ratio for 
dopamine D3 receptors.
146 S 33138 and A 437,203 are promising agents and are in Phase II 
trials for the treatment of schizophrenia. Both compounds behave as selective dopamine D3 
over D2 receptor antagonists. The pyrimidylpiperazine derivative A 437,203 has an 
influence on brain dopamine activity and has demonstrated antipsychotic properties in the 
absence of EPS.
 In vitro data have confirmed the former as a highly potent D3 receptor 
ligand acting as antagonist.
147,148  
1.3 Histamine  
The monoamine histamine (2-(1H-imidazol-4-yl)ethanamine), a neurotransmitter and 
neuromodulator in the mammalian brain, acts via biogenic amine binding GPCRs and as 
seen for dopamine receptors, histamine receptors also comprise the highly conserved 
aspartate acid in TM3. The central histaminergic system is involved in the regulation of 
various neurotransmitters, particularly in the activity of dopamine (see 1.2) transmission, 
and therefore has a high influence on neurotransmission in the central nervous system.
149 
Histaminergic cell bodies in brain are sited in the tuberomammillary nucleus of the 
posterior hypothalamus. Their neurons project to all brain areas with a strong innervation 
of the limbic system. Consequently, the brain histamine system is involved in various CNS 
functions, such as sleep/wakefulness, feeding behavior, circadian rhythm, cardiovascular 
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control, catecholamine release and the neuroendocrine regulation.
149 Neuronal histamine 
additionally regulates the release of acetylcholine in brain and is therefore implicated in 
cognitive functions, learning and memory processes.
150 The role of the central 
histaminergic system on schizophrenia is highly discussed.
151  
Histamine is synthesized from the amino acid L-histidine by the enzyme L-histidine 
decarboxylase with pyridoxalphosphate as a cofactor (Figure 1.9). Histamine is rapidly 
metabolized in brain by the intracellular enzyme N-methyltransferase to give N-tele-
methylhistamine and subsequently oxidized by monoamine oxidase and aldehyde oxidase 
to result in N-methylimidazole acetic acid. In the periphery, histamine is mainly oxidized 
by diamine oxidase (histaminase) to form imidazole acetic acid. 
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Figure 1.9 Biosynthesis of histamine.  
 
Furthermore, histamine is located in the periphery; high density is concentrated in tissue 
mast cells and enterochromaffin-like cells in the gastrointestinal tract. Lower amount of 
histamine is found in basophil leukocytes and platelets. Histamine has shown to play a 
pivotal role in a variety of physiological processes including allergic responses and 
regulation of gastric-acid release and accordingly it is implicated in pathophysiological 
conditions counting allergic reactions, immunological disorders, and gastric-acid-related 
diseases. 
Histamine Receptors  
Histamine mediates its function through histamine receptors, which belong to the family of 
the aminergic G protein-coupled receptors. Until present, the existence of four histamine 
receptor subtypes, histamine H1, H2, H3, and H4 receptors, has been identified and they 
translate extracellular signals via the G proteins, Gq, Gs, Gi/o, and Gi/o, respectively.
152 
Although all four histamine receptor subtypes have been recognized in the periphery, only 
histamine H1, H2 and H3 have been identified in the mammalian central nervous system. 
Stimulation of histamine H1 receptors is involved in inflammatory effects, associated with 
smooth muscle contraction and edema linked to allergic responses.
149 The cloning of 
histamine H1 receptor was reported in 1991.
138 Stimulating effects on gastric-acid secretion 
via histamine H2 receptors has been known for a long time and provided an important 
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target for acid-related diseases such as peptic ulcer and gastro-esophageal reflux disease. 
The cloning of the cDNA for canine histamine H2 receptors was reported in 1991.
153,154 
The histamine H3 receptor was identified by Arrang in 1983
155, cloned by Lovenberg in 
1999
156 and it is a presynaptic autoreceptor, inhibiting the synthesis and release of the 
endogenous ligand in histaminergic neurons in the CNS. It further functions as a 
heteroreceptor and regulates the release of other neurotransmitters such as dopamine, 
serotonin, glutamate, GABA, acetylcholine, noradrenaline in the CNS and periphery.
149 
The use of its antagonists in the treatment of obesity, neurological disorders such as 
Alzheimer’s disease, epilepsy, schizophrenia, sleep disturbance, and attention deficit 
hyperactivity disorder, is currently under investigation. Research in histamine H3 receptor 
variants resulted in the finding of histamine H4 receptors and its subsequent cloning in 
2000.
157 Histamine H4 receptors are mainly expressed in cells of the immune system and 
mast cells; they are also located on lymphocyte T cells, dendritic cells and basophils, 
which implicate its influence on immune response and inflammatory disease. Histamine H3 
receptors are closely related to histamine H4 receptors (37 - 43% overall H4 homology to 
H3), but displayed differences to cloned histamine H1 and H2 receptors (19 - 22 and 18 - 
20% homology, respectively).
158 The four histamine receptor subtypes have demonstrated 
agonist-independent activity, referred as constitutive activity in vitro at physiological 
concentrations; consequently antagonists have to be reclassified as inverse agonists.
158  
1.3.1 Histamine H1 Receptors  
The G protein-coupled human histamine H1 receptor consists of 487 amino acids and 
shows the putative seven transmembrane domains. The proposed structure possesses a 
large third intracellular loop and a short intracellular C terminal tail. The bovine adrenal 
medulla histamine H1 receptor was cloned by expression cloning in the Xenopus oocyte 
system in 1991,
154 followed by the cloning of histamine H1 receptor from various species 
including rat, guinea pig, mouse, and human (chromosome 3).
159-162  
1.3.2 Signal Transduction of Histamine H1 Receptors 
The histamine H1 receptor stimulation activates phospholipase C (PLC) via a pertussis 
toxin-insensitive G protein, related to the Gq/11 family of G proteins, consequently forming 
inositol-1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG), resulting in an increase in 
intracellular calcium concentration.
163 Additionally, its stimulation results in the activation 
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of a variety of signaling pathways, mostly to be secondary to changes in intracellular 
calcium concentration or activation of protein kinase C (PKC), such as stimulation of nitric 
oxide synthetase (NOS) activity, phospholipase A2 (PLA2) activity and therefore release of 
arachidonic acid from cell membrane, changes in cAMP accumulation, and promotion of 
transcription of genes controlled by nuclear factor kappa B (NF-κB) (Figure 1.10).
149,164 
For the histamine H1 receptor, constitutively activity has been described, but however its 
(patho)physiological relevance is unknown.  
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Figure 1.10 Signaling pathways of histamine H1 receptors. 
1.3.3 Distribution and Function of Histamine H1 Receptors 
Histamine H1 receptors are distributed in the mammalian brain and in the periphery. In the 
human brain high concentrations are located in nucleus accumbens, thalamus, neocortex, 
hippocampus, and posterior hypothalamus; however basal ganglia demonstrate low 
abundance. Stimulation of histamine H1 receptors consequences inhibition of firing and 
hyperpolarization in hypocampal neurons, but it causes excitation in brainsteam, thalamic 
and cortical neurons. Histamine strongly influences sleep and wakefulness via the 
histamine H1 receptor in brain, therefore the receptor plays an important role in sedative 
effects. Histamine H1 receptor activation stimulates tyrosine hydroxylase in mammalian 
brain. In the periphery, histamine H1 receptors are localized on smooth muscles in the 
respiratory tract and gastrointestinal tract, cardiovascular system, and genitourinary 
system. Additionally they are abundant on endothelial cells and lymphocytes. Activation of 
histamine H1 receptors results in contraction of smooth muscle, vascular permeability due 
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to endothelial cell contraction, release of nitric oxide, negative inotropic effects on 
myocardium, and facilitates the release of adrenaline and noradrenaline in the adrenal 
medulla.
149 A number of the effects are described as the “triple response”: red spot, itch 
and swelling; which are symptoms of allergic reactions and inflammatory disorders and 
represent the key role of histamine H1 receptors. 
1.3.4 Therapeutic Relevance of Histamine H1 Receptor Ligands 
Histamine H1 receptor antagonists or so-called ‘antihistamines’ have been used for many 
decades and are still the most important drugs in the treatment of various allergic disorders, 
such as hay fever, allergic rhinitis, and urticaria. First generation histamine H1 receptor 
antagonists (cf. 1.3.6) interfere with cholinergic, dopaminergic and serotonergic receptors 
and cause adverse central nervous system effects such as sedation, decreased cognitive 
functions and sleepiness. For that reason, these drugs have been administered for sleep 
disorders, emesis, and allergic disorders in pediatrics or with topical application. Other side 
effects were obtained such as anxiety, appetite stimulation and tachycardia; peripheral 
cholinergic antagonism resulted in dry mouth and urinary retention. The next generation 
antihistamines have improved side-effect profiles, causing less sedation, but a few 
demonstrate severe cardiovascular effects (cf. 1.3.6). Chlorpromazine, a phenothiazine 
derivative, was initially developed from H1 receptor antagonists for its antiallergic 
properties by Delay and Deniker in 1952. Finally, chlorpromazine entered the market as 
the first neuroleptic drug causing sedative effects due to its antagonist binding profile for 
central histamine H1 receptors. In most cases classical and atypical antipsychotics are 
antagonists at histamine H1 receptors, and besides the sedative effect, an anxiolytic effect 
has been reported.
66 Currently the histamine H1 receptor is under investigation due to its 
effect to induce weight gain in antipsychotic treated patients.
107,165 The therapeutic use of 
histamine H1 receptor agonists is still unclear. Betahistine, a histamine H1 receptor agonist, 
has been used in the treatment of vertebrobasilar insufficiency,
166 Ménière’s disease and as 
a prophylaxis of migraine,
167 but the therapeutic effect has not been obviously linked to its 
histamine H1 agonism. 
1.3.5 Ligand Binding Mode at Histamine H1 Receptors  
Site-directed mutagenesis has confirmed that the conserved aspartic acid (107) in TM3 of 
the human histamine H1
 receptor is crucial for the binding of histamine and histamine H1 
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receptor antagonists. Aspartate in TM3 is highly conserved among aminergic rhodopsin-
like G protein-coupled receptors and provides the negative counter-ion for the protonated 
amine group of the ligand.
168 For histamine binding, the asparagine (207) in TM5 interacts 
via hydrogen bond with the nitrogen of the imidazole ring and lysine (200) in TM5 links 
with the nitrogen of the aliphatic primary amine.
169  
1.3.6 Ligands for Histamine H1 Receptors  
Due to the uncertain therapeutic relevance of agonists, the centre of attention is put on 
ligands with antagonist properties. The first histamine H1 receptor antagonists were 
synthesized two decades after the discovery of histamine. One of the first introduced 
compounds with selectivity and high affinity for histamine H1 receptors was mepyramine 
(pyrilamine), an ethylendiamine derivative, which is still used as a radioligand for 
pharmacological testing. Other histamine H1 receptor antagonists followed such as 
diphenhydramine (Benadryl
®, Vomex A
®), chlorpheniramine (Polaronil
®) and bamipine 
(Soventol
®) in order to release allergic symptoms (Chart 1.5). These compounds are very 
lipophilic and able to penetrate into the CNS and elicit sedative side effects by antagonism 
of histamine H1 receptors. Therefore, they are mainly used for the treatment of travel 
sickness (antiemetics), sleeping disorders or with topical application for allergic 
reactions.
163 The tetracyclic compound mianserin (Mianeurin
®), a rigidized derivative of 
mepyramine, was developed as a compound with not only high antihistamine activity, but 
also high antiserotonin potency to improve antiallergic activity and reduce the central 
nervous system depressant effect (Chart 1.5).
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Chart 1.5 First generation of histamine H1 receptor antagonists. 
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In the last decades, new histamine H1 receptor antagonists with reduced lipophilic 
structures have been synthesized such as cetirizine (Zyrtec
®) and fexofenadine (Telfast
®), 
comprising diphenylmethyl substituents with high affinity for histamine H1 receptors, and 
loratadine (Lisino
®) and ketotifen (Zaditen
®), bearing a tricyclic ring system (Chart 1.6).  
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Chart 1.6 “Non sedative” second generation of histamine H1 receptor antagonists. 
 
These compounds poorly cross the blood-brain barrier and are commonly referred as non 
sedating “second generation” histamine H1 receptor antagonists because they are almost 
free from sedative side effects at the recommended clinical dose. Moreover, the second 
generation class has an improved side effect profile regarding unwanted ventricular 
arrhythmias.
149 It is noteworthy, that due to the constitutive activity in vitro of histamine 
H1 receptors (see 1.3), most histamine H1 receptor antagonists has been reclassified as 
histamine H1 receptor (partial) inverse agonists.  
1.4 The Drug Discovery Process 
The development of potential drug candidates in drug discovery has mainly concentrated 
on testing synthesized compounds in order to evaluate the ligand affinity and selectivity for 
the selected target. Based on the in vitro screening results, ligands have been identified as 
lead compounds and further optimized by iterative chemical modifications to obtain 
structure-activity relationships. Conventional drug discovery and development of novel 
ligands has resulted in a long-term, costly and highly risky procedure and the past average 
of 90% attrition rate did not provide long-term success.
171 In order to optimize the 
development of novel ligands and to contribute to a more efficient drug discovery process, 
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new lead identification strategies have been implemented in the early drug development 
stages.
172 
The drug discovery process for the selected target can be divided into three phases: the 
lead identification phase, the lead optimization phase and the clinical development. In the 
lead identification phase large compound collections received from combinatorial 
chemistry, parallel synthesis and generated compound libraries are tested at the target of 
interest with (ultra)high-throughput screening (HTS), a miniaturized and automated in 
vitro assay, to obtain novel hits and lead candidates. As a complement to HTS, structure-
based and ligand-based virtual screening (VS) have been introduced to identify novel 
structural hit classes. The former method relays on the target structure, while the latter 
approach includes topological search from well-known ligands of the target.
173 Ligand-
based VS methods can be divided into data mining techniques (e. g. clustering
174 and 
recursive partitioning
175), similarity searching, pharmacophore modeling
176 and more 
complex techniques employing models received by support vector machines (SVM)
177 or 
neural networks (NN)
178. These chemoinformatic techniques allow handling and analyzing 
the resulting large amount of data and support the medicinal chemist to gain deeper insight 
into the relationship between pharmacological data and structural features of compounds. 
1.5 Radioligand Binding Studies 
Development of novel ligands in drug discovery requires a robust assay system for 
compound screening, and the selection and development of an assay is of immense 
importance. Radioligand binding studies allow to accurately determining the affinity of 
ligands at the receptor of interest, its selectivity and to identify novel chemical scaffolds. 
The technique is basically a very straightforward method, applicable in a very wide range 
of preparations and has strongly improved receptor research for many decades. 
Furthermore, it comprises the ability to identify, characterize and elucidate receptors in 
their natural environment and also those transfected into cell lines. It enables to merely 
detect ligands that demonstrate affinity and receive large amounts of data, using smallest 
amounts of tissue and ligand, in a robust and fast high-throughput screening; therefore it 
has become an essential tool within the drug discovery process. The power of binding 
studies to provide valid quantitative estimates and high quality of binding data depends 
crucially on the assay system under investigation and experimental assay conditions need 
to be chosen carefully. Buffer composition, incubation temperature, pH value, ionic 
strength, and radioligand depletion are important parameters within the assay and 
significantly influence binding data. Particular attention has to be paid to the kinetic; the 
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appropriate incubation time has to allow ligands, especially with high affinities, to reach 
the equilibrium state. It is of importance to notice that a radioligand binding assay 
estimates the affinity of a ligand specific binding site, while a functional assay determines 
the intrinsic efficacy of the ligand. Agonist competition curves display mostly a shallow 
and biphasic shape due to the existence of multiple agonist affinity states. Nevertheless, it 
is possible for G protein-coupled receptors to assess whether the ligand is an agonist or 
antagonist by conducting a guanosine-5’-triphosphate (GTP) shift experiment. High-
affinity binding of agonists depends on the association of a receptor/G protein complex. In 
the presence of either salt and/or guanine nucleotides the complex dissociates and results in 
a significant reduction in agonist binding affinity, while antagonist binding is not 
decreased. Although radioligand binding assays are an extremely powerful tool to 
investigate in ligand-receptor interactions, some limitations have to be considered. The 
per-assay costs are highly expensive and include a high affine and selective radioligand, 
cell culture, solutions, reagents, disposable items, multiwell assay plates and precise 
instrumentations. Determined Ki affinity values of screening compounds might be different 
using dissimilar binding assay conditions, including varying radioligands, incubation 
buffers, and incubation times.  
Radioligand binding is also used to estimate ligand-receptor interactions in vivo in both 
animals and humans, applying positron emission tomography (PET) or single photon 
emission computed tomography (SPECT), in order to monitor receptor dynamics in many 
diseases, particularly in the central nervous system.  
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The aim of the thesis is the development of novel ligands influencing neurotransmission in 
the central nervous system. Due to its important role in various neurological and 
neuropsychiatric disorders such as Parkinson’s disease, schizophrenia and drug addiction, 
the focus is concentrated on the dopamine D3 receptor. The strategy is the development of 
radioligand binding assays to investigate in structure-affinity relationships (SAR) of novel 
structural classes of ligands.  
Radioligand binding assays for human dopamine D3 receptors and, for reasons of structural 
homology and selectivity, human dopamine D2S receptors, stably expressed in Chinese 
hamster ovary cells (CHO), are implemented. To gain insight into the cross affinity 
receptor profile of related biogenic amine receptors, a radioligand binding assay for human 
histamine H1 receptors stably expressed in CHO cells is validated. For functional 
classification of agonists in radioligand binding assays and consequently discrimination of 
agonists from antagonists, a GTP shift assay is performed.  
To develop novel ligands for dopamine D3 receptors, derivatives of the leads BP 897 and 
ST 198 are tested for binding affinities. Variations of discrete elements of the lead 
structures and therefore alterations of functionalities in the ligand are studied to enlighten 
structural requirements for high affinity binding and selectivity at dopamine D3 receptors.  
Ligands with antagonistic properties at dopamine D2-like receptors and at histamine H1 
receptors comprise close structural similarity. A hybrid structure approach of histamine H1 
receptor antagonists and dopamine D2/D3 receptor structural features is investigated. The 
aim is to elucidate the SAR of the histamine H1/dopamine D2-like receptor profile and to 
identify highly affine dopamine D3 receptor selective ligands. 
Structural variations of the dopamine D3 receptor agonist pramipexole and the structurally 
related dopamine agonist etrabamine are investigated. The strategy is to introduce the 
selective dopamine D3 receptor binding profile, the advanced pharmacokinetic and 
neuroprotective properties of pramipexole into novel ligands. The influence on affinity 
binding of an additional dopamine D3 receptor pharmacophore element combined with the 
dopamine agonists is assessed. The aim of this approach is to develop ligands with high 
affinity and improved selectivity for dopamine D3 receptors. 
Investigation in the identification of novel lead structures with altered chemical scaffold 
for dopamine D3 receptors is performed. Radioligand binding assays are applied on 
molecules resulting from chemoinformatic virtual screening techniques. By combining 
radioligand binding studies with computational methods the aim is to achieve a deeper 
insight into the SAR of ligands and the ligand binding mode at the dopamine D3 receptor. 
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3.1 Materials 
3.1.1 Reference Substances and Test Compounds  
Bamipine (Dr. Rentschler, Laupheim, Germany) 
BP 897 (Dr. P. Sokoloff, Paris, France, synthesized in our laboratories by Prof. Dr. H. 
Stark, Frankfurt, Germany) 
Cetirizine dihydrochloride (European Pharmacopoeia, Strasbourg, France) 
(R/S)-Chlorpheniramine maleate (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
Ciprofloxacine hydrochloride (Bayer, Leverkusen, Germany) 
Diphenhydramine hydrochloride (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
Fexofenadine hydrochloride (Prof. Dr. S. Elz, Regensburg, Germany) 
Haloperidol (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
Ketotifenhydrogenfumarate (Stada, Bad Vilbel, Germany) 
Loratadine (Prof. Dr. G. Lambrecht, Frankfurt, Germany) 
Mianserin hydrochloride (Sanofi-Aventis, Frankfurt, Germany) 
(S)-(-)-Nafadotride (Dr. P. Sokoloff, Paris, France) 
Pramipexole dihydrochloride (Böhringer Ingelheim, Ingelheim, Germany) 
Pyrilamine maleate (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
(S)-(-)-Raclopride L(+)-tartarte salt (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
Spiperone (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
ST 198 (synthesized in our laboratories by Prof. H. Stark, Frankfurt, Germany) 
Terfenadine (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
U 99194A (Tocris Bioscience, Bristol, UK) 
 
Analogues of benzhydrylpiperazine, Pramipexole and BP897 were synthesized in our 
laboratories by Prof. Dr. H. Stark and co-workers, Institute of Pharmaceutical Chemistry, 
Frankfurt am Main, Germany. 
Virtually screened synthetic compounds were ordered from SPECS, 2628 XH Delft, The 
Netherlands, and Interbioscreen (IBS), 121019 Moscow, Russia. 
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3.1.2 Cells, Cell Culture and Protein Assay 
Cells 
CHO-K1 cells stably expressing human D2S receptors (Dr. J. Shine, Sydney, Australia). 
CHO-K1 cells stably expressing human D3 receptors (Dr. P. Sokoloff, Paris, France). 
CHO-K1 cells stably expressing human H1 receptors (Prof. R. Leurs, Amsterdam, The 
Netherlands). 
Cell Culture and Protein Assay 
Bovine serum albumin (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
Cell culture dishes (TPP AG, Trasadingen, Switzerland, Greiner bio-one GmbH, 
Frickenhausen, Germany) 
Coomassie® Brilliant Blue G250 (Merck KGaA, Darmstadt, Germany) 
Dulbecco’s Modified Eagle’s Medium (PAA Laboratories GmbH, Cölbe, Germany) 
Dulbecco’s Modified Eagle’s Medium/F12 (1:1) (Invitrogen GmbH, Karlsruhe, Germany) 
Fetal bovine serum, dialyzed (PAA Laboratories GmbH, Cölbe, Germany) 
Fetal bovine serum, inactivated (PAA Laboratories GmbH, Cölbe, Germany) 
G418 sulphate (PAA Laboratories GmbH, Cölbe, Germany) 
L-Glutamine (PAA Laboratories GmbH, Cölbe, Germany) 
Non-essential amino acids (PAA Laboratories GmbH, Cölbe, Germany) 
Penicillin G/streptomycin mixture (PAA Laboratories GmbH, Cölbe, Germany) 
Trypsin/EDTA (PAA Laboratories GmbH, Cölbe, Germany) 
3.1.3 Chemicals 
All chemicals are of highest analytical grade purity commercially available. 
Dimethylsulfoxide (DMSO) (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
Disodium hydrogen phosphate dihydrate (Merck KGaA, Darmstadt, Germany) 
Ethanol (Merck KGaA, Darmstadt, Germany) 
5’-Guanylylimidodiphosphate trisodium (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany) 
N-(2-Hydroxyethylpiperazine)-N’-2-ethanesulfonic acid sodium salt (HEPES) (Carl Roth 
GmbH, Karlsruhe, Germany) 
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Magnesium chloride hexahydrate (Merck KGaA, Darmstadt, Germany) 
Phosphoric acid (87%)(Merck KGaA, Darmstadt, Germany) 
Sodium chloride (Carl Roth GmbH, Karlsruhe, Germany) 
1 M Sodium hydroxide (Merck KGaA, Darmstadt, Germany) 
Tris(hydroxymethyl)aminomethane (Tris) (Carl Roth GmbH, Karlsruhe, Germany) 
3.1.4 Buffers and Solutions 
Buffers and solutions were made of analytical grade purity chemicals and Milli-Q water. 
PBS was autoclaved.  
 
HEPES Buffer         
HEPES        20 mM 
MgCl2         10  mM 
NaCl     100  mM 
NaOH        ad pH 7.4 
 
Membrane Buffer 
Tris        10  mM 
MgCl2           5 mM 
HCl         ad pH 7.4 
 
Binding Buffer 
Tris        50  mM 
KCl            5 mM 
CaCl2           1 mM 
MgCl2    1 mM 
NaCl     120  mM 
HCl         ad pH 7.4 
 
Wash Buffer 
Tris      50  mM 
NaCl           120 mM 
HCl        ad pH 7.4 
Phosphate-Buffered Saline (PBS) 
NaCl          140 mM 
KCl         3  mM 
Na2HPO4       8 mM 
KH2PO4        1.5 mM 
H3PO4 (8.5%)  ad pH 7.4 
 
GTP-Binding Buffer (GTP Shift) 
NaCl         120 mM  
   (4-fold concentrated) 
Tris           50 mM 
KCl       5  mM 
CaCl2       1  mM 
MgCl2       2  mM 
HCl    ad  pH  7.4 
 
Control Buffer (GTP Shift) 
Tris           50 mM 
KCl       5  mM 
CaCl2       1  mM 
MgCl2       2  mM 
HCl    ad  pH  7.4 
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Bradford Reagent (Aqueous Solution) 
Coomassie® Brilliant Blue G250  0.01% (w/v) 
Ethanol             4.7%  (v/v) 
H3PO4              8.5%  (v/v) 
3.1.5 Radiochemicals and Material for Radioligand Binding Assays 
Betaplate scint (Perkin Elmer Life and Analytical Sciences, Rodgau-Jügesheim, Germany) 
Glass fibre filter; filtermat B (Perkin Elmer Life and Analytical Sciences, Rodgau-
Jügesheim, Germany) 
Polyethylenimine 50% (w/v) aqueous solution (PEI) (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany) 
[Pyridinyl-5-³H]Pyrilamine (SA 28.0 Ci/mmol) = [³H]Mepyramine (Amersham 
Biosciences Europe GmbH, Freiburg, Germany) 
Sample bag (Perkin Elmer Life and Analytical Sciences, Rodgau-Jügesheim, Germany) 
[³H]Spiperone (SA 106.0 Ci/mmol) (Amersham Biosciences Europe GmbH, Freiburg, 
Germany 
3.1.6 Technical Equipment 
Analytical scales sartorius basic (Sartorius AG, Göttingen, Germany) 
Autoclave (Getinge AB, Getinge, Sweden) 
Centrifuge ZK 380 (Hermle Labortechnik GmbH, Wehingen, Germany) 
Dispensette III Variable (Brand GmbH & Co KG, Wertheim, Germany) 
Freezer -20 °C (Liebherr Logistik GmbH, Kirchdorf, Germany) 
Freezer -70 °C (G. Kisker GbR, Steinfurt, Germany) 
Glass-glass hand held homogenizer (hand potter) (Carl Roth GmbH, Karlsruhe, Germany) 
Heater (Ehret GmbH & Co KG, Emmendingen, Germany) 
Heraeus Suprafuge 22 (Heraeus Holding GmbH, Hanau, Germany) 
Hitachi U 2000 Spectrophotometer (Hitachi Europe GmbH, Düsseldorf, Germany) 
Ika-Ultra-Turrax T 25 basic (Janke & Kunkel GmbH & Co KG, Staufen, Germany) 
Incubator Heraeus Instruments (Heraeus Holding GmbH, Hanau, Germany) 
Inotech Cell Harvester (Inotech AG, Dottikon, Switzerland) 
 Materials and Methods    43 
 
Laboratory-dishwasher G 7783 CD Mielabor (Miele & Cie GmbH & Co, Gütersloh, 
Germany) 
Laminar Air Flow Clean Air (Clean Air Deutschland GmbH, Haan/Rheinland, Germany) 
Liquid nitrogen container GT 35 (Air Liquide, Bussysaint George, France) 
Liquid nitrogen container GT 40 (Air Liquide, Bussysaint George, France) 
Magnetic hotplate IKAMAG RCT (Janke & Kunkel GmbH & Co KG, Staufen, Germany) 
Mettler MT 5-scales (Mettler Toledo, Gießen, Germany) 
MicroBeta Trilux (Perkin Elmer Life Sciences GmbH, Rodgau, Germany) 
MicroBeta Workstation ((Perkin Elmer Life Sciences GmbH, Rodgau, Germany) 
Mikroscope Telaval 31 (Karl Zeiss AG, Oberkochen, Germany) 
Multipipette plus (Eppendorf, Hamburg, Germany) 
pH-Meter CG 820 (Schott Geräte GmbH, Mainz, Germany) 
Pipetboy acu (IBS Integra Biosciences AG, Fernwald, Germany) 
Pipette Reference (Eppendorf, Hamburg, Germany) 
Refrigerator (Bosch GmbH, Gerlingen, Germany) 
Shaker GFL 1083 (GFL mbH, Burgwedel, Germany) 
Sonication Bandelin Sonopul HD 200 (Bandelin electronic GmbH & Co KG, Berlin) 
Varioclave Steam Sterilizator (H + P Labortechnik GmbH, Oberschleißheim, Germany) 
Vortexer Genie 2 (Scientific Industries, Bohemia, USA) 
Vortexer VF 2 (Janke & Kunkel GmbH & Co KG, Staufen, Germany) 
Wallac 1295-012 Heat Sealer (Perkin Elmer Life Sciences GmbH, Rodgau, Germany) 
3.2 Methods 
3.2.1 Cell culture 
CHO-Cells Expressing Human Dopamine D2S and D3 Receptors 
CHO-K1 cells, expressing the recombinant human dopamine D2(short) receptor gene, were 
grown in Dulbecco’s Modified Eagle’s Medium/F12 (1:1) supplemented with 10% 
inactivated fetal bovine serum, 100 I.U./mL penicillin G, 100 µg/mL streptomycin and 2 
mM glutamine in an atmosphere of 5% CO2 at 37 °C.
179 Human D3 receptors stably 
expressed in CHO cells were cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% dialyzed fetal bovine serum, 2 mM glutamine and were grown in 
an atmosphere of 5% CO2 at 37 °C in monolayer culture.
33 For cell culture 1 mL stocks 
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were quickly thawed in hands or in a 37 °C water bath, suspended in 10 mL cold medium 
and centrifuged at 800 rpm for 5 min at 4 °C. The cells were suspended in 10 mL growth 
medium in a 75 cm
2 cell culture flask. Cell passage was done at cell confluence three times 
a week, pointing out that CHO-D3 cells need more time for growing compared to CHO-D2s 
expressing cells. The whole medium was removed; cells were carefully washed with 5 mL 
37 °C warmed phosphate-buffered saline (PBS), loosened with 1 mL trypsin/EDTA and 
resuspended in fresh 37 °C warmed medium. Depending on cell density the splitting ratio 
was 1:4 to 1:5. Stock aliquots were obtained by washing the cells with 5 mL PBS, 
removing cells from cell culture flask with 1 mL trypsin/EDTA, inactivating trypsin with 4 
mL medium and additionally the cells were collected by centrifugation (800 rpm, 4 °C, 15 
min). The cells were resuspended in growth medium supplemented with 10% 
dimethylsulfoxide (DMSO) and slowly frozen to -70 °C before stored in liquid nitrogen. 
Two 1mL aliquots were obtained by one 75 cm
2 cell culture flask.  
CHO-Cells Expressing Human Histamine H1 Receptors 
CHO-K1 cells, stably expressing the recombinant human histamine H1 receptor gene, were 
grown in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine 
serum, 2 mM glutamine, 100 I.U./mL penicillin G, 100 µg/mL streptomycin and 0.1 mM 
non-essential amino acids in an atmosphere of 5% CO2 at 37 °C in monolayer culture. 1 
mL of stock was thawed in hands, suspended in 10 mL cold medium and centrifuged at 
800 rpm for 5 min at 4 °C. The cells were suspended in 10 mL cold medium and added 
into 20 mL of warmed growth medium in a 150 cm
2 cell culture flask. Cells were passaged 
three times a week and therefore the medium was removed, cells were washed with 15 mL 
37 °C PBS, 3 mL trypsin/EDTA were added to remove cells and they were resuspended in 
fresh medium. Due to fast growing splitting ratios of cells were 1:4 to 1:8. For preparing 
stock aliquots, cells were rinsed with PBS, trypsinized and centrifuged at 800 rpm for 15 
min at 4 °C. Consequently, the cells were resuspended in growth medium supplied with 
10% DMSO and stored at -70 °C before putting the aliquots in liquid nitrogen. Three stock 
aliquots were obtained from one 150 cm
2 cell culture flask.  
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3.2.2 Preparation of Membrane Homogenates 
Membrane Preparations of CHO-Cells Expressing Human Dopamine D2S and 
D3 Receptors 
Preparation of membrane homogenates were carried out 2-3 passages after thawing, and 
human dopamine D2S and D3 receptor expressing cell lines were grown to confluence (80 – 
100%). The medium was disposed and the cells were washed with 10 mL ice-cold PBS 
buffer. The cells were scraped from the flasks into 15 mL ice-cold medium and centrifuged 
at 3,000 rpm for 10 min at 4 °C. After centrifugation the medium was removed and the cell 
membranes resuspended in 10 mL ice-cold membrane buffer, disrupted with an Ultra-
Turax (setting 1.5, twice for 10 seconds-exposure), filled up with membrane buffer to 25 
ml volume, and finally membranes were pelleted at 20,000 rpm for 30 min at 4 °C. The 
pellets were rehomogenized in ice-cold membrane buffer (hD3: 250 µL/75 cm
2 flask, hD2S: 
125 µL/75 cm
2 flask) by ultrasonic waves (duty cycle constant, 8 - 10 seconds) and 
membrane aliquots were stored at -70 °C. During the time of storage no change of binding 
parameters could be detected. Determination of membrane protein was carried out by the 
method of Bradford.
180 
Membrane Preparations of CHO-Cells Expressing Human Histamine H1 
Receptors 
After thawing CHO-K1 cells expressing histamine H1 receptors, four passages were carried 
out before membrane homogenates were prepared. At confluence of 80 – 100%, the cells 
were rinsed with 10 mL ice-cold PBS buffer, scraped into ice-cold HEPES binding buffer 
and homogenized three times with ultrasonic waves for 15 seconds (duty cycle constant, 8 
- 10 seconds). Membranes were pelleted at 20,000 rpm for 30 min at 4 °C and resuspended 
in HEPES buffer (hH1: 200 µL/75 cm
2 flask) using a hand potter. Aliquots were stored in 
liquid nitrogen. No change in binding parameters appeared during storage. The method of 
Bradford was used for protein determination.
180 
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Protein Assay 
The protein concentration of the membrane preparation was determined with Coomassie 
Blue G 25 reagent and bovine serum albumin (0.5 mg/mL) diluted in membrane buffer as 
the standard, according to the method of Bradford
180. The absorptions of the standard 
preparation and membrane preparation were determined at 595 nm in a spectrophotometer, 
using a blank as zero. The standard curve and unknown protein concentration were 
analyzed by linear-regression curve-fitting procedures using GraphPad Prism
TM software 
(cf. 3.2.6). 
3.2.3 Radioligand Binding Studies on Human Dopamine D2S and D3 
Receptors 
Radioligand binding assays at dopamine D2S and D3 receptors stably expressed in CHO-K1 
cells were employed according to Sokoloff et al. with few modifications.
61 Assay 
conditions were established to yield the highest signal-to-noise ratio. Assays were carried 
out in triplicates and at least 3 independent experiments using 96-well plates. Test 
compounds were diluted in DMSO to make a 1 or 10 mM stock solution, depending on its 
solubility and were further diluted to the required volume with incubation buffer. BP 897 
was diluted in DMSO to receive a 1 mM stock solution and further dissolved in incubation 
buffer. The radioligand dilution of [³H]spiperone was prepared with incubation buffer. 
Incubations were run at 25 °C for 2 h and terminated by rapid filtration through GF/B glass 
fibre filters, presoaked for 30 min and at 4 °C in 0.3% polyethylenimine solution, using a 
cell harvester. Unbound radioligand was removed with four washes of 300 µL ice-cold 
wash buffer. Filters were dried at 55 °C for 50 – 60 min in the oven and afterwards soaked 
in 9 mL scintillant. Bound radioactivity was counted (5 min/well) in a β-counter at 45% 
counter efficiency.  
Saturation Binding Experiments 
Saturation binding experiments were performed to determine the total number of receptors 
(Bmax) of the membrane preparation and the equilibrium binding dissociation constant (Kd) 
of the radioligand. A constant amount of cell membrane preparation with the subtype 
receptor of interest was incubated with increasing concentrations of radioligand in the 
absence and presence of unlabeled ligand used to define non-specific binding. Assays were 
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carried out by diluting [³H]spiperone to 10 concentrations in the range of 0.01 – 10 nM 
(final concentration). Cell membrane preparations with human dopamine D2S or D3 
receptors were thawed and rehomogenized in incubation buffer using ultrasonic waves 
(duty cycle constant, 10 sec) at 4 °C. The amount of protein was 10 µg/200 µL for 
dopamine D2 receptors and 2 µg/200 µL for D3 receptors. 50 µL of incubation buffer to 
determine total binding or 50 µL 10 µM BP 897 for monitoring non-specific binding, 50 
µL diluted [³H]spiperone and 100 µL cell membrane suspension were incubated. Data 
were analyzed by the software GraphPad Prism
TM (cf. 3.2.6). 
Competition Binding Experiments 
To obtain the inhibition constant Ki of unlabeled test compounds, competition binding 
experiments were investigated. A constant concentration of labeled ligand and seven 
varying concentrations of the unlabeled test compound were incubated with cell membrane 
preparation containing the receptor of interest. Therefore test compound and [³H]spiperone 
were diluted and cell membrane preparations with human dopamine D2s or D3 receptors 
were thawed, rehomogenized in incubation buffer using ultrasonic waves (duty cycle 
constant, 10 sec) at 4 °C. Final membrane protein concentrations of dopamine D2s 
receptors was 10 µg/200 µL and for D3 receptors 2 µg/200 µL. 50 µL of test compound 
dilution or 50 µL of incubation buffer to determine total binding or 50 µL of 10 µM BP 
897 to measure non-specific binding were incubated with 50 µL 0.2 nM [³H]spiperone 
(final concentration) and 100 µL cell membrane suspension. Data were analyzed by the 
software GraphPad Prism
TM (cf. 3.2.6). 
3.2.4 Radioligand Binding Studies on Human Histamine H1 Receptors 
The assay procedure for radioligand binding studies on histamine H1 receptors stably 
expressed in CHO-K1 cells was carried out according to Smit et al. with some alteration, 
considering the best signal-to-noise ratio.
181 The experimental ingredients were added in 
triplicates into 96-well plates and binding data were received by at least 3 independent 
experiments. DMSO was used to prepare a 1 or 10 mM stock of test compound, which was 
further diluted in HEPES buffer. (R/S)-Chlorpheniramine maleate and the radioligand 
[³H]mepyramine were diluted in HEPES buffer. Incubations were run at 25 °C for 2 h and 
terminated by rapid filtration through GF/B glass fibre filters, presoaked for 30 min at 4 °C 
in 0.3% polyethylenimine solution, using a cell harvester. Unbound radioligand was 
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removed with four washes of 300 µL ice-cold HEPES buffer. Before the filters were 
soaked in 9 mL scintillant, they were dried at 55 °C for 50 – 60 min in the oven. Bound 
radioactivity was counted for 5 min per well in a β-counter at 45% counter efficiency. 
Saturation Binding Experiments 
General procedures and considerations have been described above.  
A serial dilution of 10 concentrations in the range 0.05 – 50 nM (final concentration) of 
[³H]mepyramine were prepared and cell membrane preparations with human histamine H1 
receptors were thawed and rehomogenized in HEPES buffer using ultrasonic waves (duty 
cycle constant, 10 sec) at 4 °C. The amount of protein was 30 µg/200 µL for histamine H1 
receptors. 50 µL HEPES buffer to monitor total binding or 50 µL of 10 µM (R/S)-
Chlorpheniramine maleate for non-specific binding, 50 µL diluted radioligand 
[³H]mepyramine and 100 µL cell membrane suspension were mixed. Data were analyzed 
by the software GraphPad Prism
TM (cf. 3.2.6). 
Competition Binding Experiments 
General procedures and considerations have been described above. Cell membrane 
preparations with human histamine H1 receptors were thawed and rehomogenized in 
HEPES buffer using ultrasonic waves (duty cycle constant, 10 sec) at 4 °C (protein 
concentration: 30 µg/200 µL). 50 µl of 1.0 nM [³H]mepyramine (final concentration), 50 
µL of test compound dilution or 50 µL of HEPES buffer to determine total binding or 50 
µL of 10 µM (R/S)-Chlorpheniramine maleate to define non-specific binding and 100 µL 
cell membrane suspension were incubated to equilibrium. Data were analyzed by the 
software GraphPad Prism
TM (cf. 3.2.6). 
3.2.5 GTP Shift Competition Binding Experiments 
GTP shift competition binding experiments are carried out under similar assay conditions 
to competition binding experiments for dopamine D2S and D3 receptors with few 
modifications (cf. 3.2.3). Assays were carried out in triplicates and at least 3 independent 
experiments using 96-well plates. Frozen cell membrane preparations with human 
dopamine D2S or D3 receptors were thawed, rehomogenized in control buffer (GTP-shift) 
using ultrasonic waves (duty cycle constant, 10 sec) at 4 °C. Final membrane protein 
concentrations of dopamine D2S receptors was 10 µg/200 µL and for D3 receptors 2 µg/200 
 Materials and Methods    49 
 
µL. Test compound and [³H]spiperone were diluted in control buffer (GTP-shift) (final 
concentration 0.2 nM). Either 50 µL of test compound dilution or 50 µL of control buffer 
(GTP-shift) to determine total binding or 50 µL of 10 µM BP897 in control buffer (GTP-
shift) to measure non-specific binding were applied. In the next step, 50 µL GTP-binding 
buffer, 50 µL control buffer (GTP-shift) or 50 µL 100 µM Gpp(NH)p in GTP-binding 
buffer were added to the microtiter plate, respectively. Finally, 50 µL 0.2 nM 
[³H]spiperone (final concentration) and 50 µL cell membrane suspension were applied. 
Samples were incubated at 25 °C for 2 h and terminated by rapid filtration through GF/B 
glass fibre filters, presoaked for 30 min and at 4 °C in 0.3% polyethylenimine solution, 
using a cell harvester. Unbound radioligand was removed with four washes of 300 µL ice-
cold wash buffer. Filters were dried at 55 °C for 50 – 60 min in the oven and afterwards 
soaked in 9 mL scintillant. Bound radioactivity was counted (5 min/well) in a β-counter at 
45% counter efficiency. Data were analyzed by the software GraphPad Prism
TM (cf. 3.2.6). 
3.2.6 Data Analysis and Statistics 
Data were analyzed by the software GraphPad Prism
TM (GraphPad Software Inc., 2000, 
version 3.02, San Diego, CA, USA). Binding experiments were calculated using non-linear 
least squares fit. Specific binding was analyzed by subtracting the non-specific binding 
from the measured total binding for each data point. 
Saturation Binding Experiments 
One-site binding model 
Data from saturation studies were fitted to the equation 3.1 to determine the equilibrium 
dissociation constant (Kd) of the radioligand and the total amount of binding sites (Bmax) 
[cpm]. Kd is a constant that is equal to the concentration of radioligand at which half of the 
total number of receptors are occupied, 
 
) (
max
x K
x B
y
d +
⋅
=                          ( 3.1) 
 
y is the amount of specific binding [cpm] and x is the concentration of radioligand [nM]. 
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To calculate the concentration values [nM] from determined cpm data, equation 3.2 was 
used: 
 
concentration [nM] 
SA V
e cpm
⋅ ⋅
⋅
=
2200
,                  ( 3.2) 
 
e is the counting efficacy factor (2.222), V is the assay volume, SA is the specific activity 
of the radioligand [Ci/mmol]. 
 
For displaying data, saturation experiments were transformed to create a Scatchard plot. 
Bound/free ligand was plotted versus specific binding [cpm] before linear regression was 
conducted.  
Two-site binding model 
Data from saturation binding experiments were fitted to the equation 3.3 using a two-site 
binding model.  
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Fitting data calculated by equations 3.1 and 3.3 were compared with an F-test. 
Competition Binding Experiments 
One-site binding model 
Data from competition binding experiments were fitted to the equation 3.4 to calculate Hill 
coefficient (nH). 
 
H n x IC
B
y ⋅ − +
= ) (log
0
50 10 1
                       ( 3.4) 
 
Data were fitted to equation 3.5 to calculate the IC50 value of the competing compound.  
 
50 log
0
10 1
IC x
B
y − +
=                        (3.5) 
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y is the specific binding of radioligand, x is the logarithm of the competitor concentration. 
B0 is the amount of specific radioligand binding in a single experiment in the absence of 
competitor (or its concentration is infinitesimal).  
 
To obtain the inhibition constant (Ki) of the competing ligand from the determined IC50 
value, which is the concentration of unlabeled competitor displacing 50% of the 
specifically bound radioligand, the Cheng-Prusoff equation
182 3.6 was applied. Ki value is 
equal to its equilibrium dissociation binding constant and defines its affinity. 
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=                         (3.6) 
 
where L is the radioligand concentration, Kd is the equilibrium dissociation constant of the 
radioligand. 
Two-site binding model 
If the obtained Hill coefficient was significantly different from unity the competition 
curves were reanalyzed and fitted to a two-site binding model of high- and low-affinity 
binding. The equation 3.7 describes the competition of a competing ligand for two binding 
sites with different affinities while the radioligand has identical affinity for both sites. 
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fraction 1 is the fraction of the receptors that have an affinity described by logIC50_1, while 
the remaining receptors have an affinity described by logIC50_2. If logIC50_1 is smaller than 
logIC50_2, then fraction_1 is the fraction of high affinity sites.  
 
For comparing non-linear regression fits for one- and two-site binding models, data were 
calculated by equations 3.5 and 3.7 and compared with an F-test (equation 3.8).  
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where SS is the residual sum of the squares, df are the degrees of freedom (1 = one-site 
model, 2 = two-site model).The two-site model is assumed to be a better fit than the one-
site model if the F value has a  P < 0.05. 
GTP Shift 
The comparison of the non-linear regression fits was performed according to Graeser and 
Neubig.
183 One- and two-site binding models of control data (c) and Gpp(NH)p treated 
data (e) were calculated by equations 3.5 and 3.7 and each set of data was compared by 
applying F-test statistics (equation 3.8).  
 
) /(
) /( ) (
2 2
2 1 2 1
df SS
df df SS SS
F
− −
=                    ( 3.8) 
 
SS is the residual sum of the squares, df is the degrees of freedom (1 = one-site model, 2 = 
two-site model). The two-site model is assumed to give a better fit than the one-site model 
if the F value has a P < 0.05. In competition binding that was fitted best by a two-site 
binding model, inhibition constants for the higher (KH) and lower (KL) affinity site and the 
% higher affinity sites (RH) were obtained.  
A third data set was created by combing control data (c) and Gpp(NH)p treated data (e) 
and were analyzed by the one-site binding model (3.5) to generate SSce and dfce. Statistical 
significance of differences between c and e was determined by calculating the F-test (P < 
0.05) from equation (3.9). 
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SSc and SSe represent the residual sum of the squares of c and e, respectively, dfc and dfe are 
the degrees of freedom of c and e, respectively. 
Statistics 
Unless it is stated otherwise, data are presented as means with standard deviation (±SD) of 
at least three independent experiments carried out in triplicates. Statistical significance was 
assessed using Student’s t-test with P < 0.05.  
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3.2.7 Virtual Screening Methods 
Virtual Screening methods were performed by the working group of Professor Gisbert 
Schneider, Johann Wolfgang Goethe-University, Department of Biochemistry, Chemistry 
and Pharmaceutical Sciences, Frankfurt/Main.  
Software program packages 
MOE (Version 2005, Molecular Operating Environment, Chemical Computing Group Ltd., 
Montreal, Canada), 
CORINA (Molecular Networks GmbH, Erlangen, Germany), 
GOLD (Version 2.2, The Cambridge Crystallographic Data Centre, Cambridge, UK), 
SIMCA-P+ 10.5 (Umetrics, Umea, Sweden), 
LIBSVM (Version 2.5, http://www.csie.ntu.edu.tw/~cjlin/libsvm),
184 
PyMOL (Version 0.99, DeLano Scientific LLC., Palo Alto, USA). 
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4 Results and Discussion 
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4.1 Assay Validation 
The principle method for the determination of ligand binding affinity is the competition 
radioligand binding assay. To obtain accurate estimates of the equilibrium dissociation 
constant  Kd of the radioligand in saturation binding experiments and of the inhibition 
constant Ki for the test ligand in competition binding experiments, a subsequent validation 
of the assay system was of absolute necessity. For setting up a new binding assay general 
considerations were investigated and best assay conditions were established by carrying 
out a series of preliminary experiments to provide the best signal-to-noise ratio.
185 To 
validate the binding assay, ligand binding has to confirm the law of mass action.
186 Due to 
a finite number of receptors in the tissue, specific binding has to be saturable with 
increasing radioligand concentrations. Non-specific binding continues to increase as a 
function of radioligand, however displays minimal non-specific binding (< 20% of the total 
binding), consequently increasing the precision of the assay by an escalating signal-to 
noise ratio. Radioligand binding has to be reversible, consistent with its physiological 
mechanism. It is recommended that the used radioligand concentration should be in the 
range of the radioligand Kd, but in order to avoid depletion, less than 10% of the added 
radioligand is allowed to bound to the receptors.
185,186 Parameters within the assay such as 
buffer composition, incubation temperature, pH value, tissue preparation and ionic strength 
were carefully chosen (cf. 3.2). Initial binding experiments regarding the incubation time, 
tissue preparation, amount of protein and cell-harvesting with varying rinses were 
investigated on a trial-and error basis to increase the precision of the assay. Incubation time 
is important to allow competitor and radioligand to attain equilibrium. At equilibrium the 
rate of association and dissociation of the ligand-receptor complex are equal, leading to a 
constant concentration of the ligand-receptor complex. Kinetic binding experiments have 
not been performed due to previous characterizations of the receptor subtypes and 
radioligands by other groups in related studies.
33,181,187 Suitable incubation times (cf. 3.2) 
have been adapted according to literature protocols.
125,181,186,188 
4.1.1 Saturation Binding Experiments 
In order to determine the equilibrium binding dissociation constant Kd of the radioligand 
and the total number of specific binding sites Bmax of the membrane preparation with the 
receptor of interest, saturation binding experiments were performed. A constant amount of 
cell membrane preparation, containing either dopamine hD2S, hD3 (cf. 3.2.3) or histamine 
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hH1 receptors (cf. 3.2.4), was incubated with increasing concentrations of radioligand until 
virtually all of the receptors were occupied. At each radioligand concentration the total 
binding and non-specific binding were defined in the absence and presence of an unlabeled 
ligand, respectively. The specific binding is the total binding minus the non-specific 
binding. Figures 4.1 - 4.3 show total, specific and non-specific binding determined in 
saturation binding experiments.  
Dopamine hD2S and hD3 Receptors 
Representative saturation binding isotherms and Scatchard plots of [³H]spiperone at 
dopamine hD2S and hD3 receptors stably expressed in CHO-cells were analyzed (cf. 3.2.6) 
and are shown in Figures 4.1 and 4.2. In the experiments BP 897 was used in a 
concentration of 10 µM for dopamine hD2S receptors (Figure 4.1), while either 10 µM BP 
897 (Figure 4.2A) or 10 µM haloperidol (Figure 4.2B) was investigated for hD3 receptors 
to achieve non-specific binding.  
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Figure 4.1 Saturation binding isotherms and Scatchard plot of [³H]spiperone at dopamine hD2S 
receptors. Non-specific binding was determined with 10 µM BP 897.  
 
In all saturation binding experiments specific binding of [³H]spiperone calculated for 
dopamine hD2S and hD3 was saturable as the concentration of the radioligand increased and 
consistent with a one-site binding model. Non-specific binding was not saturated with 
radioligand and therefore it was linear within increasing concentrations of radioligand. 
Non-specific binding was negligible (< 20% of the total binding) and confirmed the 
precision of the assay. Scatchard analysis of the specific [³H]spiperone binding at both 
receptor subtypes resulted in linear plots consistent with a single class of binding sites 
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without any co-operativity. Equilibrium dissociation constants Kd and the total number of 
specific binding sites Bmax values of [³H]spiperone binding to CHO-cell membranes stably 
expressing dopamine hD2S or hD3 obtained are presented in Table 4.1.  
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Figure 4.2 Saturation binding isotherms and Scatchard plot of [³H]spiperone at dopamine hD3 
receptors. A Non-specific binding was determined with 10 µM BP 897. B Non-specific binding 
was determined with 10 µM haloperidol.  
 
Table 4.1 Equilibrium dissociation constants and total number of specific binding sites derived 
from [³H]spiperone saturation binding experiments.  
Receptor Non-specific  binding  Kd [nM]  Bmax [fmol/µg] 
hD2S  10 µM BP897  0.11 ± 0.01  0.41 ± 0.02 
hD3  10 µM BP897  0.22 ± 0.02  4.53 ± 0.22 
hD3  10 µM haloperidol  0.22 ± 0.02  3.77 ± 0.19 
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The estimated Kd values are in good agreement with results previously described for 
dopamine hD2S (Kd = 0.10 nM)
189 or hD3 receptors (Kd = 0.26 nM)
189 expressed in CHO-
cells. In transfected cell lines, including CHO-cells, Kd values for [³H]spiperone are 
reported as 0.04 to 0.15 nM at dopamine D2S receptors,
10,190,187,191 and 0.2 to 0.5 nM at 
dopamine D3 receptors.
189 Highest concentrations of binding sites were determined for 
membranes containing the dopamine hD3 receptor subtype, while lower concentrations 
were revealed for dopamine hD2S receptors.
192 The density of sites and specific binding 
varies within CHO-cell lines.
186 Although there was no difference between the Kd values of 
dopamine hD3 determined with 10 µM BP 897 and 10 µM haloperidol, the Bmax was 
significantly lower (P < 0.05, unpaired t-test) using 10 µM haloperidol. A possible 
explanation might be that haloperidol is an inverse agonist
193,194 on dopamine D2-like 
receptors while BP 897 behaves as a partial dopamine D3 receptor agonist and stabilizes 
different conformational states of the receptor. Due to the close structural similarity of the 
butyrophenone derivatives haloperidol and [³H]spiperone, BP 897 was chosen to determine 
non-specific binding for further assay development in order to avoid isotope dilution.
186 
The non-specific binding of a radioligand is assessed in the presence of a high 
concentration of an unlabeled ligand, which is recommended to be chemically different 
from the radioligand, polar and affine, and adequate to prevent radioligand binding to its 
target site. The data received from saturation binding experiments confirmed a well 
established assay system for further determination of binding affinity constants of novel 
compounds in competition binding assays. 
Histamine H1 Receptors 
Saturation binding isotherms and Scatchard plots of [³H]mepyramine at histamine H1 
receptors stably expressed in CHO-cells were analyzed (3.2.6) and are demonstrated in 
Figure 4.3. 10 µM chlorpheniramine was investigated for hH1 receptors to achieve non-
specific binding. The binding of [³H]mepyramine at the human H1 receptor expressed in 
CHO-cells was specific and saturable at higher concentration of radioligand. Non-specific 
binding increased with rising concentrations of radioligand and were less than 20% of total 
binding in the concentration range of interest. Scatchard transformation of the 
[³H]mepyramine saturation isotherm resulted in a linear plot and displayed that the binding 
was to single class of binding sites without any co-operativity. The estimated Kd value (cf. 
3.2.6) is in good agreement with the Kd data of 1.2 nM previously described by Anthes et 
al. for histamine hH1 receptors in CHO-cells (Table 4.2).
181,195  
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Figure 4.3 Saturation binding isotherms and Scatchard plot of [³H]mepyramine to histamine hH1 
receptors.  
 
 
Table 4.2 Equilibrium dissociation constant and total number of specific binding sites derived from 
[³H]mepyramine saturation binding experiments.  
Receptor  Non-specific binding   Kd [nM]  Bmax [fmol/µg] 
hH1  10 µM chlorpheniramine  1.28 ± 0.06  1.87 ± 0.36  
 
4.1.2 Competition Binding Experiments 
In order to validate competition binding assays a variety of well characterized reference 
drugs with antagonist properties at dopamine hD2S, hD3 (cf. 3.2.3) or histamine hH1 
receptors (cf. 3.2.4) were tested. Increasing concentrations of unlabeled ligand competed 
for the receptor with a constant concentration of radioligand. The concentration of 
competitor which inhibits 50% of specific binding, the IC50, and the slope of the inhibition 
curve, the Hill slope nH, have been estimated to determine the dissociation constant of the 
competitor, Ki (cf. 3.2.6). It is of importance that the non-specific binding is less than 20% 
of the total binding at the radioligand concentration equivalent to its Kd. The selection of 
reference compounds considered an affinity range of at least three orders of magnitude to 
give variations in selectivity profile. The obtained inhibition constants (Ki) of unlabeled 
test compounds were compaired to literature data.  
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Dopamine hD2S and hD3 Receptors 
For validation of the competition radioligand binding assay with [³H]spiperone at 
dopamine hD2S and hD3 receptors, reference compounds with antagonist properties at 
dopamine D2-like receptors were assessed. Representative competition binding curves are 
shown in Figures 4.4 and 4.5 for dopamine hD2S and hD3 receptors, respectively. Data are 
presented as a percentage of maximal specific binding. The determined inhibition constants 
Ki (cf. 3.2.6) of reference substances investigated for assay validation at dopamine hD2S 
and hD3 receptors are presented in Table 4.3. 
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Figure 4.4 Competition curves of reference drugs at [³H]spiperone binding sites for hD2S receptors. 
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Figure 4.5 Competition curves of reference drugs at [³H]spiperone binding sites for hD3 receptors. 
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Competition between the radioligand [³H]spiperone and inhibitor was consistent with the 
law of mass action and has demonstrated constantly a one-site binding model for dopamine 
hD2S and hD3 receptors (cf. 3.2.6). The Hill coefficients were mostly not significantly 
different from unity, otherwise it has been mentioned. The non-specific binding was less 
than 20% of the total binding and in addition, less than 10% of the added radioligand was 
depleted by the receptor. The determined Ki values of tested reference drugs were 
consistent with results performed by other groups (reference data: BP 897: Ki (D2) = 61 
nM, Ki (D3) = 0.92 nM;
140,61 haloperidol: Ki (D2) = 2.4 nM, Ki (D3) = 4.8 nM;
10 (S)-(-)-
nafadotride: Ki (D2) = 3 nM;
138 (S)-(-)-raclopride: Ki (D2) = 2.9 nM, Ki (D3) = 3.5 nM;
196 
spiperone: Ki (D2) = 0.25 nM, Ki (D3) = 0.61 nM;
10 ST 198: Ki (D2) = 780 nM, Ki (D3) = 12 
nM;
83 U 99194A: Ki (D2) = 2280 nM, Ki (D3) = 223 nM
104).  
Spiperone/[³H]spiperone competition binding experiments using dopamine hD2S and hD3 
receptors yielded spiperone dissociation constants (Ki) higher than Kd values of 
[³H]spiperone assessed in saturation binding experiments. These results are in agreement 
with literature data, indicating that the Ki value of a compound deviates with the affinity of 
its radiolabeled complement.
188 In summary, the binding assays provided a good signal-to-
noise ratio and determined data were reproducible and reliable.  
 
Table 4.3 Inhibition constants Ki and Hill coefficients (in parentheses) of determined dopamine 
reference compounds.  
Compound  Ki [nM] hD2S  Ki [nM] hD3 
BP 897      52 ± 11.7 (1.12 ± 0.30)  0.91 ± 0.23 (0.98 ± 0.28) 
Haloperidol   2.26 ± 0.30 (0.95 ± 0.05)  4.65 ± 0.22 (1.04 ± 0.15) 
(S)-(-)-Nafadotride   6.46 ± 0.21 (1.03 ± 0.05)  n.d.
a 
(S)-(-)-Raclopride   4.51 ± 0.11 (1.07 ± 0.12)  2.50 ± 0.87 (0.85 ± 0.14) 
Spiperone   0.27 ± 0.01 (0.99 ± 0.15)  0.68 ± 0.07 (1.02 ± 0.22) 
ST 198  1272 ± 99 (0.95 ± 0.11)  8.72 ± 0.21 (0.76 ± 0.11) 
U 99194A  3852 ± 672 (0.84 ± 0.16)   314 ± 92 (0.82 ± 0.06) 
an.d., not determined. 
Histamine H1 Receptors 
For the evaluation of the radioligand competition binding assay at histamine H1 receptors 
(cf. 3.2.4), a variety of reference histamine H1 receptor antagonists, first and second 
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generation of antihistamines, has been tested for competition binding with 
[³H]mepyramine. A selection of representative competition binding curves for histamine 
H1 receptors is shown in Figure 4.6.  
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Figure 4.6 Competition curves of reference drugs at [³H]mepyramine binding for hH1 receptors. 
 
Data are presented as a percentage of maximal specific binding. The determined inhibition 
constants (Ki) of reference drugs were analyzed (cf. 3.2.6) and are summarized in Table 
4.4.  
 
Table 4.4 Inhibition constants Ki and Hill coefficients (in parentheses) of determined histamine 
reference compounds. 
Compound  Ki [nM] hH1 
Bamipine     12 ± 0.9 (1.16 ± 0.51) 
Cetirizine     28 ± 7.0 (0.79 ± 0.18) 
Chlorpheniramine     17 ± 2.56 (1.00 ± 0.19) 
Diphenhydramine     35 ± 1.6 (0.86 ± 0.07) 
Fexofenadine     34 ± 2.0 (0.86 ± 0.12) 
Ketotifen  0.34 ± 0.07 (1.05 ± 0.13) 
Loratadine   130 ± 54 (1.00 ± 0.06) 
Mepyramine  1.75 ± 0.12 (0.79 ± 0.02) 
Mianserin  0.84 ± 0.26 (1.18 ± 0.12) 
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The compounds behaved as competitive inhibitors of [³H]mepyramine binding and 
competition binding curves were consistent with the law of mass action and indicated a 
one-site binding model due to the Hill coefficients, not significantly different from unity 
(cf. 3.2.6). The non-specific binding was less than 20% of the total binding. Less than 10% 
of the added radioligand was depleted by the receptor. The determined Ki values of tested 
reference drugs were consistent with results performed by other groups (reference data: 
bamipine: no reference Ki data are available at cloned histamine hH1 receptors; cetirizine: 
Ki (H1) = 30 nM; chlorpheniramine: Ki (H1) = 14 nM;. diphenhydramine: Ki (H1) = 45 nM; 
fexofenadine: Ki (H1) = 52 nM; ketotifen: Ki (H1) = 0.14 nM; mepyramine: Ki (H1) = 1.7 
nM; mianserin: Ki (H1) = 0.85 nM; loratadine: Ki (H1) = 138 nM).
149,195,197 As already 
observed for [³H]spiperone and spiperone in competition binding experiments at dopamine 
hD2S and hD3  receptors, the Ki value for mepyramine is higher than the Kd data of 
[³H]mepyramine. Conclusively, the assessed data were reproducible, reliable and in good 
agreement with literature data, providing precise assay conditions.
149,181,195 
4.1.3 GTP Shift Assay for Discriminating Agonists 
Agonist binding is in general more complex than antagonist binding to G protein-coupled 
receptors. This different binding behavior allows distinguishing agonists from antagonists 
in simple radioligand competition binding studies. The use of disrupted cell membrane 
preparations in low ionic strength media containing magnesium and lack of sodium forms 
a high-affinity agonist/receptor/G protein ternary complex.
198 Under these assay 
conditions, binding curves of agonists demonstrate a shallow shape, appear multiphasic 
and are analyzed according to a multiple, independent-site model. At least two apparent 
affinity states are determined; described KH (high affinity) and KL (low affinity). This 
agonist-induced isomerisation is also recognized for dopamine receptors. The high affinity 
ternary complex is effectively modulated by guanine nucleotides such as guanosine-5’-
triphosphate (GTP) (Chart 4.1). In the presence of GTP the high-affinity binding state of 
the receptor is eliminated, and results in a rightward shift of the competition curve, the so-
called “GTP shift”, and a monophasic binding curve, mostly with steepening of the 
shallow Hill slope to unity. It represents the lower affinity of the bimolecular agonist-
receptor complex (KiGTP), but it is noteworthy that the KL is not equivalent to KiGTP (Figure 
4.7).
185 
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In this study the effect of the nonhydrolysable GTP analogue 5’-guanylyl-imidodi-
phosphate [Gpp(NH)p] (Chart 4.1) on ligand binding to dopamine D2S and D3 receptors 
has been investigated.  
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Chart 4.1 Structures of Gpp(NH)p and GTP. 
 
It was of great interest to examine whether there are high and low affinity states for both 
receptor subtypes in the presence of an agonist, antagonist and partial agonist, and whether 
there is an alteration in affinity binding of ligands induced by added Gpp(NH)p resulting in 
a GTP shift at dopamine D2S and D3 receptors. For a more detailed discussion of the GTP 
shift see Figure 4.16. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Scheme of the GTP shift. 
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Radioligand competition binding studies were performed using [³H]spiperone and selected 
ligands were assessed under different assay conditions as described by Mierau et al.
135 
According to literature, the binding of [³H]spiperone has not been effected by the addition 
of Gpp(NH)p or sodium ions.
199 
100 µM Gpp(NH)p and 120 mM NaCl were applied to observe the effect on affinity 
binding in order to produce a GTP shift (cf. 3.2.5). These concentrations have been used on 
regular basis by other groups in related studies, and produced maximal response and 
ensured complete conversion of higher affinity sites to lower affinity sites.
199 For 
dopamine D2S and D3 receptor agonist binding pramipexole (cf. 1.2.6) and its seleno 
analogue compound 54 (2-amino-6-(ethylamino)-4,5,6,7-tetrahydrobenzo[1.3]selenazole) 
(cf. 4.2.3) were selected. The methoxyphenylpiperazine derivative BP 897 was chosen as a 
partial agonist at dopamine D3 and antagonist at dopamine D2 and 1,2,3,4-
tetrahydroisoquinoline compound ST 198 represented the antagonist at dopamine D2 and 
D3 receptors (cf. 1.2.6). 
In the absence of Gpp(NH)p, competition binding experiments for pramipexole and 
compound 54 at dopamine D2S receptors were best described by a two-site binding model 
(F-test, P < 0.001) (cf. 3.2.6) and the affinities of higher and lower affinity sites (KH and 
KL) and their proportion (RH) were derived (Figures 4.8 and 4.10). In the presence of 100 
µM Gpp(NH)p competition curves were best described by a one-site binding model (F-
test, P < 0.05) and Ki Gpp(NH)p was assessed (cf. 3.2.6) as illustrated in Figures 4.8 and 
4.10. 
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KH [nM]  %RH  KL [nM]  n  Ki Gpp(NH)p [nM]  n 
hD2S  3.07 ± 0.83  23 ±7  348 ± 143  3  4989 ± 865 
(0.80 ± 0.12) 
4 
Figure 4.8 Pramipexole binding at dopamine D2S receptors (Hill coefficients in parentheses).  
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Kcontrol [nM]  n  Ki Gpp(NH)p [nM]  n 
hD3   1.19 ± 0.06  
(0.72 ± 0.21)  3       12 ± 3.0  
(0.94 ± 0.20)  4 
Figure 4.9 Pramipexole binding at dopamine D3 receptors (Hill coefficients in parentheses). 
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Figure 4.10 Compound 54 binding at dopamine D2S receptors (Hill coefficients in parentheses).  
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Ki control [nM] n  Ki Gpp(NH)p [nM]  n 
hD3   3.18 ± 0.72  
(0.78 ± 0.17)  3      19 ± 3.6  
(0.89 ± 0.22)  3 
Figure 4.11 Compound 54 binding at dopamine D3 receptors (Hill coefficients in parentheses).  
 
The affinity of the lower affinity site (KL) assessed in the absence of Gpp(NH)p compared 
to the single site observed in the presence of Gpp(NH)p (Ki Gpp(NH)p) were not similar 
for pramipexole and also for compound 54. This observation has already been reported for 
pramipexole.
135 The percentage of the high-affinity binding site (RH) for pramipexole and 
compound 54 was 23 ± 7%, and 33 ± 5%, respectively. In the case of binding at dopamine 
D3 receptors, the competition curves in the absence and presence of Gpp(NH)p were best 
described by a one-site binding model for both ligands (F-test, P < 0.05) as demonstrated 
in Figures 4.9 and 4.11. There was a significant decrease in affinity binding and 
consequently an observed GTP shift for pramipexole and compound 54 in the presence of 
the guanine nucleotide analogue (F-test,  P < 0.05). The studies have shown that 
pramipexole has a preference for binding to human D3 receptors over the D2S receptor.
135 
By comparing data received from the high affinity state (KH) at dopamine D2S with the Ki 
control value in the absence of Gpp(NH)p at dopamine D3 for compound 54, similar 
dissociation constants were assessed displaying neither preference for one of the receptor 
subtypes.  
Competition binding curves for the partial agonist BP 897 at dopamine D3 and antagonist 
at D2S receptors were best described by a one-site binding model (cf. 3.2.6) in the absence 
and presence of Gpp(NH)p (F-test, P < 0.05) and were characterized by Hill slopes not 
significantly different from unity (Figures 4.12 and 4.13). Binding data at dopamine D2S 
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receptors demonstrated no significant difference between the absence and presence of 
Gpp(NH)p, but an increase in affinity binding of BP 897 in the presence of guanine 
nucleotide at dopamine D3 receptors (F-test, P < 0.05). 
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Ki control [nM] n  Ki Gpp(NH)p [nM]  n 
hD2S       79 ± 0.5  
(1.18 ± 0.27)  3       53 ± 2.2 
(1.30 ± 0.20)  3 
Figure 4.12 BP 897 binding at dopamine D2S receptors (Hill coefficients in parentheses).  
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Ki control [nM] n  Ki Gpp(NH)p [nM]  n 
hD3    1.74 ± 0.16  
(0.80 ± 0.21)  3   0.76 ± 0.12  
(1.10 ± 0.03)  3 
Figure 4.13 BP 897 binding at dopamine D3 receptors (Hill coefficients in parentheses).  
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For the antagonist ST 198 tested in each dopamine receptor subtype cell line in the absence 
and presence of Gpp(NH)p the competition curves were considered by Hill slopes not 
significantly different from unity and were best fitted by a one-site binding model (cf. 
3.2.6) (F-test,  P < 0.05) as shown in Figures 4.14 and 4.15. There was no difference 
between competition binding curves in the absence and presence of Gpp(NH)p at 
dopamine D2S receptors. However an apparent effect of guanine nucleotide was observed 
for dopamine D3 receptors and it faintly shifted the competition binding curve to the left 
sight and resulted in an improved affinity profile (F-test, P < 0.05).  
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Ki control [nM] n  Ki Gpp(NH)p [nM]  n 
hD2S  1830 ± 142  
(0.84 ± 0.10)  4  1071 ± 143  
(0.86 ± 0.18)  4 
Figure 4.14 ST 198 binding at dopamine D2S receptors (Hill coefficients in parentheses).  
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Ki control [nM] n  Ki Gpp(NH)p [nM]  n 
hD3       55 ± 8.4  
(0.86 ± 0.06)  3   7.67 ± 1.20  
(0.93 ± 0.16)  4 
Figure 4.15 ST 198 binding at dopamine D3 receptors (Hill coefficients in parentheses).  
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The model of the ternary complex and its extension allow to illustrate a GTP shift.
198 In the 
ternary complex model (Figure 4.16A) the receptor (R) can bind simultaneously an agonist 
(A) and a G protein (G) to form a ternary complex (ARG).  
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Figure 4.16 A The ternary complex. A represents the agonist ligand with an affinity of KA, G 
represents a G protein with an affinity of KG for the receptor, and α is a co-operativity factor 
reflecting the change in affinity of agonist ligand or G protein when the receptor is occupied by the 
other ligand (adapted from Lazareno and Birdsall).
200 B Extended ternary complex. Proportions of 
ground state (R) and active state (R*) are determined by the isomerisation constant (Kiso). β is a co-
operativity factor and determines the difference of agonist affinity for the ground and active state 
(adapted from Lazareno and Birdsall).
200 C G protein activation. Exchange of GDP/GTP on G 
protein activates the receptor and GTP binding induces the dissociation of Gα from Gβγ (adapted 
from Roberts and Waelbroeck).
201 
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Accordingly, the G protein is activated when bound to the receptor. Agonist binding to the 
receptor induces G protein activation by enhancing the affinity of the receptor for the G 
protein. The agonist has a higher affinity for the G protein-coupled receptor (RG) than for 
the free receptor (R). The agonist binding contributes to the stabilisation of the ternary 
complex of agonist/receptor/G protein (ARG) and the extent of stabilisation should 
determine the efficacy of agonist action.
202 In the extended ternary complex model (Figure 
4.16B), the receptor exists in two states, in a ground state (R) and in an activate state (R*), 
and the latter couples to the G protein to form the activate (R*G) high affinity state and the 
effective ternary complex (AR*G). An agonist (A) prefers the activate (R*) rather than the 
ground state (R) and shifts the receptor to the activate state.
203 The agonist also stabilizes 
the formation of the R*G complex. Both effects of the agonist promote the formation of 
the ternary complex (AR*G). In the ternary complex (Figure 4.16C), the exchange of GDP 
for GTP on the G protein leads to the dissociation of the complex in to the GαGTP and Gβγ 
subunits of the G protein, which regulate the activity of effector molecules.  
The GTP shift represents the ratio of the affinity obtained in the presence of GTP (KiGTP) or 
the nonhydrolysable GTP analogue Gpp(NH)p (KiGpp(NH)p) and of the higher agonist 
affinity (KH) obtained in the absence of GTP (KiGTP/KH) or Gpp(NH)p (KiGpp(NH)p/KH). It 
may provide a quantitative measurement of the agonist to promote coupling of the receptor 
to G protein and subsequently to determine the efficacy of the ligand within a particular 
assay system.
204,205 The correlation between the GTP shift and relative efficacies in 
functional assays has been studied successfully for dopamine D2 receptors,
206 nevertheless 
studies carried out by other groups have not been able to demonstrate any significant 
correlation.
149,207  
The study presented has verified that agonists have different binding characteristics 
depending on their properties as full agonists such as pramipexole or as partial agonists 
such as BP 897. In the absence of added guanine nucleotide, the full agonist pramipexole 
and compound 54 exhibit competition curves best described by a two-site binding model 
with higher and lower affinities (KH and KL) (F-test, P < 0.001) and by a one-site binding 
model in the presence of guanine nucleotides at dopamine D2S receptors (F-test, P < 0.05). 
Pramipexole (KiGpp(NH)p/KH = 1625) and compound 54 (KiGpp(NH)p/KH = 964) exhibited a 
significant GTP shift at dopamine D2S receptors. For further investigations, the efficacies 
of pramipexole and compound 54 need to be evaluated in a functional assay in our 
laboratory and to be compared to the results with the extent of the GTP shift. Binding 
affinities of pramipexole and compound 54 at dopamine D3 receptors in the absence and 
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presence of guanine nucleotides were better described by a one-site binding model (F-test, 
P < 0.05). Pramipexole studies of other groups’ best described the competition curve in the 
absence of GTP by a two-site binding model.
135 In this study the low ionic strength and the 
lack of guanine nucleotides used did not provide a biphasic curve. Competition binding of 
the dopaminergic agonist pramipexole and its analogue compound 54 demonstrated that 
Gpp(NH)p decreased affinity for dopamine D3 receptors, increased Hill slopes of 
competition curves close to unity and a slight but significant GTP shift has been displayed 
for both compounds. GTP shifts in dopamine D3 receptor binding have been revealed in a 
number of studies using different cell lines,
191 although other groups observed a lack of 
guanine sensitivity.
33 Generally, the difference between the high and the low affinity state 
exhibited for dopamine D3 is much smaller than obtained for dopamine D2 receptors and 
consequently more delicate to detect in competition binding assays.
22,192 In this 
investigation, a high affinity agonist binding and its resulting biphasic curve has only 
revealed for competition binding at dopamine D2S receptors, but not for dopamine D3 
receptors. Accordingly, experimental considerations need to be re-evaluated. It is 
necessary to eliminate entire endogenous GTP of the membrane preparation to receive 
high-affinity agonist binding. Although membrane preparations of the different receptor 
subtypes have been prepared with an identical method, one possible explanation for the 
lack of a two-binding site model might be the existence of endogenous GTP in the 
membrane preparation of dopamine D3 receptors. One might argue that then Ki control and 
Ki Gpp(NH)p have similar values, but the lack of sodium ions under these assay conditions 
could explain the difference in affinity binding in the absence and presence of Gpp(NH)p. 
An advanced protocol for the membrane preparation with reduced guanine nucleotides or 
an increase in volume to dilute any endogenous guanine nucleotides could improve the 
coupling of G protein to the receptor. Additionally, it is of great importance to consider 
that an adequate amount of G protein molecules is available for receptor-coupling. In order 
to calculate GTP shift data using a two-site binding model it is of immense significance to 
increase the number of data points. In this case, 12 - 15 concentrations in each independent 
experiment with an extended range using 3 different concentrations per log unit are 
required and determination of the relative proportion of the high and low affinity states for 
agonists is feasible. The more complex mathematical model requires enough data to attain 
statistical reliability in the fitting of a two-site model. In this experiment, only 7 
concentrations applied in triplicates were used to determine binding data, an increase in 
data points may improve the fitting of the data and its analysis.  
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A possible explanation of the biphasic binding curve of agonists is still highly discussed. 
As explained by the extended ternary complex illustrated in Figure 4.16B, agonist binding 
changes the equilibrium between the ground, inactive (R) and active (R*) state of the 
receptor. The agonist couples to the R*G form with high agonist affinity (KH) in the 
absence of GTP (Figure 4.16B). In the presence of GTP the receptor dissociates from 
GαGDP which is presumed to have low agonist affinity (KiGTP) (Figure 4.16C). The low 
affinity state (KL) seen for agonists in the absence of GTP is hardly explainable; it may 
result from a depletion of G protein molecules. It has already been discussed in literature 
that the shape of an agonist curve in the absence of guanine nucleotides strongly depends 
on the stoichiometry of receptor to the G protein.
208 Depletion of G protein could prevent 
the formation of the high affinity state of the receptor and agonists bind to the free 
receptor. It has been reported that agonist efficacy and affinity at the same receptor subtype 
varies between different assay systems due to coupling to different G proteins resulting in 
activation of diverse signaling pathways.
209 The GTP shift is applicable when comparing 
different ligands under comparable conditions and therefore it may be used as ad hoc 
measurement of relatively efficacy. The greater the GTP shift, the greater the efficacy. It is 
not possible to compare reference data of pramipexole due to many varying parameters 
under assay conditions. Different research groups have presented different Ki values, which 
are highly influenced by their selected assay conditions, such as radioligand and ionic 
strength of buffer composition.
61,129 
An agonist activates the receptor and induces an intracellular response of the signaling 
system, which is referred to as efficacy. Structurally diverse agonists exhibit different 
degrees of agonism, i.e. full-agonism, partial agonism, inverse agonism. In order to 
evaluate the efficacy of an agonist, functional assays measuring receptor/G protein 
coupling are efficient techniques, such as the [
35S]GTPγS ([
35S]guanosine-5’-O-(γ-
thiotriphosphate)) binding assay at dopamine D2 and D3 receptors.
210,211 The assay 
determines the increase in GDP/[
35S]GTPγS exchange at G proteins stimulated via receptor 
activation as a result of agonist binding. The [
35S]GTPγS binding assay accurately assesses 
the agonist efficacy and maximal functional effect, while the GTP shift assay only allows 
precisely to determine agonist affinity in the absence or presence of Gpp(NH)p and might 
provide a measure of the stabilization of the coupled form of the receptor/agonist. For a 
correlation between the extent of stabilization and efficacy, a comparison of the ratio of 
affinities of the lower and higher affinity states (KiGTP/KH) revealed in the GTP shift assay 
and the efficacy determined in the [
35S]GTPγS binding assay is required.
199 Other 
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functional assays include second messenger methods. For dopamine D2 and D3 receptors 
the cyclic AMP accumulation assay is applied and the ability of an agonist to inhibit the 
stimulation of [³H]cAMP accumulation in response to forskolin is determined.
62,212 
Recently, assays based on agonist-induced stimulation of mitogen-activated protein (MAP) 
kinase phosphorylation,
213 and activation of G protein-coupled inwardly rectifying 
potassium channels (GIRKs) have been described for dopamine D2 receptors,
213 while 
ERK1/2 phosphorylation has been investigated for both dopamine receptor subtypes.
214 
Functional coupling of dopamine D2 and D3 receptors can also be assessed using a 
mitogenesis assay, which measures the incorporation of [³H]thymidine.
212 It is worth 
mentioning, that functional assays highly depend on the expression system of receptors.
62 
For BP 897, a one-site model provided a better description of binding at dopamine D2S and 
D3 in the presence and absence of Gpp(NH)p. Hill coefficients were not significantly 
different from unity. It is noteworthy that Gpp(NH)p slightly but significantly has 
increased the affinity at dopamine D3 receptor subtype for BP 897 compared to control, but 
did not alter affinity for dopamine D2S receptors. BP 897 is a selective dopamine D3 over 
D2 receptor ligand. In vitro BP 897 acts as a partial dopamine D3 receptor agonist and as a 
dopamine D2 receptor antagonist.
140 Other investigations suggested that BP 897 might act 
as an antagonist rather than a partial agonist at dopamine D3 receptors.
142 Partial agonists 
display lower intrinsic activity than full agonist at receptors and it has been assumed that 
partial agonists may stabilize different activated states of receptors. They either behave as a 
functional antagonist in the presence of a full agonist, while in the absence of an agonist 
they function as an agonist. It is expected that partial agonists, like full agonists, 
discriminate high- and low affinity states in the absence of guanine nucleotides, but indeed 
a single site has been recognized for dopamine D3 receptors. Instead, Gpp(NH)p has 
shifted the competition curve of BP 897  to the left and increased affinity binding. 
Conclusively, the uncoupled receptor state has been favoured by BP 897. In contrast, a 
GTP shift has not been recognized for dopamine D2 receptor binding. This result has been 
expected since full antagonists have likely similar affinities for both receptor states.
215  
A similar observation has been noticed for the dopamine D2 and D3 receptor antagonist ST 
198. At dopamine D2S and D3 receptors, binding data of ST 198 have been best described 
by a one-site binding model. Hill coefficients did not significantly vary from unity. As 
already mentioned for BP 897, the presence of guanine nucleotides increased the affinity 
for dopamine D3 receptors and resulted in a “reverse” GTP shift, but did not alter affinity 
for dopamine D2S receptors. ST 198 did not discriminate high- or low affinity state at 
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dopamine D2 receptors, but obviously preferred the uncoupled state of dopamine D3 
receptors. This binding behavior has been shown for inverse agonists at multiple targets,
201 
among them dopamine D2 and D3 receptors. Inverse agonists preferentially stabilize the 
uncoupled state of the receptor and reduce the basal G protein activity.
216 The termination 
of precoupling of receptor/G protein by guanine nucleotides results in a higher affinity 
state for inverse agonists.
201,217 It is noteworthy that inverse agonism is always associated 
with high constitutive activity, revealed as a common result of recombinant (over 
expressed) receptor systems,
218 but it is also found in native in vivo systems.
219  
From this study, clear evidence has been obtained that G proteins couple to dopamine D2S 
receptors and this course of action has been eliminated by guanosine nucleotides. For 
dopamine D3 receptors, clear confirmation for G protein coupling is still missing since a 
biphasic binding curve for the agonist pramipexole and its derivative in the absence of 
Gpp(NH)p has not been revealed. One explanation of the observed results might be that 
assay procedure and conditions are not completely optimized and an increase in data points 
could improve binding outcome. Another assumption is that agonist binding to dopamine 
D3 receptors might not couple to G proteins in the recombinant expression system as 
already recognized by other groups.
33,191 Competition binding of the dopamine D3 receptor 
partial agonist and D2 receptor antagonist BP 897 and antagonist ST 198 resulted in 
unaffected binding affinities for dopamine D2S. Nevertheless, a significant increase in 
binding affinities for dopamine D3 receptors by addition of Gpp(NH)p and consequently a 
GTP shift to the left has been shown. Conclusively, the data reported show that it is likely 
to categorize agonist and partial agonist or antagonist by GTP shift experiments in 
preliminary investigations, but not to give quantitative values in terms of the effect.  
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4.2 Pharmacological Results and Structure-Affinity Relationships 
4.2.1 Analogues of BP 897 and ST 198 
Starting from our lead structure BP 897 (cf. 1.2.6), a partial agonist with high affinity 
binding and selectivity for dopamine D3 receptors, series of analogues have been prepared 
and investigated with the aim to enlighten structure-affinity relationships for further 
improvement of affinity binding at dopamine D3 receptors. Therefore, BP 897 was 
structurally divided into three elements: (I) a hydrophobic aryl moiety connected to an 
amide consisting of a naphthalen-2-carboxamide residue, (II) an alkyl spacer represented 
by a linear tetramethylene chain, and (III) a lipophilic basic, aryl substituted alkanamine 
residue, comprising a 4-(2-methoxyphenyl)piperazine moiety (Figure 4.17). This structural 
pattern can be applied for most dopamine D3 receptor ligands with partial agonist and 
antagonist properties as the structure ST 198 (cf. 1.2.6). 
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Figure 4.17 Structural pattern of BP 897. 
 
The concept of modification consisted of the structurally division of the lead structure into 
the three different subunits followed by a new combination of the three elements and their 
bioisosteric analogues. The exchange of particular substructures and as a result the 
rearrangement of functionalities might lead to more potent and selective dopamine D3 
receptor ligands. As a bioisosteric replacement of the naphthalen-2-carboxamide residue 
structural variations included cinnamide residues, (hetero)aryl substituted-, and cyclo alkyl 
substituted carboxamide moieties. The basic aryl alkanamine residue was either 
represented by the BP 897 scaffold 4-(2-methoxyphenyl)piperazine (S1) or 1,2,3,4-
tetrahydroisoquinoline (S2), known as the core structure of ST 198. In the first series, the 
tetramethylene chain remained unchanged (Table 4.5).  
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Table 4.5 Ki values and Hill coefficients (in parentheses) of 4-(2-methoxyphenyl)piperazine and 
1,2,3,4-tetrahydroisoquinoline derivatives.  
 
N
N
OCH3 (CH2)4
R N
(CH2)4
R
S1 S2  
 
Ki [nM]  No. S  R 
hD2S hD3 
Ki (hD2S) /  
Ki (hD3) 
BP 897  S1  N
H
O
 
  52 ± 12 
(1.12 ± 0.3) 
0.91 ± 0.2 
  (0.98 ± 0.28)  57 
1  S1  N
H
O
S
 
44 ± 7 
 (1.06 ± 0.19) 
0.45 ± 0.22 
 (0.92 ± 0.15)  98 
2  S1  N
H
O
S
N
 
 55 ± 17 
 (1.04 ± 0.18) 
5.63 ± 1.81 
(0.95 ± 0.33)  10 
3  S1  N
H
O
 
52 ± 7 
 (1.09 ± 0.25) 
2.04 ± 0.20 
 (1.02 ± 0.20)  26 
4  S1  N
H
O
 
59 ± 4 
 (0.96 ± 0.13) 
3.09 ± 0.37 
 (1.00 ± 0.19)  19 
ST 198  S2  N
H
O
 
1272 ± 99 
    (0.95 ± 0.11) 
8.72 ± 0.21 
 (0.76 ± 0.11)  146 
5  S2  N
H
O
S
 
815 ± 56 
  (0.85 ± 0.08) 
82 ± 14 
 (0.87 ± 0.23)  10 
6  S2  N
H
O
S
 
791 ± 119 
 (1.08 ± 0.01) 
24 ± 4 
 (0.86 ± 0.12)  33 
 
Determined equilibrium dissociation constant values of BP 897 are in good agreement to 
literature data (Ki (D3) = 0.92 ± 0.2 nM and Ki (D2) = 61 ± 0.2 nM).
140 4-(2-Methoxy-
phenyl)piperazine substituted compounds 1 - 4 have shown binding affinities in the low 
nanomolar to subnanomolar concentration range for dopamine D3 receptors and nanomolar 
Ki values for dopamine D2 receptors. The bioisosteric replacement of the naphthalen-2-
carboxamide by heteroaromatic or alicyclic residues has not altered affinities for dopamine 
D2 receptors, but has influenced affinities for dopamine D3 receptors. The introduction of a 
benzo[b]thiophen-2-yl residue (1) has markedly demonstrated an improved binding with 
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subnanomolar affinity and enhanced selectivity for dopamine D3 receptors compared to BP 
897. Compound 1 has been already described by another research group and is known as 
FAUC 346 (reference data: Ki (D3) = 0.23 ± 0.016 nM and Ki (D2) = 52 ± 1.0 nM).
125 The 
benzo[b]thiophen-2-yl residue is also found in FAUC 365 (cf. 1.2.6), a ligand with high 
affinity and selectivity binding for dopamine D3 receptors.
125 An additional heteroatom led 
to the basic benzo[b][1,4]thiazol-2-yl residue compound 2 and has not been able to 
improve neither affinity binding nor selectivity for dopamine D3 receptors compared to 
compound  1. Introducing alicyclic unsaturated residues (3,  4) has been well tolerated, 
noteworthy that the double bound in 1-position (3) has been slightly favoured over the 3-
position (4). The unsaturated function in vicinity to the carboxamide causes a more rigid 
molecule, which might affect binding affinities. Data indicate that a heteroaromatic or 
aromatic ring system is not of absolute necessity to achieve affine and selective ligands.  
The following modifications include the introduction of the 1,2,3,4-tetrahydroisoquinoline 
moiety. This structural motif has been successfully applied in the cinnamoyl derivative ST 
198, a dopamine D3 receptor selective antagonist (reference data: Ki (D3) = 12 ± 0.5 nM 
and Ki (D2) = 780 ± 30 nM).
83 The 1,2,3,4-tetrahydroisoquinoline derivatives (5, 6) have 
displayed moderate nanomolar affinities for dopamine D2S and nanomolar affinities for 
dopamine D3 receptors. The lipophilic anellated aryl residue in compound 6 has slightly 
increased affinity binding and selectivity for dopamine D3 receptors compared to the 
thiophen-2-yl bearing compound 5 due to possible additional hydrophobic interactions 
with the receptor binding site. It is noteworthy that the 4-(2-methoxyphenyl)piperazine 
analogue 1 of compound 6 has demonstrated higher affinities for dopamine D2S and D3 
receptors and also improved selectivity for dopamine D3 receptors. This result is in good 
agreement with literature data.
220 By replacing the 4-(2-methoxyphenyl)piperazine residue 
with the 1,2,3,4-tetrahydroisoquinolin-2-yl moiety the degree of rigidity of the ligand has 
increased. This scaffold is a structural combination of a benzyl- and a phenylethyl residue 
and therefore provides a rigid feature. A possible explanation of the aforementioned 
decline in affinity at both receptor subtypes and a decreased selectivity at dopamine D3 
receptors is an altered distance of the basic amine to the aromatic system in the 1,2,3,4-
tetrahydroisoquinolin-2-yl residue compared to the phenylpiperazine moiety. Furthermore, 
the 4-(2-methoxyphenyl)piperazine residue is more flexible and the methoxy substitution 
in position 4 on the phenyl ring contributes to additional interactions with the receptor 
binding site. In previous studies 1,2,3,4-tetrahydroisoquinoline compounds have mostly 
demonstrated antagonist properties,
221 whereas it is assumed that the less rigid 4-(2-
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methoxyphenyl)piperazine moiety of BP 897 is responsible for its partial agonist properties 
at dopamine D3 receptors. 
Conclusively, in the series of 4-(2-methoxyphenyl)piperazine derivatives, modifications on 
the naphthalen-2-carboxamide of BP 897 resulted in compounds with high affinity and 
selectivity for dopamine D3 receptors (1 - 4). Particularly the replacement of naphthalen-2-
carboxamide by benzo[b]thiophen-2-carboxamide provided compound 1, also known as 
FAUC 346, and has demonstrated superior affinity and selectivity for dopamine D3 
compared to BP 897. Exchanging the cinnamide residue of the 1,2,3,4-
tetrahydroisoquinoline derivative ST 198 with an aryl heterocycle (5) or annellated aryl (6) 
has resulted in ligands with nanomolar affinities and selectivity for dopamine D3 receptors, 
but the modifications have not enhanced binding data when compared to ST 198.  
 
The following development of ligands (Table 4.6) has been performed to evaluate the 
concept of the reversed structural rearrangement of amid functionalities. Therefore, a 
structurally reversed functional amide group has been linked via an alkyl spacer varying in 
lengths to the basic alkanamine moiety, represented by either an unsubstituted 4-
phenylpiperazine (S1) or 1,2,3,4-tetrahydroisoquinoline (S2) residue. This approach has 
been based on the inverse amide compound ST 314 (1,5-bis(4-phenylpiperazinyl)pentan-1-
one), which comprises dopamine D3 receptor selectivity (Ki (D3) = 6.5 ± 5.3 nM and Ki 
(D2) = 467 ± 178 nM, selectivity ratio Ki (D2)/Ki (D3) = 71.9) and the properties of a 
dopamine D3 receptor partial agonist (intrinsic activity 0.8).
222 Here, the amine group of 
the amide functionality is part of the piperazine ring and is integrated into the lipophilic 
moiety. Moreover, the second amine of the piperazinyl system (anilino amine) has only 
weak basic properties. Accordingly, the amide functionality has been structurally inversed 
compared to the previous arrangement in the lead structure BP 897. 
Due to its transformed structural characteristics, ligand-receptor interactions of inverse 
amides are altered. Firstly, the nitrogen of the amide has changed into a weak hydrogen 
bond acceptor. Subsequently, the alkyl chain has been extended to one additional carbon 
atom and the distance between the basic nitrogen of the alkanamino moiety (subunit III) 
and the amide oxygen as a hydrogen bond acceptor has been decreased. Consequently, it 
was of interest not only to investigate in the influence of diverse inverse amide moieties 
and basic alkanamino residues, but also to consider different chain lengths. It has also been 
investigated in the substitution pattern on the inverse amides.  
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Table 4.6 Ki values and Hill coefficients (in parentheses) of inverse amide compounds.  
 
N
N
(CH2)n
S1
N
(CH2)n
S2
O O
R R
 
 
Ki [nM]  No.  S R n 
hD2S hD3 
Ki (hD2S) / 
Ki (hD3) 
7  S1  N
 
4  1482 ± 296 
  (0.84 ± 0.07) 
138 ± 39 
  (0.85 ± 0.09)  11 
8  S1 
N
 
4  563 ± 135 
(1.04 ± 0.08) 
136 ± 20 
  (0.92 ± 0.02)  4 
9  S1 
N
 
3  1057 ± 185 
 (1.03 ± 0.22) 
120 ± 12 
  (1.05 ± 0.02)  9 
10  S1 
N
 
4  1020 ± 99 
   (0.80 ± 0.11) 
185 ± 66 
  (1.02 ± 0.20)  6 
11  S1 
N
 
5     841 ± 184 
   (1.02 ± 0.16) 
25 ± 2.8 
(0.98 ± 0.16)  34 
12  S2 
N
 
3  198 ± 69 
  (0.97 ± 0.14) 
48 ± 14 
(1.01 ± 0.06)  4 
13  S2 
N
 
4  2839 ± 820 
  (0.92 ± 0.11) 
516 ± 43 
  (0.98 ± 0.10)  6 
14  S2  N
N
 
3  649 ± 122 
 (0.93 ± 0.12) 
97 ± 7 
  (0.89 ± 0.34)  7 
 
In the first series the 4-phenylpiperazine residue is linked via an alkyl spacer to piperidin-
1-carbonyl (7), 4-phenyl-1,2,3,6-tetrahydropiperidin-1-carbonyl (8) or 2,3-dihydro-1H-
isoindol-1-carbonyl (9,  10,  11). The 4-phenyl-1,2,3,6-tetrahydropiperidine residue 
combines structural properties of the phenylpiperazine and the 1,2,3,4-
tetrahydroisoquinoline moiety, while the 2,3-dihydro-1H-isoindole structure bears the 
symmetry of phenylpiperazine and the partial benzyl amine feature of 1,2,3,4-
tetrahydroisoquinoline.
222  
The modification resulted in compounds with nanomolar affinities at dopamine D3 
receptors and nanomolar to micromolar affinity binding at dopamine D2S receptors. 
Comparing compounds only varying in the inverse amide residues (7,  8, and 10) has 
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clearly shown an alteration in affinity binding for dopamine D2S receptors but has slightly 
influenced affinities for dopamine D3 receptors. Structural diminishment of the aryl-
substituted alkanamine residues (8 and 10) to an aliphatic heterocyclic system (7) has been 
tolerated by dopamine D3 receptors but demonstrated a decrease in affinity binding at 
dopamine D2S. This result indicate that the presence of an aryl system substituted to the 
alkanamine residue is not of absolute necessity since the aliphatic heterocyclic compound 
still has affinities for both receptor subtypes. In the series of isoindole derivatives 
enlargement of the alkyl chain (9 → 10 → 11) has markedly affected affinity binding at 
dopamine D3 receptors. Alternate binding data have been received with increasing chain 
lengths with the pentyl spacer bearing compound 11 demonstrating enhanced affinity 
binding and selectivity for dopamine D3 receptors. It is noteworthy, that the altered 
arrangement into an inverse amide has changed the position and orientation of the carbonyl 
group. The distance between the carbonyl functionality and the basic amino group is 
shorter. In order to compensate the reduction of the space, the alkyl chain requests to be 
increased to an additional methylene group. In previous modeling studies, and also 
confirmed by pharmacological binding data of analogues and related structures of BP 
897,
126 a tetramethylene spacer accomplish the required distance of about 6.5 Å between 
the basic aliphatic nitrogen and hydrogen bond acceptor for high dopamine D3 receptor 
affinity binding. Consequently, the favourable alkyl length for inverse amides is a pentyl 
spacer, as seen in compound 11. In the series of inverse amides this ligand has shown the 
highest affinity and selectivity for dopamine D3 receptors. It is worth mentioning that 
ligands at the dopamine D3 receptor adopt not only an extended but also more linear 
conformation, while ligands the dopamine D2 receptor favour a more bent 
conformation.
125,126 This relation has been confirmed for compounds 9, 11 and 12 at the 
dopamine D3 receptors. 
Replacement of the 4-phenylpiperazine residue by a 1,2,3,4-tetrahydroisoquinoline moiety 
has revealed compounds with nanomolar to micromolar affinity binding for dopamine D2S 
receptors and nanomolar affinities for dopamine D3 receptors.. Increasing the alkyl spacer 
in the 2,3-dihydro-1H-isoindole derivatives (12 → 13) has demonstrated decreased binding 
affinities for both dopamine receptor subtypes. The remarkably reduction of affinity 
binding at dopamine D2 receptors is in contrast to previous dopamine D2 affinity data 
described for their structural analogues coupled to 4-phenylpiperazine (9 → 10). Moderate 
affinity binding value has been gained for the 1,2,3,4-tetrahydroisoquinoline compound 
(14) when combined with 1-phenylpiperazine. The reversed restructuring of the amide 
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functionality resulted in inverse amide compounds with new structural properties. The new 
concept provided compounds, which have been well tolerated at dopamine D3 and at 
dopamine D2S receptors. The inverse amide compounds presented here have evidently 
demonstrated the consequence of different orientations of carbonyl oxygen in the binding 
site and the importance of the distance between basic nitrogen and the hydrogen bonding 
functional group. The results obtained propose that the length of the alkyl linker 
connecting the basic alkanamino aryl residue to the inverse amide plays a pivotal role in 
affinity binding behaviour (9 → 11, 12 → 13). It strongly influences the steric orientation 
of the ligand in the binding pocket and the interaction with the receptor binding sites. 
When comparing the aryl substituted basic alkanamino residues, it is important to consider 
that the phenylpiperazine residue is more flexible while the 1,2,3,4-tetrahydroisoquinoline 
moiety has increased the rigidity of the ligand. This might influence the orientation of the 
ligand in the binding pocket when increasing the alkyl spacer. For compound 11 the 
elongated alkyl spacer shifted the alkanamino residues to an optimal distance between 
carbonyl oxygen and basic nitrogen of the phenylpiperazine moiety and increased binding 
at dopamine D3 and D2S receptors and selectivity for D3 receptors.  
Conclusively, changing the structural order from an aryl carboxamide into an inverse 
amide has only revealed modest binding affinities and low selectivity ratios for dopamine 
D3 receptor. However, the inverse amide approach provides compounds with a novel 
structural scaffold. Further comprehensive investigations in structural modifications and 
functional activities might confirm the inverse amide as a worthwhile new lead structure. 
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4.2.2 Benzhydrylpiperazine Derivatives 
Antipsychotic drugs have become first line treatment of schizophrenia despite their 
interactions with several neurotransmitter receptors, including histamine H1 receptors, 
serotonine 5-HT2A receptors, and α1/α2 adrenergic receptors.
107 This multireceptor affinity 
has been considered to effect both therapeutic advantages but also adverse effects.
223 The 
antagonist binding profile of antipsychotics for central histamine H1 receptors has been 
well demonstrated by chlorpromazine, a phenothiazine derivative, initially developed for 
its antiallergic properties by Delay and Deniker in 1952.
224 Additionally, histamine H1 
receptor antagonists containing tri- and tetracyclic structures display high affinity for 
diverse catecholamine receptors, due to the highly conserved ligand-receptor interaction of 
biogenic amine receptors by an aspartate (Asp) residue in transmembrane (TM) 3.
122,225,226 
Similar structural requirements of antagonists on the binding site of dopamine D2-like 
receptors and histamine H1 receptors are found in a lipophilic/aromatic moiety connected 
to a basic nitrogen atom
225 and are often claimed as “privileged structures” for GPCRs.  
In order to elucidate the structure-affinity relationships of the histamine H1/dopamine D2-
like receptor profile, a hybrid structure development of novel benzhydrylpiperazines 
(diphenylmethylpiperazine residues) and analogues to identify highly affine dopamine D3 
receptor selective ligands has been investigated. An approach was undertaken by 
synthesizing hybrid molecules containing substructures of histamine H1 receptor 
antagonists and fragments of dopamine D3 receptor-preferring ligands. The (semi)rigid 
components of histamine H1 receptor antagonists comprised basic substructures of 
cetirizine ([(4-chlorophenyl)phenylmethyl]piperazine), mianserin (4-(2,3,4,5,10,15-
hexahydro-1H-dibenzo[b:e]pyrazino[2,1-g])azepine),  ketotifen (4-[4-(10-oxo-9,10-
dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophen)-4-yliden]piperidine), loratadine (4-[(8-
chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin)-11-yliden]piperidine), and 
bamipine  (N-benzyl-N-piperidin-4-ylaniline). Structures of histamine H1 receptor 
antagonists are shown in cf. 1.3.6. These residues were connected via a tetramethylene 
chain to naphtalen-2-carboxamide, cinnamide, benzo[b]thiophen-2-carboxamide, or 
phthalimide moiety, as represented in BP 897, ST 198, FAUC 365 (cf. 1.2.6) and 
NAN190, respectively. NAN190 (N-(4-[4-(2-methoxyphenyl)piperazinyl]butyl)isoindolin-
1,3-dion) has demonstrated lower binding affinity and selectivity for dopamine D3 
receptors (Ki (D3) = 38 ± 5.7 nM and Ki (D2) = 50 ± 6 nM, selectivity ratio Ki (D2)/Ki (D3) 
= 1) compared to BP 897, ST 198 and FAUC 365, and has shown to bind with high affinity 
 Results and Discussion    84 
 
at the serotonin 5-HT1A receptor (Ki = 0.6 nM).
227 The phthalimide residue, comprising 
two amide functionalities, might represent a potential novel scaffold. A model of the 
hybrid design approach is illustrated in Figure 4.18. 
 
Arylamide
Cinnamide
Phthalimide
Butyl Spacer
Histamine H1
Receptor Antagonist 
Fragment
Arylamide
Cinnamide
Phthalimide
Butyl Spacer
Histamine H1
Receptor Antagonist 
Fragment
Figure 4.18 Model of the hybrid design approach. 
 
The aim was to evaluate the influence of both, variations of diverse arylamides and related 
moieties, and structural modifications on the basic nitrogen atom including aryl residues, 
tri- and tetracyclic ring substitutions.  
41 novel hybrid compounds were synthesized and binding affinities were preliminary 
screened using a competition binding screening with six-point measurements in duplicates 
only. This first rough screening was not carried out in-house but externally tested (cf. 10). 
Radioligand binding assays were carried out using HEK cells transfected with human D2S 
and CHO cells transfected with human D3 receptor cDNA and [
3H]spiperone (cf. 
10.1.2).
192 25 out of 41 novel hybrids that promised the most potential chemical 
substructures for dopamine D3 receptor binding were selected. From each series containing 
different (semi)rigid histamine H1 receptor antagonist substructures the compounds with 
the highest affinity and/or selectivity for dopamine D3 receptors or related parent leads 
were chosen. Besides, the various aryl amide moieties such as naphtalen-2-carboxamide, 
and benzo[b]thiophen-2-carboxamide were considered and as well as phthalimide, and 
cinnamide residues to compare potentially bioisosteric features. Consequently, a second 
precise [³H]spiperone displacement binding to cloned human D2S, and D3 receptors stably 
transfected in CHO cells was carried out using 7 different concentrations of test compound 
in triplicates in at least 3 independent experiments. Determined pharmacological binding 
data are shown in Tables 4.8 - 4.10. For reasons of selectivity, histamine H1 receptor 
affinity binding of a selected subset of compounds has been determined (Tables 4.8 - 4.10). 
For a comprehensive data evaluation dopamine D2, D3, and histamine H1 receptor affinities 
of the above mentioned parent antihistaminergic H1 receptor antagonists were assessed 
(Table 4.11). 
As expected inconsistencies were obtained by comparing the pharmacological binding data 
received via rough screening using six-point measurements (see Appendix Table 4.7) and 
via precise competition binding assay procedures. Compound 36 has displayed Ki values of 
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0.3 nM at dopamine D3 receptors and of 703 nM at hD2S receptors in the rough screening 
assay. In the reevaluation, the binding data significantly changed for dopamine D3 (Ki = 
140 nM) and but did not significantly differ for dopamine D2S receptors (Ki = 573 nM). On 
the contrary, similar binding affinity data at dopamine D2S and D3 receptors were received 
for compound 39,  although the experiments were carried out under different assay 
conditions.  Using dissimilar binding assay conditions, including different final 
concentrations of radioligands, varying incubation buffers, incubation times, different host 
cells as an expression system for dopamine receptors, solvent for test compounds, and 
dissimilar reference compounds to determine non-specific binding has resulted in 
significantly different Ki affinity values and consequently different dopamine D2/D3 
selectivity ratios. The tested compounds have shown calculated logP values in the range of 
2.65 – 6.53 (cf. Appendix Table 4.7). Ligands demonstrating logP values in the range of 5 
are not well suited for automated screening procedures due to poor solubility and might 
give an explanation for the observed differences of data. It is noteworthy that SAR should 
be predicted from data received from one and the same laboratory carrying out precise and 
repetitive competition binding assays. Consequently the ensuing SAR can be based only on 
the data presented in Tables 4.8 - 4.10, since they fulfill the above mentioned prerequisites.  
In the following sections, the SAR is enlighted concerning the effects of antagonist H1 
receptor fragments and it is focused on changes in dopamine D2/D3 receptor selective 
substructures.  
Unsubstituted or  differently substituted benzhydrylpiperazine residues based on the 
structural element of the antihistaminergic cetirizine have been combined with diverse aryl 
amides, cinnamide and phthalimide moieties (15 - 27). The benzhydrylpiperazine element 
has been substituted either with a chlorine at 4-position or methoxy group(s) at 2-
position(s) of the phenyl ring(s) related to BP 897. Moreover the piperazine ring has been 
replaced by 1,4-diazepane. Among the series of benzhydrylpiperazine derivatives, 
compounds have shown nanomolar affinities for dopamine D3 receptors and moderate 
nanomolar to micromolar binding affinities for dopamine D2S receptors. Introduction of a 
piperazine ring extension to a 1,4-diazepane in the phthalimide derivative 16 and has 
demonstrated a 2-fold decrease in binding affinities at both dopamine D2S and D3 receptors 
compared to compound 15. This reduction of binding affinity due to 1,4-diazepane 
substitution has also been obtained for the cinnamide containing compound 18  when 
extended to 22. Compound 22 has a 3-fold decreased affinity for dopamine D3 receptors 
and a 2-fold decreased affinity for D2S receptors. Conclusively, ring extension has proved 
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to decline affinities for D2S and D3 receptors and to reduce selectivity for dopamine D3 
over D2 receptors within these examples.  
In order to evaluate the influence of variations of the aryl amide substituent, the 
naphthalen-2-carboxamide moiety in 17 has been replaced by cinnamide in 18.  The 
replacement has resulted in minor retention of affinity binding at dopamine D3 receptors 
but clear reduction at D2S receptors, consequently the selectivity for D3 receptors has 
increased. In compounds 15 and 19 - 21  the phenyl ring of the benzhydrylpiperazine 
residue has been substituted with a chloro atom in 4-position. Substitution of the 
phthalimide moiety (15) by naphthalen-2-carboxamide (19), cinnamide (20) or 
benzo[b]thiophen-2-carboxamide (21) had only minor influence on affinity binding at 
dopamine D3 receptors, but the cinnamide (20) and the benzo[b]thiophen-2-carboxamide 
(21) have shown a noticeable decrease in affinities at dopamine D2S receptors compared to 
the naphthalen-2-carboxamide compound 19 and the phthalimide derivative 15, resulting 
in a slightly increase in selectivity for dopamine D3 receptors. The affinity and selectivity 
profiles of benzhydrylpiperazine derivatives 25 - 27, which are methoxy disubstituted at 2-
position of the phenyl rings, have been strongly influenced by variations of amide residues. 
The naphthalen-2-carboxamide residue bearing compound 25 has displayed the highest 
affinity for D3 receptors, but only a 4-fold selectivity ratio for dopamine D3 receptors, 
whereas the cinnamide compound 26 has been 11-fold selective for D3 receptors versus D2 
receptors. The benzo[b]thiophen-2-carboxamide 27 has had only moderate affinities for 
D2S receptors and D3 receptors. In the ring extended series with diphenyl-1,4-diazepane the 
exchange from cinnamide (22) to benzo[b]thiophen-2-carboxamide (23) has resulted in 
reduced affinities for dopamine D3 and D2S receptor binding and a decrease in selectivity 
for dopamine D3 over D2 receptors. 
Another aim has been the characterization of alterations in the substitution pattern on the 
phenyl ring(s) of the benzhydrylpiperazine residue and its consequence on the 
conformation of the ligand. Among the series of benzhydryl derivatives either 
unsubstituted or in 2-position of the phenyl rings methoxy disubstituted, compounds with 
cinnamide residues (18, 26) have shown the highest preference for dopamine D3 over D2 
receptors in this series. A favored binding behavior of cinnamide bearing compounds for 
dopamine D3 over D2 receptors could be obtained for compound 22 in the series with 
unsubstituted diphenylmethyl-1,4-diazepane derivatives. When the naphthalen-2-
carboxamide compound 17 was compared to in 4-position chloro substituted (19) and 2-
positions methoxy disubstituted (25) benzhydryl analogues, the affinities for D3 receptors 
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Table 4.8 Ki values and Hill coefficients (in parentheses) of cetirizine-based hybrids. 
N
N
(CH2)4 R
R²
R1
n  
Ki [nM] K i [nM] 
No. R  R
1 R
2 n 
hD2S hD3 
Ki 
(hD2S/ 
hD3)  hH1 
Ki 
(hH1/ 
hD3) 
15  N
O
O  
4-Cl H  1 
184 ± 66 
(0.89 
 ± 0.01) 
67± 18  
(1.18 
 ± 0.26) 
3 
34 ± 9 
(1.33 
 ± 0.50) 
0.5 
16  N
O
O  
4-Cl H  2 
313 ± 152 
(1.70 
 ± 0.30) 
150 ± 1.7 
(1.04 
 ± 0.70) 
2 n.d.
a  n.d.
a 
17  N
H
O
 
H H  1 
243 ± 39 
(1.40 
 ± 0.14) 
39 ± 0.8 
(1.65 
 ± 0.42) 
6 
21 ± 6 
(1.23 
 ± 0.13) 
0.5 
18  N
H
O
 
H H  1 
767 ± 119 
(1.14 
 ± 0.17) 
55 ± 15 
(0.88 
 ± 0.15) 
14 
7 ± 
0.42 
(1.29 
 ± 0.17) 
0.1 
19  N
H
O
 
4-Cl  H 1 
180 ± 35 
(1.28 
 ± 0.09) 
49 ± 24 
(1.04 
 ± 0.06) 
4 n.d.
a  n.d.
a 
20  N
H
O
 
4-Cl  H 1 
292 ± 39 
(1.11 
 ± 0.30) 
60 ± 16 
(1.85 
 ± 0.75) 
5 n.d.
a  n.d.
a 
21  N
H
S
O
 
4-Cl H  1 
318 ± 69 
(1.33 
 ± 0.2) 
54 ± 11 
(1.20 
 ± 0.20) 
6 n.d.
a  n.d.
a 
22  N
H
O
 
H H  2 
1261 
 ± 242 
(1.29 
 ± 0.78) 
144 ± 85 
(1.47 
 ± 0.61) 
9 
26 ± 5 
(1.30 
 ± 0.24) 
0.2 
23  N
H
S
O
 
H H  2 
1708 
 ± 852 
(2.43 
 ± 0.21) 
394 ± 70 
(1.70 
 ± 0.61) 
5 
50 ± 12 
(1.77 
 ± 0.50) 
0.1 
24  N
H
S
O
 
2-H3CO H 1 
457 ± 23 
(1.31 
 ± 0.05) 
134 ± 46 
(1.49 
 ± 0.17) 
4 n.d.
a  n.d.
a 
25  N
H
O
 
2-H3CO  H3CO  1 
138 ± 13 
(1.56 
 ± 0.3) 
36 ± 13 
(1.68 
 ± 0.59) 
4 n.d.
a  n.d.
a 
26  N
H
O
 
2-H3CO  H3CO 1 
736 ± 228 
(0.95 
 ± 0.20) 
67 ± 11 
(1.25 
 ± 0.37) 
11 
20 ± 5 
(0.92 
 ± 0.15) 
0.3 
27  N
H
S
O
 
2-H3CO H3CO 1 
523 ± 118 
(1.07 
 ± 0.18) 
111 ± 29 
(1.24 
 ± 0.31) 
5 n.d.
a  n.d.
a 
an.d., not determined.  
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did not significantly changed, but an increase in affinity for dopamine D2 occurred (17 → 
19 → 25). The cinnamide derivatives 18, 20, and 26 showed similar results regarding the 
affinities for D3 receptors. The chloro substituted compound 20 has demonstrated higher 
affinity binding compared to that of the unsubstituted (18)  and methoxy disubstituted 
derivatives (26) at the dopamine D2 receptor. 
In the series of benzo[b]thiophen-2-carboxamide (21,  24, 27) derivatives the 4-chloro 
substituted compound (21) has displayed a 2-fold enhanced affinity for dopamine D3 
receptors compared to that of the methoxy analogues (24, 27). Here introduction of the 
additional methoxy group (27) did not significantly change affinities for dopamine D2 and 
D3 receptors. In summary, modifications of the substitution pattern on the phenyl ring(s) of 
the benzhydryl residue have not clearly changed affinity binding for dopamine D3 
receptors when hybridized with naphthalen-2-carboxamide (17, 19, 25) or cinnamide (18, 
20, 26), but binding affinities have been influenced by incorporation of benzo[b]thiophen-
2-carboxamide (21, 24, 27). In contrary, no clear structure-activity relationship was found 
for dopamine D2 receptors when substituted with different aryl amide moieties and related 
residues and varying substitutions on the phenyl ring with chloro or methoxy residues, 
reflecting putative differences in binding sites of dopamine D3 and D2 receptors. 
 
In compounds 29 - 34 the tetracyclic substructure of mianserin and the tricyclic fragments 
of ketotifen and loratadine have been included (Table 4.9).  
Incorporation of the hexahydrodibenzopyrazinoazepine (S1) residue, the substructure of 
mianserin, has displayed modest nanomolar affinity binding at dopamine D2S and D3 
receptors. The bioisosteric exchange of the (aryl) amide moieties has exposed similar 
affinity binding values at both receptor subtypes for naphthalen-2-carboxamide (28) and 
cinnamide (29). For the benzo[b]thiophen-2-carboxamide compound (30)  the affinity 
binding at dopamine D3 receptors has been reduced 2-fold while the affinity for dopamine 
D2S receptors has been slightly improved. The data indicate that an increase in steric 
bulkiness and rigidity has not revealed compounds with enhanced affinity and selectivity 
for dopamine D3 receptors.  
Benzothienylcycloheptadienpiperidine (S2), the substructure of ketotifen, has been 
integrated in compound 31 and 32  and the modification has resulted in moderate 
nanomolar binding affinities for dopamine D3 and D2S receptors. Compared to the 
phthalimide derivative (31), the naphthalen-2-carboxamide residue (32) has improved the 
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selectivity ratio for dopamine D3 over D2 receptors by enhancing the affinity for dopamine 
D3 receptors (4-fold).  
 
Table 4.9 Ki values and Hill coefficients (in parentheses) of tri- and tetracyclic compounds. 
N
N
(CH2)4 R
S1
N S
O
(CH2)4 R
S2
N
N
Cl
(CH2)4 R
S3  
Ki [nM] K i [nM] 
No. S  R 
hD2S hD3 
Ki  
(hD2S/ 
 hD3)  hH1 
Ki  
(hH1/ 
 hD3) 
28 S1  N
H
O
 
513 ± 217 
(1.75 ± 0.05) 
201 ± 153 
(1.61 ± 0.27)  3 n.d.
a  n.d.
a 
29 S1  N
H
O
 
472 ± 100 
(1.47 ± 0.26) 
228 ± 50 
  (1.06 ± 0.09)  2     7 ± 0.3 
(1.40 ± 0.36)  0.03 
30 S1  N
H
S
O
 
      387 ± 97 
(1.96 ± 0.03) 
455 ± 158 
(2.14 ± 0.36)  1 n.d.
a  n.d.
 
31 S2  N
O
O  
      525 ± 66 
(1.19 ± 0.10) 
145 ± 52 
  (0.87 ± 0.11)  4  9 ± 4 
(1.09 ± 0.29)  0.1 
32 S2  N
H
O
 
769 ± 195 
(1.01 ± 0.22) 
48 ± 13 
(1.29 ± 0.59)  16  26 ± 9  
(1.27 ± 0.44)  0.5 
33 S3  N
H
O
 
230 ± 76 
  (1.61 ± 0.23) 
96 ± 31 
(1.29 ± 0.10)  3 n.d.
a  n.d.
a 
34 S3  N
H
S
O
 
261 ± 19 
  (1.65 ± 0.38) 
177 ± 56 
  (1.19 ± 0.32)  2  13 ± 3  
(1.52 ± 0.53)  0.1 
an.d., not determined.  
 
The loratadine ring system (S3) was included in compounds 33  and 34 and this has 
resulted in molecules with nanomolar affinities for dopamine D3 receptor binding. 
Introducing this bulky residue has been well tolerated by dopamine D2S receptors effecting 
improved binding affinities and clearly shown for 33 when compared to compounds 28 and 
32. As confirmed by previous findings for the series of mianserin derivatives, the 
naphthalen-2-carboxamide substitution has demonstrated higher affinity for dopamine D3 
receptors as the substitution with benzo[b]thiophen-2-carboxamide, but both aryl amide 
residues showed similar binding data for dopamine D2 receptors. In summary, ketotifen 
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derivatives have demonstrated higher affinities and dopamine D3 receptor-preference (32) 
than those containing mianserin (28) and loratadine (33) substructures. Comparing the 
different heterocyclic hybrid molecules, the loratadine hybrid approach has displayed 
compounds with highest affinity for dopamine D2S receptors.  
For a comprehensive series of potentially privileged structures of histamine H1 receptor 
antagonists, derivatives of the benzyl-N-piperidin-4-ylaniline fragment of bamipine were 
synthesized (35 - 40) (Table 4.10).  
 
Table 4.10 Ki values and Hill coefficients (in parentheses) of bamipine-based hybrids. 
N
N
R²
(CH2)4 R
R1
 
Ki [nM] K i [nM] 
No. R  R
1 R
2 
hD2S hD3 
Ki 
(hD2S
/ 
hD3)  hH1 
Ki 
(hH1/ 
hD3) 
35  N
O
O  
H 
 
340 ± 60 
 (1.36 ±0.67) 
   225 ± 70 
(1.52±0.36)  2 n.d.
a  n.d.
a 
36  N
H
O
 
H 
 
   573 ± 77 
(1.55 ± 0.19) 
   140 ± 50 
(1.93±0.82)  4 n.d.
a  n.d.
a 
37  N
H
S
O
 
H 
 
423 ± 102 
(1.30 ± 0.44) 
60 ± 22 
(1.20±0.59)  7 n.d.
a  n.d.
a 
38  N
H
O
 
2-H3CO  O
 
 8066 ± 242 
(0.99 ± 0.18) 
  512 ± 66 
(1.4 ± 0.47)  16 n.d.
a  n.d.
a 
39  N
H
O
 
2-H3CO H    962 ± 7 
(0.90 ± 0.14) 
7.4 ± 2.6 
(0.9 ± 0.01)  130 
17 ± 4 
(1.03 ± 
0.08) 
2.3 
40  N
H
S
O
 
2-H3CO H    843 ± 40 
(0.71 ± 0.05) 
 7.9 ± 0.6 
(0.95±0.19)  107 n.d.
a  n.d.
a 
an.d., not determined.  
 
The bamipine substructure has been combined with phthalimide (35), cinnamide (36) or 
benzo[b]thiophen-2-carboxamide (37) connected via a butyl linker and the modification 
resulted in nanomolar affinities for dopamine D3 and D2S receptors. Among the series, the 
phthalimide variation has displayed the lowest affinity for dopamine D3 and the highest 
affinity for D2S receptors (35), a preference which has already been described for the 
cetirizine derivative 15 (Table 4.8) and the ketotifen related compound 31 (Table 4.9). 
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Compared to molecule 35 and 36 the benzo[b]thiophen-2-carboxamide (37) has shown 
improved affinity for dopamine D3  receptor with dopamine D3 receptor-preference. 
Replacement of the benzyl ring (36) of the bamipine derivative by a benzoyl residue (38) 
and the additional introduction of a methoxy substitution in 2-position of the phenyl ring 
has not been tolerated and has caused a reduction of dopamine D3 receptor binding and 
even a greater loss of binding at dopamine D2S receptors. Assumingly an additional 
hydrogen bond acceptor moiety has not been favored. 
In the following compounds 39 and 40, the benzyl-N-piperidin-4-ylaniline scaffold of 
bamipine has been structurally diminished into a phenylaminopiperidine moiety with 
methoxy substitution in 2-position on the phenyl system. This modification was further 
varied by introducing a cinnamide residue (39) and a highly selective ligand has been 
obtained. This promising  ligand has presented a pharmacological profile with low 
nanomolar binding data for D3 receptors and a 130-fold selectivity for dopamine D3 over 
D2 receptors. The phenylaminopiperidine (39) residue is an analogue of the 4-(2-
methoxyphenyl)piperazino moiety as seen in BP 897 (cf. 1.2.6). Combined with the 
cinnamide substructure of ST 198 (cf. 1.2.6) the modification has impressively improved 
affinity binding for dopamine D3 receptors. Exchange of the cinnamide residue by the 
potential bioisostere benzo[b]thiophen-2-carboxamide (40) led to a slightly decrease in 
selectivity for dopamine D3 over D2. This observation has been previously described for 
the cetirizine derivatives (26 → 27). 
 
Since many of the moieties introduced into the novel dopamine ligands are well-known 
histamine H1 receptor antagonists, selected compounds were further evaluated on their 
histamine H1 receptor binding properties (Table 4.8 - 4.10). Low nanomolar binding data 
have been obtained for the benzhydryl derivative 18 and the 
hexahydrodibenzopyrazinoazepine derivative 29, both ligands are connected via a butyl 
linker to a cinnamide moiety. Disubstitution of methoxy groups in 2-position on the phenyl 
rings of the benzhydrylpiperazine residue slightly decreased binding affinity for histamine 
H1 receptors (26) compared to its unsubstituted analogue (18). Extension of a piperazine 
ring to 1,4-diazepane (18 → 22) has resulted in reduced binding affinity for histamine H1 
receptors as already seen for D2-like receptors. One may argue that the introduction of 
second generation histamine H1 receptor antagonists may not be the optimal choice since 
these compounds have been prepared for not penetrating the brain and thereby reducing the 
e.g. sedating side effects. It could be shown that the physicochemical as well as the 
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pharmacological properties were largely changed by derivatisations performed leading to 
novel compounds which newly have to be investigated on the brain penetrating or 
multidrug resistance protein binding properties in further studies.  
As intended, introducing dopamine D2/D3 selective (aryl) amide or imide moieties 
connected via a butyl linker to histamine H1 receptor substructure analogues resulted in 
compounds displaying improved binding affinity profiles for dopamine D2 and D3 
receptors compared to their parent histamine H1 receptor antagonists, so called 
“antihistamines”. Hybrid compounds have demonstrated declined binding affinities at 
histamine H1 receptors compared to that of the antihistamines with the exception of 
loratadine derivatives. In Table 4.11 it is demonstrated, that the marketed antihistaminergic 
drugs have shown low binding affinities for dopamine D2S and D3 receptors (Ki ≥ 1 000 
nM for dopamine D2 and D3). As expected with such a hybrid approach most of the 
compounds tested were more potent at histamine H1 receptors than at dopamine D3 or D2 
receptors. Compound 39 was the only exception and showed a 2-fold selectivity for 
dopamine D3 versus histamine H1 receptors. The binding data have demonstrated that the 
binding pocket of the histamine H1 receptor tolerated additional (aryl) amide or imide 
residues. It may be speculated that the additional residues might positively contribute to the 
interaction of the molecules with the histamine H1 receptor binding site. The positive 
binding data thus has reflected the close evolutionary relationship of aminergic receptors. 
 
Table 4.11 Ki values and Hill coefficients (in parentheses) of histamine H1 receptor antagonists. 
Ki [nM]  Compound 
hD2S  hD3  hH1 
Cetirizine  >150.000 >60.000      28 ± 7 
(0.79 ± 0.18) 
Mianserin     2563 ± 845 
  (0.99 ± 0.27) 
1644 ± 87 
(1.23 ± 0.25) 
 0.84 ± 0.26 
(1.18 ± 0.12) 
Ketotifen     4855 ± 1277 
  (1.09 ± 0.33) 
1301 ± 762 
(0.86 ± 0.37) 
 0.34 ± 0.07 
(1.05 ± 0.13) 
Loratadine  43.000 ± 2135 
   (0.82 ± 0.14)  >10.000    130 ± 54 
(1.00 ± 0.06) 
Bamipine     1925 ± 440 
  (1.01 ± 0.09) 
1035 ± 119 
(1.07 ± 0.04) 
    12 ± 0.87 
(1.16 ± 0.51) 
 
Conclusively, the hybrid approach combining substructures of histamine H1 receptor 
antagonists and fragments of dopamine D3 receptor-preferring ligands, related to BP 897, 
ST 198 and analogues, resulted in compounds showing nanomolar affinities for dopamine 
D3 and nanomolar to micromolar affinities for dopamine D2 receptors. The affinity profiles 
of structural modified histamine H1 receptor antagonists have been optimized and 
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improved for dopamine D2 and D3 receptor binding. Binding affinities at histamine H1 
receptors have been decreased for mianserin- and ketotifen-related hybrids, have improved 
for loratadine analogues and have not mainly changed for bamipine- and cetirizine-
substructure bearing compounds. Incorporation of histamine H1 receptor antagonist 
substructures has been tolerated for flexible residues, such as phenylaminopiperidine and 
benzhydryl, while rigid and bulky tricyclic or tetracyclic ring systems were not tolerated by 
dopamine D2 and D3 receptors in this hybrid approach (Figure 4.19). Tri- and tetracyclic 
aromatic residue are fundamental substructures of several antipsychotics with affinities for 
dopamine D2 and D3 receptors. But in this context and applying this hybrid approach, the 
results might indicate a discriminating conformation of the tri- and tetracyclic aromatic 
residue and possibly unfavorable interaction between the basic nitrogen and the conserved 
Asp in TM3 in the binding pocket of dopamine D2 and D3 receptors. Potentially 
bioisosteric variations of the (aryl) amide and imide moieties had only moderate influence 
on D3 receptor binding, but significantly changes on D2S receptor binding were obtained as 
already observed in previous studies.
228 In this investigation clear improvements in 
selectivity ratios for D3 over D2 receptors were gained when cinnamide substituted (Figure 
4.19), with the impressively enhancement of compound 39, exhibiting the highest affinity 
and selectivity for dopamine D3 receptors. This results confirm previous investigation,
126 
suggesting an improved binding of cinnamide residue due to its elongated and rigid 
geometry, noteworthy the linear conjugated structure. By the presented hybrid approach 
deeper insight into ligand binding behavior on several related aminergic receptors has been 
presented. This refined SAR might be useful to design more potent and selective drugs 
with a designed pharmacological profile on multiple targets. 
  R²
N
H
O
N
H
O
N
N
N
R²
R1
n
N
R1
N S
O
Affine and Selective
Dopamine D3 Receptor 
Ligands
 
 
 
N
O
O
N
H
O
N
H
S
O
N
O
O
N
H
O
N
H
S
O N
N
N
N
Cl
 
 
 
 
 
 
 
 
 
Figure 4.19 Model on performed variations. X, fragments of dopamine D3 receptor-preferring 
ligands; Y, elements of histamine H1 receptor antagonists. The green cycle indicates optimization, 
while the red cycle indicates negative influence. 
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4.2.3 Pramipexole and Etrabamine Derivatives 
Considerable advances have been made in defining the pathogenesis and pathology of 
Parkinson’s disease. The effort resulted in the development of novel drugs available for its 
treatment. The pharmacotherapy is still focused on the dopamine precursor levodopa (cf. 
1.2) and in addition, on dopamine agonists such as pramipexole (Sifrol
®, Mirapex
® 
(Boehringer Ingelheim), cf. 1.2.6). One strategy in our laboratory was the synthesize of 
structural variations of the full agonist pramipexole ((S)-(-)-2-amino-6-propylamino-
4,5,6,7-tetrahydrobenzothiazole) and the structurally related dopamine agonist etrabamine 
(6-methylamino-4,5,6,7-tetrahydrobenzothiazole).
133,135,229 Pramipexole has shown agonist 
activity at the presynaptic and postsynaptic dopamine receptors belonging to the D2-like 
receptor family, with highest affinity at dopamine D3 receptors and has been demonstrated 
to be efficacious in treating Parkinson’s disease.
84 Etrabamine has been developed as a new 
long-lasting dopamine agonist for Parkinson’s disease in the 1980’s. It has been 
demonstrated to be more effective than the dopamine agonist apomorphine, has decreased 
the prolactine secretion and did not modify adenylyl cyclase activity.
229  
Starting with 6-alkylamino-4,5,6,7-tetrahydrobenzothiazole, variations were carried out by 
increasing the alkyl chain length on the secondary nitrogen atom in 6-position and as well, 
different substitution pattern in 2-position were constructed (41 - 51). Furthermore, 
modifications on the heteroaromatic moiety were derived by the replacement of the sulphur 
atom by a selenium atom (52 - 54). Results are shown in Table 4.12. Radioligand binding 
studies were carried out under physiological conditions with sodium ions. Competition 
binding curves demonstrated mostly a Hill slope not significantly different from unity and 
were fitted best by a one-site binding model (P < 0.05). In the case of calculated Hill 
slopes significantly different from unity, a better fit of equations indicated a one-site 
binding model under these assay conditions. Dissociation constants (Ki) of pramipexole are 
in good agreement with literature data describing the low affinity site of dopamine D2S and 
D3 receptors (Ki (D2) = 1600 ± 200 nM and Ki (D3) = 15 ± 1 nM).
61 The compounds (41 - 
54) have displayed nano- to micromolar affinity binding at dopamine D3 receptors and 
micromolar affinity binding for dopamine D2S receptors. Among the series of 6-
alkylamino-4,5,6,7-tetrahydrobenzothiazole derivatives, an enlargement in the alkyl chain 
length from methyl (41) to ethyl (42) and propyl (43) has resulted in a clear enhanced 
affinity for dopamine D3 receptor binding and moderately increased affinity at D2S 
receptors, achieving an enhanced selectivity ratio for dopamine D3 over D2 receptors. The 
variations have not resulted in affinity binding and selectivity data superior to pramipexole.  
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Table 4.12 Ki values and Hill coefficients (in parentheses) of pramipexole analogues and related 
compounds.  
S
N
H
N
R
S1
(CH2)n H
  
Se
N
H
N
R
S2
(CH2)n H
 
Ki [nM]  No. S  R
  n
 
hD2S hD3 
Ki (D2S) / 
Ki (D3) 
Pramipexole  S1 NH2  3   2626 ± 267 
   (0.66 ± 0.04) 
     6.59 ± 4.96 
     (0.72 ± 0.09)  399 
41  S1 H 1   21430 ± 3846 
   (0.70 ± 0.05) 
   1112 ± 279 
     (0.92 ± 0.16)  19 
42  S1 H 2    26490 ± 11830 
    (n.d.) 
   210 ± 24 
     (0.94 ± 0.02)  126 
43  S1 H 3   18011 ± 5033 
   (0.58 ± 0.09) 
     93 ± 15 
     (0.93 ± 0.07)  194 
44  S1 Cl 3   11637 ± 1481 
   (0.73 ± 0.11) 
     78 ± 2.4 
    (0.89 ± 0.12)  150 
45  S1 Br 3     7398 ± 1482 
   (0.96 ± 0.08) 
    92 ± 10 
    (1.00 ± 0.19)  80 
46  S1 H3CO 3   18043 ± 5580 
   (0.86 ± 0.12) 
    46 ± 20 
    (0.71 ± 0.05)  392 
47  S1 H5C2O 3   63960 ± 4342 
    (n.d.) 
1205 ± 22 
(0.92)  53 
48  S1 H7C3O 3    2139 ± 945 
    (0.87 ± 0.11) 
 2302 ± 205 
   (1.04 ± 0.06)  0.9 
59  S1  Isoprop-
oxy  3     75925 ± 34896 
   (0.94 ± 0.02) 
  1255 ± 414 
    (0.82 ± 0.13)  61 
50  S1 
Cyclo- 
propyl-
ethoxy 
3  >1000 >1000   
51  S1  F3C- 
H2CO  3      42930 ± 14170 
   (0.55 ± 0.06) 
 1305 ± 556 
    (0.94 ± 0.24)  33 
52  S2 H 2   8030 ± 871 
   (0.80 ± 0.05) 
  118 ± 18 
    (1.02 ± 0.06)  68 
53  S2 Cl 2   10440 ± 2391 
   (0.63 ± 0.03) 
  272 ± 63 
    (0.90 ± 0.30)  38 
54  S2 H2N 2   1798 ± 668 
   (0.71 ± 0.13) 
     15 ± 2.6 
    (0.85 ± 0.17)  120 
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To gain further improvement, the N-propyl substitution has been chosen in the following 
compounds (44 - 51). Introduction of a chlorine (44) or bromine (45) atom in 2-position on 
the heterocyclic aryl moiety has displayed lower affinities for dopamine D3 and D2S 
receptors compared to pramipexole. A markedly impact on binding with higher affinity 
and prominent selectivity for dopamine D3 over D2S receptors has been revealed for the in 
2-position methoxy substituted compound 46, while further enlargement to ethoxy, 
propoxy, isopropoxy and cyclopropylethoxy residues has not been tolerated by both 
receptor subtypes as indicated by compounds 47 → 48 → 49 → 50. Introduction of the 
2,2,2-trifluoro-ethoxy residue in 2-position has also resulted in low binding affinities for 
dopamine D2S and D3 receptors and a moderate selectivity ratio (51). In compounds 52 - 54 
the influence of exchanging the sulphur atom of the thiazole ring by a selenium atom has 
been investigated. The compounds possess an ethyl chain on the basic nitrogen atom in 6-
position and vary in residues in 2-position. The hydrogen substituted compound 52 has 
demonstrated a enhanced binding profile for dopamine D3 and D2S receptors compared to 
the sulphur containing analogue 42,  but has not shown an improved selectivity for 
dopamine D3 receptors. Incorporation of a chlorine atom in compound 53 resulted in 
reduced affinities for dopamine D3 and D2S receptors, while introducing an amino 
functionality (54) has clearly displayed a benefit for dopamine D2S receptor and dopamine 
D3 receptor binding affinities with an increased selectivity for dopamine D3 over D2 
receptors, but has not exceeded the ratio data of pramipexole.  
The development of pramipexole started with the rigidification of the neurotransmitter 
dopamine and the itemisation of the agonist apomorphine ensuing in hydroxyl substituted 
aminotetralin derivatives. It had always been a challenge to replace the catechol or phenol 
structure with a bioisosteric heteroaromatic moiety to avoid but improve metabolically 
instability and low oral bioavailability.
132 Exchange of the phenol feature of aminotetralin 
derivatives by a more lipophilic 2-aminothiazole resulted in pramipexole.
133 In this 
investigation, clear insights into structure-affinity relationships of pramipexole derivatives 
have been gained. It is already known that the length of the alkyl substituent on the 
secondary nitrogen atom in 6-position is important for affinity binding at dopamine D2 and 
D3 receptors and best results have been demonstrated for a N-propyl residue, as found in 
pramipexole and rotigotine (cf. 1.2.6).
133,230 The extension of the N-alkyl chain on the 
secondary basic nitrogen from methyl to ethyl and propyl (41  →  42  →  43) and 
subsequently the improved binding affinities for both dopamine receptor subtypes clearly 
confirm these previous results.
132,230 The lipophilic character of the propyl chain and the 
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possibility of the N-propylamine to freely rotate might contribute to the interaction of the 
positive charged nitrogen under physiological conditions with the highly conserved 
aspartate of the dopamine D2 and D3 receptor. Furthermore it has been previously shown in 
our research group (data not shown)
231 and by Schneider et al.,
133 that a primary 6-amino 
function is less affine. Another outcome of this structure-affinity relationship is the 
importance of the amino group in 2-position of the thiazole ring. Pramipexole and 
compound 54 have shown an increased affinity binding for both dopamine D2S and D3 
compared to the hydrogen, halogen or ether substituted compounds. The exocyclic amino 
group may substitute for the hydroxyl group of the catechol structure and as a hydrogen-
bond donor it interacts with the serine residues in TM5 of the dopamine receptors. The 
methoxy substituted compound 46 has shown high affinity binding for dopamine D3 and 
micromolar affinity binding for dopamine D2 receptors, and the modification has 
demonstrated as remarkable selectivity for dopamine D3 receptors comparable to 
pramipexole. The methoxy group, comprising electron donor properties, might interact as a 
hydrogen-bond acceptor with the binding site; however, further enlargement of the alkyl 
chain (47 - 50) and additional fluoro substitution (51) have not been tolerated at both 
dopamine receptor subtypes. Worth mentioning that the propoxy substituted compound 48 
has shown similar micromolar binding affinities at dopamine D3 and D2 receptors without 
any receptor preference. The electron rich and withdrawing halogen atoms in compound 
44, 45, and 53 have also decreased binding affinities compared to that of pramipexole. This 
can be explained by the lack of forming hydrogen bonds to the receptor binding sites. The 
replacement of the sulphur atom by a selenium atom increased affinities for dopamine D2S 
and D3 receptors (42  →  52). Furthermore, the selenium derivative 54 has the closest 
structural similarity to pramipexole and has demonstrated the highest affinity for dopamine 
D3 receptors among this series of pramipexole analogues. An increase in lipophilicity due 
to the exchange of sulphur by selenium might cause interference with other important 
interaction points. Additional beneficial effects of selenium are its antioxidative and free 
radical scavenger properties and may possibly reduce the progression of Parkinson’s 
disease.
232 
Positively encouraged by the results of the pramipexole analogues and related compounds 
(see Table 4.12), the studies have been continued and extended. It was of interest to 
investigate in combining two structural dopamine D3 receptor pharmacophore elements, 
namely the 6-amino-4,5,6,7-tetrahydrobenzothiazole moiety and the naphthalen-2-
carboxamide residue, with high affinity and selectivity for dopamine D3 receptors in order 
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to further improve affinity binding and selectivity. The 6-amino-4,5,6,7-
tetrahydrobenzothiazole moiety is not only the substructure of pramipexole, it also presents 
the structural motif of etrabamine, a dopamine agonist developed for Parkinson’s 
disease.
229 The naphthalen-2-carboxamide moiety is found in the D3-receptor preferring 
compound BP 897 and has confirmed to enhance high dopamine D3 receptor affinity 
binding.
140 It had been assumed that introducing an additional dopamine D3 receptor 
pharmacophore element has a positive impact on the interaction with dopamine D3 receptor 
binding sites. Therefore the naphthalen-2-carboxamide residue has been coupled to the 
etrabamine motif via an alkyl chain varying in length. Moreover, alterations in the 
substitution pattern on the basic nitrogen of the etrabamine derivative have been conducted 
to examine its influence on affinity binding (Table 4.13).  
 
Table 4.13 Ki values and Hill coefficients (in parentheses) of naphthalen-2-carboxamide 
derivatives.  
S
N
N
R
N
H
O
(CH2)n
 
Ki [nM]  No. R n 
hD2S hD3 
Ki (D2S) / Ki (D3) 
55  C2H5 2   2549 ± 302 
   (0.78 ± 0.01) 
 68 ± 21 
 (0.93 ± 0.15)  38 
56  H 4  20997 ± 2552 
   (0.75 ± 0.16) 
147 ± 30 
   (0.99 ± 0.23)  143 
57  CH3  4     3824 ± 1104 
   (0.85 ± 0.16) 
 25 ± 9.6 
(0.79 ± 0.13)  153 
58  C2H5 4    1567 ± 303 
    (0.64 ± 0.09) 
2.7 ± 0.9 
 (1.00 ± 0.29)  580 
59  C3H7 4    873 ± 388 
  (0.89 ± 0.10) 
1.16 ± 0.2 
 (1.23 ± 0.06)  753 
60  Allyl 4  459 ± 83 
   (0.89 ± 0.18) 
0.95 ± 0.2 
 (1.12 ± 0.05)  483 
61  Propargyl 4   9078 ± 684 
   (0.69 ± 0.04) 
7.76 ± 1.4 
 (1.06 ± 0.36)  1170 
 
Compounds linked via a tetramethylene spacer (56 – 61) have shown low nanomolar to 
nanomolar affinity binding for dopamine D3 receptors and moderate micromolar to 
nanomolar binding at dopamine D2S receptors. Compound 56,  possessing secondary 
nitrogen, has displayed only moderate affinity for dopamine D3 and resulted in a loss of 
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affinity binding for D2S receptors compared to its tertiary analogues 57 - 61. Compounds 
with an increasing saturated alkyl chain (methyl (57) → ethyl (58) → propyl (59)) on the 
basic nitrogen of the etrabamine element have demonstrated an improved binding profile 
with low nanomolar affinity data for the dopamine D3 receptor and moderate micromolar 
to nanomolar binding affinities for dopamine D2 receptors. Consequently, this 
modification has led to a superior selectivity for dopamine D3 receptors. Shorten the 
tetramethylene spacer of the ethyl substituted derivative (58) to 2 methylene units (55) has 
significantly reduced D3 receptor affinity and has moderately decreased D2S receptor 
affinity. For a comprehensive investigation, the saturated propyl chain (59) has been 
replaced by an unsaturated allyl (prop-2-enyl) residue (60) and this variation has improved 
the affinity for dopamine D3 receptors with the most promising subnanomolar Ki value in 
this series, although the positive impact on dopamine D2S receptor binding slightly has 
decreased the selectivity ratio for dopamine D3 over D2 compared to the saturated analogue 
(59). Exchange of the allyl (60) by a propargyl (prop-2-inyl) (61) moiety has exhibited 
high affinity binding for the dopamine D3 receptor but further enhancement compared to 
compound 60 has not been revealed. Whereas the introduction of the propargyl residue has 
caused a loss of affinity binding at dopamine D2S receptors and to this point the most 
selective compound in this current approach has been achieved.  
Investigation in structure-affinity relationships has apparently demonstrated that the 
existence of basic tertiary nitrogen has positive impact on receptor-ligand interaction. 
Compound 56 has a secondary nitrogen atom and this modification has shown reduced 
binding affinities for both dopamine receptor subtypes. This result emphasizes the 
importance of the protonated nitrogen of ligands allow them to interact with Asp 110 (D3) 
and Asp 114 (D2) in TM3 and to serve as a main anchor point for receptor-ligand 
interaction, which is conserved among aminergic GPCRs.
122 As already discussed for 
pramipexole derivatives (see Table 4.12, 43 – 51) the enlargement of the alkyl substituent 
on the nitrogen atom is crucial for affinity binding and dopaminergic activity. A N-propyl 
specific binding pocket has been proposed which is responsible for hydrophobic 
interaction between the alkyl chain of the ligand and the binding site of the receptor.
230 The 
pharmacological data (57 → 58 → 59) of this study are in good agreement with these 
previous studies. It is noteworthy that the unsaturated allyl residue (60) increased affinity 
binding for both receptor subtypes compared to the saturated propyl analogue (59) 
probably caused by π-electron interaction and a rigidized alkyl residue. Nevertheless, 
compound 60 has not enhanced selectivity for dopamine D3 over D2 receptors. Introducing 
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a linear and π-electron rich moiety such as a propargyl moiety (61) has strongly decreased 
dopamine D2S affinity binding and moderately lowered dopamine D3 affinity binding 
resulting in an superior selectivity for dopamine D3 receptors. The propargyl residue is also 
found in selegilin (Movergan
®) and rasagilin (Azilect
®),
233,234 two selective MAO-B-
inhibitors for the treatment of Parkinson’s disease. The alkinyl residue covalently binds to 
a flavin-cofactor and consequently causes irreversible inhibition.
21 Moreover both 
compounds demonstrate neuroprotective properties and it is proposed that the propargyl 
moiety is involved in multiple survival signaling transduction pathways.
26,233,235 It might be 
of interest to investigate in MAO-B-inhibiting activities of compound 61. Another crucial 
aspect is the effect of the tetramethylene spacer as a linker. Extension of an ethyl (55) to a 
butyl spacer (58) has only moderate influence on dopamine D2S binding affinity but has 
caused major improvement on dopamine D3 receptor affinity. The extended and more 
linear ligand conformation has been favoured by dopamine D3 receptors while dopamine 
D2S receptor ligands have a bent and shorter conformation. This influence has already been 
described by our working group in previous studies.
126 The hydrophobic aryl moiety 
connected to an amide, here represented by naphthalen-2-carboxamide, has to have a 
certain distance to the basic nitrogen in order to allow interference with diverse interaction 
points in the binding site. In summary, by incorporating an additional dopamine D3 
receptor-preferring pharmacophore element compounds with enhanced affinities and high 
selectivity for dopamine D3 receptors have been achieved.  
Taking into account, that the tetramethylene spacer has proved to be favourable for affinity 
binding and selectivity for dopamine D3 receptors and furthermore considering the positive 
effect on binding affinity for dopamine D3 when the basic nitrogen is propyl substituted, a 
bioisosteric replacement of naphthalen-2-carboxamide by a cinnamoyl residue has 
consequently been constructed for further development of affinity binding and selectivity 
for dopamine D3 receptors (Table 4.14). The cinnamoyl residue has been recognized in ST 
198 (cf. 1.2.6) and incorporation of the structural element into molecules has demonstrated 
high affinity and selectivity for dopamine D3 receptors (cf. 4.2.2).
228 Furthermore, the 
influence of halogen substitution in para- and/or ortho-positions on the phenyl ring of the 
cinnamide residue has been investigated. 
The halogen unsubstituted hybrid molecule 62 has demonstrated low nanomolar binding 
data for dopamine D3 receptors and micromolar affinity binding at dopamine D2S 
receptors, subsequently a high selectivity for the dopamine D3 receptor has been revealed. 
Introducing chlorine substitution in ortho- and para-position (63) on the phenyl ring 
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increased affinity for dopamine D3 and D2S compared to that of the unsubstituted 
compound (62), but unfortunately this substitution pattern also reduced selectivity for 
dopamine D3 receptors. Further modification on the phenyl system gave the para-
substituted fluoro compound 64. The fluorine incorporation has prominently improved 
binding and resulted in subnanomolar affinities for dopamine D3 receptors. Whereas a 
diminished binding at dopamine D2 receptors remarkable enhanced selectivity and the 
most affine and selective dopamine D3 ligand not only in this series but also in the series of 
pramipexole and etrabamine derivatives has been recognized. 
 
Table 4.14 Ki values and Hill coefficients (in parentheses) of cinnamoyl derivatives.  
S
N
N
N
H
O R1
R 
Ki [nM]  No. R  R
1 
hD2S hD3 
Ki (D2S) / Ki (D3) 
62  H H   4015 ±383 
    (0.47 ± 0.08) 
8.11 ± 1.2 
  (1.00 ± 0.23)  495 
63  Cl Cl    445 ± 55 
    (0.81 ± 0.05) 
  2.41 ± 1.06 
  (1.02 ± 0.27)  185 
64 
(ST 625)  F H   842 ± 35 
   (0.67 ± 0.02) 
  0.57 ± 0.04 
  (0.90 ± 0.22)  1477 
 
With the exchange of the naphthalen-2-carboxamide moiety into a cinnamide residue, a 
bioisosteric rigid structure has been introduced. This E-cinnamide element, taken from ST 
198, has been known as a high selective pharmacophore feature for dopamine D3 receptors. 
Mono-, di-, and trisubstituted cinnamoyl derivatives have been entirely discussed in our 
working group,
126 but in this research the moiety has been coupled to an etrabamine 
residue for the first time. As expected for this structural class, the preference for dopamine 
D3 receptors has been remarkably demonstrated. The fluorine monosubstitution (64) on the 
phenyl ring of the cinnamide residue has been favoured to chlorine disubstitution (63) and 
has been superior to the unsubstituted compound (62). The 4-fluoro substituent on the 
phenyl system (64, ST 625) is electron-rich and electron-withdrawing and has shown 
enhanced binding data with an impressive selectivity for dopamine D3 over D2 receptors. 
Additional lipophilic interaction with the receptor site might contribute to the promising 
results. On the other hand, a disubstitution (63) restricts the orientation of the cinnamide 
towards the basic nitrogen and the thiazole ring to a certain position and might decrease the 
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affinity. Compound 64  (ST 625)  represents a promising potential radioligand for PET 
studies and further investigation in functional test systems and in vivo studies is highly 
required. Conclusively, the approach of combining two important dopamine D3 receptor 
structural pharmacophore elements has been successful and compounds, in particular when 
para-fluoro substituted, have been achieved with high affinity and selectivity for dopamine 
D3 receptors. Prospectively, to complete structure-affinity relationships differently halogen 
substituted cinnamoyl compounds need to be synthesised and studied.  
In the first approach (Table 4.13), the aryl amide of the lead structure BP 897 has been 
incorporated. In the following study the basic amine aryl residue of BP 897, 4-(2-
methoxyphenyl)piperazine, has been coupled to the etrabamine structure. This strategy 
considered different alkyl chain length as spacer while the basic nitrogen of the etrabamine 
residue has been substituted with an ethyl residue (Table 4.15). 
 
Table 4.15 Ki values and Hill coefficients (in parentheses) of 4-(2-methoxyphenyl)piperazine 
derivatives.  
S
N
N
N
N
H3CO
(CH2)n
 
Ki [nM]  No. n 
hD2S hD3 
Ki (D2S) / Ki (D3) 
65  2  148 ± 23 
  (1.00 ± 0.06) 
14 ± 1.1 
(0.92 ± 0.22)  11 
66  3  140 ± 22 
(1.03 ± 0.1) 
89 ± 1.7 
(0.92 ± 0.09)  2 
67  4  480 ± 51 
  (0.86 ± 0.18) 
55 ± 16 
(0.84 ± 0.13)  9 
 
All compounds have demonstrated nanomolar binding affinities at dopamine D3 and D2S 
receptors with moderate preference for the dopamine D3 receptor. Two and four methylene 
units as a spacer were well tolerated at dopamine D3 receptors (65, 67), while two and 
three methylene units have been more favored by dopamine D2S receptors (65, 66). By 
coupling a 4-(2-methoxyphenyl)piperazine residue to an etrabamine feature, a second basic 
tertiary amine has been introduced. Under physiological conditions at least two of the three 
nitrogen atoms are protonated. It is assumed that the basic aryl amine component of BP 
897 is important for its partial agonism.
126 Data indicate that the additional protonated 
nitrogen of the ligand has been well tolerated at dopamine D2S receptors, while further 
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improvement in binding at dopamine D3 receptors has not been revealed. Nevertheless, due 
to its nanomolar affinities at both dopamine receptor subtypes, compound 66 might be an 
interesting and worthwhile ligand for the treatment of Parkinson’s disease.  
It might be of high interest to investigate in computer-based approaches and study the 
docking of the combined dopamine D3 receptor pharmacophore elements bearing 
molecules into the binding pocket of dopamine D3 and D2 receptors. It is most likely that 
the ligands have two different orientations to allow reinforced ionic bonds of the 
protonated nitrogen with the highly conserved aspartate in TM3. Additionally, the results 
have shown that dopamine D2 receptors favour ligands with a short and bend conformation 
(65, 66) while dopamine D3 receptors prefer ligands with a more linear conformation (65, 
67).
126 This assumption has already been confirmed by binding data of compounds 55 and 
58. 
In the next step, varied heteroaryl amide moieties, including benzo[b]thiophen-2-
carboxamide and its structural analogue benzo[b]thiazol-2-carboxamide, have been linked 
via butyl chain to the etrabamine structure (Table 4.16). The benzo[b]thiophen-2-
carboxamide residue is taken from FAUC 365, a dopamine D3-preferring ligand (cf. 1.2.6). 
In previous studies the tetramethylene spacer has been clearly preferred by dopamine D3 
receptors and consequently it has been used for further improvement of ligand binding. As 
already mentioned in earlier studies, the extension of the alkyl substituent on the basic 
nitrogen is considered to be critical to the dopaminergic activity. Therefore, evaluation of 
varying alkyl length has been carried out. 
In the series of benzo[b]thiophen-2-carboxamide compounds (68 - 71) the growing alkyl 
chain on the basic nitrogen has produced molecules exhibiting steadily increasing affinity 
binding for dopamine D2S receptors. The affinity for dopamine D3 constantly increased 
from the unsubstituted (68) to methyl-, (69) and ethyl-substituted (70) ligand. Introduction 
of the ethyl substituent (70) on the basic nitrogen resulted in the most promising ligand 
within this series, demonstrating low nanomolar affinity at dopamine D3 receptors while its 
affinity for dopamine D2S proved to be in the micromolar range. Consequently, the 
modification resulted in a remarkably selectivity ratio for dopamine D3 receptors. Further 
extension to propyl substitution (71) has slightly decreased affinity binding for dopamine 
D3 receptors compared to compound 70 and accordingly lowering the selectivity ratio. 
Bioisosteric replacement of benzo[b]thiophen-2-carboxamide with a benzo[b]thiazol-2-
carboxamide moiety has led to compound 72 and 73. While secondary nitrogen bearing 
compound 72 has revealed a loss of affinity binding for dopamine D2S and micromolar 
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affinity binding for dopamine D3 receptors, tertiary N-propyl substituted compound 73 has 
demonstrated improved binding affinity for both dopamine receptor subtypes compared to 
71 and 72, and an increase in selectivity for dopamine D3 receptors.  
 
Table 4.16 Ki values and Hill coefficients (in parentheses) of heteroaryl amide derivatives.  
S
N
N
(CH2)4
R
R1
 
Ki [nM]  No. R  R
1 
hD2S hD3 
Ki (D2S) /  
Ki (D3) 
68  H  N
H
S
O
 
 23420 ± 1217 
   (1.02 ± 0.23) 
292 ± 41 
  (0.92 ± 0.18)  80 
69  CH3  N
H
S
O
 
 3388 ± 388 
   (1.13 ± 0.20) 
  53 ± 5.1 
  (1.06 ± 0.22)  64 
70  C2H5  N
H
S
O
 
 2496 ± 463 
   (0.58 ± 0.06) 
  2.92 ± 0.48 
  (0.96 ± 0.15)  855 
71  C3H7  N
H
S
O
 
 2278 ± 105 
   (0.88 ± 0.12) 
16 ± 6 
  (0.93 ± 0.17)  142 
72  H  N
H
O
N
S
 
24480 ± 7580 
(0.81) 
1895 ± 510 
 (0.73 ± 0.21)  13 
73  C3H7  N
H
O
N
S
 
 1667 ± 602 
   (0.55 ± 0.04) 
  4.53 ± 0.91 
 (1.04 ± 0.37)  368 
74  C2H5  N
H
O
N
S
 
 2101 ± 327 
   (0.76 ± 0.13) 
5.61 ± 0.3 
  (0.92 ± 0.24)  375 
75  C3H7  N
H
O
N
S
 
   347 ± 133 
   (0.78 ± 0.19) 
  0.65 ± 0.09 
  (0.82 ± 0.08)  534 
 
To further evaluate regiochemistry, the benzo[b]thiazole residue has been attached to the 
carboxamide moiety in 6-position (74,  75). The N-ethyl substituted ligand (74) has 
displayed micromolar affinity binding for dopamine D2S and nanomolar affinity and high 
selectivity for dopamine D3 receptors. N-propyl substitution (75) has resulted in nanomolar 
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affinity for dopamine D2S and subnanomolar affinity binding for dopamine D3 receptors 
with improved selectivity ratio.  
Heteroaromatic moieties play a major role in dopamine D3 receptor affinity and selectivity. 
Introducing benzo[b]thiophen-2-carboxamide, benzo[b]thiazol-2-carboxamide, and 
benzo[b]thiazol-6-carboxamide residues led to high affine and selective dopamine D3 
receptor ligands. In this series, the FAUC 365 related compound 70 has displayed the 
highest selectivity for dopamine D3 receptors. The benzo[b]thiophen-2-carboxamide 
scaffold in FAUC 365 has also proved to effect high selectivity for dopamine D3 receptors. 
An additional heterocyclic nitrogen atom in molecule (71 → 73, 75) has increased affinity 
binding for both receptor subtypes and enhanced selectivity ratio for dopamine D3 
receptors. Similar to sulphur, the nitrogen is able to form a hydrogen-bond with the binding 
sites of the dopamine receptor. Attaching the heteroaromatic residue in 6-position seems to 
be beneficial for the steric orientation of the etrabamine residue and benzo[b]thiazole-6-
carboxamide moiety and allows stronger interaction with the dopamine receptor as 
indicated by compound 75. Structural analogues of the propyl substituted etrabamine 
derivative 70 have been already discussed in Table 4.14 (62 - 64). As seen before (56), 
etrabamine derivatives with a secondary nitrogen (68, 72) have shown a complete loss of 
affinity for dopamine D2S and micromolare to moderate nanomolar affinities for dopamine 
D3 receptors. Data confirm the importance of the tertiary basic nitrogen to interfere with 
aspartate in TM3. By varying the N-alkyl chain the importance of the N-propyl binding 
motif has been verified for benzo[b]thiazole carboxamide ligands (72 → 73, 74 → 75), but 
it has not been demonstrated for benzo[b]thiophen-2-carboxamide derivatives (68 → 71). 
In summary, this process has been successfully applied by combining etrabamine 
derivatives with heteroaryl amide moieties. 
Diverse structural elements such as a phenyl substituted thiazole carboxamide residue; a 
phenyl moiety or saturated propyl chain, have been coupled to either the etrabamine 
structure or pramipexole (Table 4.17). The etrabamine derivative 76 has been linked to a 
thiazole carboxamide, and this moiety has been extended by a para-chloro phenyl 
substituent. This enlargement has been well-tolerated by the dopamine D3 receptor 
demonstrating nanomolar affinity binding, but introducing the lipophilic aromatic residue 
has caused moderate affinity binding at dopamine D2S. In compound 77 the lipophilicity 
has been increased by combining the etrabamine motif linked via a butyl spacer to a phenyl 
substituent. The ligand has only displayed micromolar affinity for both dopamine receptor 
subtypes. The lack of hydrogen-bond donor or acceptor atoms, mostly represented by 
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amide functionality, and the incorporation of a lipophilic, flexible extended residue might 
have caused the decreased affinities. Compound 78 has close structural similarity with 
pramipexole. Introducing an additional methylene unit between the 2-
aminotetrahydrobenzothiazole and the propylamine residue has induced a lack of affinities 
at dopamine D2S  and D3 receptors demonstrated by binding data in the micromolar 
range.
133 This result has shown that the positions of the exocyclic amino functionality and 
thiazole system relative to the basic nitrogen play an important role for affinity binding.  
 
Table 4.17 Ki values and Hill coefficients (in parentheses) of diverse structural elements.  
Ki [nM] 
No. Structure 
hD2S hD3 
Ki (D2S) / 
Ki (D3) 
76  N S
N
N
H
O
N
S Cl
 
 2522 ± 144 
   (1.08 ± 0.10) 
83 ± 2 
  (1.16 ± 0.24)  30 
77 
H
N
N
S
 
 8437 ± 195 
   (0.87 ± 0.21) 
1447 ± 526 
  (1.06 ± 0.21)  6 
78 
S
N
H2N
N
H
 
>20.000 >15.000   
 
The combination of dopamine D3 receptor pharmacophore features has been successfully 
applied; combining the etrabamine motif with aryl amide residues has resulted in 
compounds with high affinity and prominent selectivity for dopamine D3 receptors. In 
contrast, incorporating aryl residues linked via a butyl spacer has revealed ligands which 
have not obviously discriminated the dopamine receptors.  
Further investigations contain in vitro functional assays to assess intrinsic activities and 
also  in vivo studies to determine the pharmacological effects. Pramipexole has 
demonstrated a remarkable receptor profile. It has shown a high selectivity for dopamine 
D2-like receptors with highest affinity for dopamine D3 receptors, whereas only small 
interaction with aminergic receptors has been noticed.
236,237 This binding profile lowers the 
risk of dyskinesia and cardiovascular side-effects. Pharmacokinetic studies revealed no 
potential to interact with other drugs via the cytochrome P450 enzyme system.
238 
Pramipexole also provides neuroprotective effects and therefore may delay disease 
progression.
84 Consequently, prospect studies might concentrate on a homogeneity in 
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receptor binding profiles, pharmacokinetic properties and neuroprotective effects of the 
novel pramipexole and etrabamine derivatives. 
It is of interest, if these large molecules still allow the receptor to change its conformation 
in order to fully activate the receptor. It is noteworthy to mention, that agonist binding is 
far more complex than antagonist binding. If agonist binding is directly measured with an 
agonist radioligand, then only the high affinity binding of the ligand may be observed and 
show higher affinity in inhibiting agonist radioligands than antagonist radioligands. 
Radioligand agonist competition is more relevant assessing receptor selectivity data for 
agonists; otherwise an overestimation of selectivity might be concluded.  
In summary, introducing an additional dopamine D3 receptor pharmacophore element into 
pramipexole or etrabamine resulted in numerous compounds with high affinity and 
remarkable selectivity for dopamine D3 receptors. Further studies might underline the 
potential of the ligands as drug candidates. 
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4.3 Virtual Screening Leading to New Scaffolds  
Due to the lack of a crystal structure of dopamine receptors an accurate three-dimensional 
(3D) structure of the receptor has not been available.
121 Therefore ligand binding at 
dopamine receptors and the structural requirements for affine and subtype selective ligands 
is not completely resolved.
121 Knowledge has principally based on investigations in 
structure-activity relationships of ligand binding and new lead finding is a difficult task. It 
is noteworthy that dopamine D2 and D3 receptors display a high sequence identity and the 
similarity of binding sites is still a challenge to obtain an improved selectivity for 
dopamine D3  receptor ligands.
24,239 Since much effort has been made in the field of 
chemical synthesis, investigation in computational chemistry as an alternative and 
worthwhile approach has been done to identify novel lead candidates with high affinity 
binding and dopamine D3 receptor-preference.
121,126,240 As one complement to HTS, 
ligand-based virtual screening methods have been successfully applied. Especially the 
support vector machine (SVM) approach, originally implemented to solve binary class/non 
class separation tasks,
177 has been introduced successfully for pharmaceutical data analysis 
and has shown promising applications in the prediction of GPCR ligands.
241,242 
Consequently, this method was investigated for virtual screening at dopamine D2 and D3 
receptors in order to find new leads. Achieved and ordered compounds were 
pharmacologically tested (see 4.3.1). Encouraged by the results of the SVM approach, 
further various classification techniques were applied to succeed in novel lead 
identification. Clustering-based VS methods, regression-based VS and pharmacophore-
based VS approaches were employed to improve the lead finding process. Identified 
molecules were assessed for affinity binding at dopamine D2S and D3 receptors (see 4.3.2). 
4.3.1 Support Vector Machine Based Virtual Screening 
Support vector machine (SVM) based virtual screening was performed to find novel lead 
structures with high affinity and selectivity for dopamine D3 receptors. The detailed 
screening procedure is described by Byvatov et al.
9 Generally, SVM classifiers are 
generated by a two step-procedure: first, sample data are described by labeled vectors and 
are projected to a high-dimensional space. Then the algorithm finds a class-separating 
linear hyperplane in this high-dimensional space, and finally, this hyperplane is projected 
back to the original data-space.
177 The aim of a classifier is to generate the hyperplane with 
the largest margin separating classes of a data vector. In the first step, a SVM was trained 
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on a reference (training) active dataset (N = 395) using analogues and related derivatives of 
BP 897 with defined Ki values of dopamine D2 and D3 receptor affinities. Each compound 
was described by a fingerprint of three-point pharmacophores (3PP). In addition to the 
binary SVM optimized, a regression SVM was generated to predict the logarithm of the 
ratio between Ki values for dopamine D2 and D3 receptors. By combining theses models 
dopamine D3 receptor-selective ligands should be identified. Virtual screening of synthetic 
compounds from the collection of Interbioscreen (IBS) (N = 25,601, release February 
2004, Interbioscreen Ltd., 121019 Moscow, Russia) resulted in 169 molecules predicted to 
be active. Regarding poor solubility, potential chemical reactivity, and dissimilarity to 
dopamine leads, eleven compounds were manually selected and screened for binding 
affinities at dopamine D2S and D3 receptors. Data are shown in Table 4.18. 
Table 4.18 Dopamine receptor affinities of compounds from the first virtual screening cycle. 
Ki [µM]  No. Structure 
hD2S hD3 
79 
                     
N
N  
< 2  < 2 
80 
      
O
O
N
O
O
O
 
2 - 6  < 2 
81 
    
N
N
 
2 - 6  2 - 6 
82 
N
N
 
> 6  2 - 6 
83 
    
O
N
 
> 6  2 - 6 
84 
     
O
N
 
> 6  2 - 6 
85 
                 
N N O  
> 6  > 6 
86 
     O
N
F
N O
O
 
> 6  > 6 
87 
                     
N
O
O
N
 
> 6  > 6 
88 
               
N
O
N
NO2 
> 6  > 6 
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Table 4.18 (continued) 
Ki [µM]  No. Structure 
hD2S hD3 
89 
     
O
N
O
 
> 6  > 6 
 
Although most of the compounds have shown binding affinities in the micromolar range at 
dopamine D2S and D3 receptors, compounds 79 and 80 have demonstrated < 2 µM binding 
affinities at the dopamine D3 receptor. Compound 80 was the most promising ligand with a 
Ki(D3) < 2 µM and Ki(D2) 2 – 6 µM and was used for further optimization.  
For the purpose of improving dopamine D3 receptor affinity and selectivity, an 
optimization of compound 80 was performed using a similarity search approach based on 
3PP pharmacophores which were important for the SVM prediction. Virtual screening of 
the SPECS collection (N = 229,685, release January 2004, SPECS, 2628 XH Delft, The 
Netherlands) was carried out. 134 compounds were obtained and manually selected by 
criteria of drug-likeness, diversity and novelty. Finally, five compounds were tested for 
binding affinities at both dopamine receptor subtypes (Table 4.19). A short overview of the 
design of the experiment is shown in Figure 4.20. 
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Figure 4.20 Design of the experiment of support vector machine approach. 
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Table 4.19 Dopamine receptor affinities of compounds from the second virtual screening cycle 
(from Specs catalogue). 
Ki [nM]  No. Structure 
hD2S hD3 
Ki (D2S) /  
Ki (D3) 
90 
N
N
 
1414 ± 516 
(1.35 ± 0.43) 
1408 ± 1068 
(1.38 ± 0.5)  1 
91 
   
O
N
O
N
N Cl
 
554 ± 97 
(1.13 ± 0.22) 
40 ± 6 
(1.06 ± 0.15)  14 
92 
   
O
N
O
N
N Cl
 
417 ± 60 
(1.12 ± 0.13) 
139 ± 17 
(1.18 ± 0.15)  3 
93 
N
H
N
O
 
201 ± 48 
(1.03 ± 0.13) 
96 ± 21 
(1.09 ± 0.30)  2 
94 
             
N
O
 
4395 ± 497 
(0.87 ± 0.08) 
914 ± 307 
(1.10 ± 0.17)  5 
 
In the similarity search,
9 four out of five compounds have displayed nanomolar affinities at 
dopamine D3 receptors. Compounds 91 - 93 possess the structural important features for 
dopamine D2 and D3 antagonist binding: a basic amine aryl moiety, represented by the 4-
phenylpiperazine motif (91, 92) as seen in BP 897 (cf. 1.2.6) or phenylpiperidine (93) 
found in the dopamine D2-preferring haloperidol (cf. 1.2.6), a linear tetramethylene chain, 
and an aryl substituted hydrogen-bond acceptor. In this series the benzo[1.4]oxazin-3-one 
compound  91 has demonstrated high affinity binding and a clear preference for the 
dopamine D3 receptor. In this molecule, the amide functionality is rigidly incorporated into 
the heteroaromatic moiety. This favorable orientation contributes to the binding profile. 
Docking of compound 91 into a homology model of dopamine D3 has been constructed 
based on a 2.8 Å resolution rhodopsin crystal structure (PBD-code 1F88).
9 Insight in 
protein-ligand binding interactions has been shown in Figure 4.21. In the active site the 
residues Asp110, Ser192, Phe345, and Phe346 are predicted to be important for ligand 
binding, exemplified by 91, to the dopamine D3 receptor. Introducing an additional methyl 
residue into the benzo[1.4]oxazin-3-one moiety (92) has clearly decreased affinity binding 
for dopamine D3 receptors. In compound 94 the non-polar N,N-dipropyl residue was 
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recognized, a feature which has already described for diverse dopamine D3 agonist such as 
(R)-(+)-7-OH-DPAT (cf. 1.2.6).  
The results of the first cycle have been of limited success only and might be explained by 
the manual post-selection of the molecules. The goal of this investigation was a maximum 
of diverse and dissimilar compounds with affinity binding for dopamine D3 receptors. This 
concept has resulted in reduced binding affinities for both receptor subtypes. The SVM 
was trained on a data set of analogues of BP 897 represented by the general structural 
pattern of a hydrophobic residue connected to an amide, an alkyl spacer and a basic 
lipophilic amine aryl moiety.
9,243 
 
Phe 345
Phe 346
Ser 192
Asp 110
Phe 345
Phe 346
Ser 192
Asp 1
 
 
10
 
 
 
 
 
 
 
 
 
 
Figure 4.21 Docking of compound 91 into homology model of human dopamine D3 receptor.
9 
 
In the first cycle all obtained compounds had basic tertiary nitrogen atoms, but only 
compounds 79 and 80 generally fulfilled requirements of this structural pattern and gave 
moderate binding affinities for dopamine D2S and D3 receptors. Some compounds had two 
basic nitrogen atoms, lacked of hydrogen-bond functionality, or demonstrated enlarged 
spacer with an additional ether function. This might give an explanation for the missing 
affinity binding. In the second cycle, a focused SVM based-similarity search was 
employed. All important features for interaction between ligand and dopamine receptor, 
such as basic nitrogen, hydrogen-bond functionality, and aromatic residue, were 
considered. Unfortunately, but not unexpected, compounds 91 - 93 have displayed 
structural similarity to the reference set, while 80, 90, 93 and especially 94 have contained 
novel structural features. These promising leads can be further optimized by chemical 
modifications to improve binding affinity and selectivity for dopamine D3 receptors. The 
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applied iterative virtual screening cycles with SVM have been successful and lead 
scaffolds have been identified. 
4.3.2 Lead Identification Strategies for Dopamine D3 Receptor Ligands  
To increase the success rate in the lead identification process for dopamine D3 receptors 
several classification techniques were employed to generate novel lead scaffolds. Detailed 
procedures are described by Böcker.
244 Clustered-based virtual screening was applied 
using two hierarchical clustering methods,
245 namely NIPALSTREE and hierarchical k-
means, and self organizing maps (SOM). 472 compounds with defined Ki binding affinity 
values at dopamine D2 and D3 receptors and the SPECS catalogue (released June 2003) 
were taken as a data set. The 472 ligands are mainly analogues of our lead structure BP 
897 (cf. 1.2.6), a selective dopamine D3 receptor partial agonist, which can be divided into 
three different features: (i) an aryl amide moiety, (ii) an alkyl spacer, (iii) a basic 
alkanamine residue with aryl substitution. All molecules were described by descriptors. 
Subsequently the SPECS compound collection with the included 472 compounds (N = 
230,130) were virtually grouped based on similar molecular properties. SPECS molecules 
of clusters enriched with dopamine D3 receptor ligands were pooled. In total 207 
compounds were obtained. 17 out of 207 compounds were extracted by considering drug-
like properties, the presence of positively charged nitrogen essential for receptor binding 
and dissimilarity to the training set. For this diverse subset of molecules binding affinities 
were determined at dopamine D2S and D3 receptors (Table 4.20). The design of the 
experiment is shown in Figure 4.22. 
Pharmacological testing
Pharmacological testing
Clustering based 
virtual screening
Regression based 
activity prediction
Docking
Pharmacophore based 
virtual screening
Chemical synthesis 
for lead optimization
Pharmacological testing
Pharmacological testing
Clustering based 
virtual screening
Regression based 
activity prediction
Docking
Pharmacophore based 
virtual screening
  Clustering based 
virtual screening
Chemical synthesis 
for lead optimization
Pharmacological testing
Pharmacological testing
Regression based 
activity prediction
Docking
Pharmacophore based 
virtual screening
 
 
 
 
 
 
 
 
 
  Chemical synthesis 
for lead optimization
 
Figure 4.22 Design of the experiment of virtual screening approach. 
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Table 4.20 Dopamine receptor affinities of compounds from clustering-based virtual screening. 
Ki [nM] 
No. 
 
Structure 
hD2S hD3 
Ki (D2S) 
/  
Ki (D3) 
95 
               N
N
O
N
H
O
 
901, 730 
(0.88 ± 0.11) 
65 ± 7.26 
(0.95 ± 0.23)  12.6 
96 
S
N
H
O
Cl
N  
894, 666 
(0.93 ± 0.14) 
289, 244 
(1.11 ± 0.79)  2.9 
97 
         
N
N O
O
N
 
7750, 4900 
(0.83 ± 0.43) 
1367, 621 
(0.88 ± 0.34)  6.4 
98 
             
N N
H
O
N  
11716 ± 6172 
(0.54 ± 0.06) 
3212, 1935 
(0.66 ± 0.34)  4.6 
99 
      
N S
N
H
O
N  
3351, 4766 
(1.28 ± 0.46) 
214, 297 
(0.88 ± 0.25)  15.9 
100 
            
N
H
O
O
N
 
2812, 2363 
(1.14 ± 0.15) 
573, 572 
(0.91 ± 0.05)  4.5 
101 
               
O
N
H
O N
 
1092, 779 
(1.26 ± 0.18) 
983, 938 
(0.63 ± 0.02)  1.0 
102 
                   
N
O
O
N
N  
>10.000 
(n.d.
a) 
4526, 4280 
(0.91 ± 0.28)  3.6 
103 
                          
N
O
O
N  
801, 743 
(1.13 ± 0.26) 
264 ± 163 
(0.93 ± 0.20)  2.9 
104  N
H
O
O
Cl
N
 
>10.000 
(n.d.
a) 
2007, 2037 
(0.69 ± 0.18)  8.5 
105 
         
O
N
H
O N
 
7013, 4431 
(0.97 ± 0.51) 
2299, 2268 
(0.80 ± 0.23)  2.5 
106 
                   
N
H N
O
N
 
23713  
± 11540 
(0.76 ± 0.06) 
3466, 10320 
(0.72 ± 0.27)  3.4 
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Table 4.20 (continued) 
107 
         
N
O
N N
 
>10.000 
(n.d.
a) 
3016, 6542 
(1.15)  12.3 
108 
              
O
O
N
 
3212, 5549 
(0.61 ± 0.28) 
190 ± 58 
(0.99 ± 0.26)  23.1 
109 
                   
N
N
O
O
N
 
>50.000 
(n.d.
a) 
>5.000 
(n.d.
a)  3.7 
110 
                  F
N
O
HO
 
216, 284 
(0.90 ± 0.19) 
2707, 2464 
(1.24 ± 0.18)  0.1 
111 
                     
O
O
Cl
N
H
N
 
495, 575 
(0.78 ± 0.16) 
1093, 621 
(0.77 ± 0.16)  0.6 
an.d., not determined. All compounds were aligned according to the basic nitrogen. 
 
In this series, a Ki of below 1 µM was defined a “hit”. The pharmacological testing has 
revealed nine active molecules at dopamine D3 receptors and six active compounds at 
dopamine D2S receptors. Among these molecules, a Ki value below 300 nM at dopamine 
D3 receptors has been presented by compounds 95, 96, 99, 103, 108 and at dopamine D2S 
receptors by compound 110. Six molecules (98,  102,  104,  106,  107,  109) have 
demonstrated a loss of affinity binding for dopamine D2S receptors (> 10 µM) and low 
affinity binding for D3 receptors (2 - 7 µM). The most promising molecule 95 has 
displayed a Ki (D3) value of 65 nM and a 13-fold preference for dopamine D3 receptors. 
The ligand has the 4-(2-methoxyphenyl)piperazine motif of BP 897. Referring to the 
classical division of antagonists and partial agonists, the hydrophobic aryl moiety has been 
replaced by a non-aromatic bicycle[2.2.1]heptane residue. Aryl-thioether moieties have 
been noticed in compound 96 and 99  and  have moderate affinities for both receptor 
subtypes with preference for dopamine D3 receptors. It is noteworthy that the amide 
functionality is absent in compound 103 and moderate affinity for dopamine D2 and D3 
with a slight preference for D3 receptors has been obtained. The two ether oxygen atoms 
are conjugated with the phenyl ring and have a partial charge comparable to the amide 
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oxygen of BP 897 (partial charge calculation were performed with the software package 
Gaussian, data not shown).
244 An acceptable selectivity profile (23-fold) for dopamine D3 
receptors has been obtained with the dibenzocycloheptadiene derivative 108, a compound 
with similar structural features to tricyclic antipsychotic drugs such as clozapine.
224 The 
butyrophenone derivative 110 is closely related to haloperidol (cf. 1.2.6),
131 a neuroleptic 
drug, and as expected, it has displayed moderate affinity binding and selectivity (10-fold) 
for dopamine D2 receptors. This dopamine D2-preferring binding behavior has also been 
observed for compound 111, a chromen-2-one derivative. The encouraging binding data of 
these structurally diverse molecules were further highlighted by the benzamide moiety as a 
promising linker recognized for compounds 95 - 100. Considering the common structural 
requirements for dopamine D2/D3 receptor ligands with antagonist properties, the 
benzamide scaffold has been incorporated in between the aryl moiety and the basic amine 
aryl moiety. Benzamide residues in dopamine D2-like compounds are already well-known. 
Representatives of benzamides are the atypical antipsychotics sulpride and raclopride with 
high affinity binding for dopamine D2 and D3 receptors (cf. 1.2.6).
132 In our previous 
studies a replacement of an alky chain into a rigid xylene spacer resulted in moderate to 
good affinity binding for both dopamine subtype receptors.
243 Our training set has also 
included these xylene spacer compounds and gave a positive impact on the screening. A 
clear advantage of the benzamide as a spacer is that this structure is synthetically easy 
accessible and synthetic modifications can be carried out with an appropriate effort. 
Additionally, parallel synthesis might be possible for lead optimization.  
With the aim of prospectively predict the affinities for the 17 ordered compounds a 
regression based affinity prediction trained by support vector based regression,
9 neural nets 
and partial least squares 
246 using different descriptor sets was investigated. The application 
to the 17 compounds was of limited success only (data not shown). This result clearly 
shows that in this context experimental determination of binding affinity values for new 
structural molecules is of absolute necessity since techniques of computational chemistry 
are thus far not able to predict reliable affinity values. 
To enlighten the binding mode of the SPECS compounds in the binding pocket docking 
analysis was performed. A 3D homology model
9 (see 4.3.1) of the dopamine D3 receptor 
was employed and 17 compounds were docked using GOLD docking.
247 The positive 
score values indicated a successful fitting of all compounds into the binding pocket (data 
not shown).
244 The binding modes observed suggested a second alternative binding pocket 
for the aryl moiety. For further elucidation of this putative binding mode a pharmacophore 
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model for dopamine D3 receptor antagonists was constructed requiring both aryl moieties 
simultaneously. A 3D pharmacophore model was used (model not shown) and containing 
an aromatic potential pharmacophore point (PPP) for both aryl moieties, an acceptor PPP 
at the position of the oxygen amide, a hydrophobic or aromatic PPP in the spacer region, 
an essential cationic PPP and an aromatic PPP in the amine residue. All PPPs were 
required as crucial except the acceptor and spacer element. The SPECS catalogue (N = 
229,658) was screened and 35 molecules were identified. After manual selection 
considering the aspect of the diverse binding mode four molecules were ordered and tested 
for binding affinities at dopamine D2S and D3 receptors (Table 4.21). 
Compounds  112 and 113 have shown moderate affinity and dopamine D3 receptor-
preference. Both ligands contain a benzhydrylidene substituted pyrrolidindione residue as a 
hydrophobic aryl moiety, and a phenylpiperazine moiety. Compound 112 demonstrates 
structural similarity to the phthalimide derivative NAN190 (N-(4-[4-(2-
methoxyphenyl)piperazinyl]butyl)isoindolin-1,3-dion), which only has demonstrated 
slightly lower binding affinity for dopamine D3 (Ki  = 38 ± 6) than for D2 (Ki = 50 ± 6) 
receptors.
222 Although the molecules are planar and rigidized they seem to fit into the 
binding site. Compound 112 contains the 4-(2-methoxyphenyl)piperazine motif of BP 897 
and has shown unexpectedly good results for dopamine D3 but also D2 receptor binding. 
By replacing the methoxy functionality in 2-position with a chlorine in 3-position (113) on 
the phenyl ring the affinities for both receptors have been decreased but the selectivity ratio 
has not changed. The enlarged substituents in compound 114 and 115 had a negative 
impact on affinity binding for dopamine D2 and D3 receptors. The flexible 
dibenzylcarbamoylbenzyl substituted 1,2,3,4-tetrahydroisoquinoline (114) was more 
tolerated than the bulky and rigid benzoimidazo substituted phenylpiperazine (115). By 
comparing 112 and 114 in an alignment, the molecules split at different distances to the 
acceptor functionality. This might give an explanation of the dissimilar binding 
characteristics. In summary, several compounds were identified with novel structural 
elements in a short-term period and a cost-saving procedure applying different 
classification techniques of chemoinformatic approaches. A benzamide residue has been 
recognized incorporated as a spacer element. This promising scaffold is chemically easy 
accessible and allows performance of parallel synthesis to generate SAR of analogues. 
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Table 4.21 Dopamine receptor affinities of compounds from pharmacophore based virtual 
screening. 
Ki [nM] 
No Structure 
hD2S hD3 
Ki 
(D2S) / 
Ki (D3) 
112 
N
O
O
N
N
O
 
162 ± 26 
(1.20 ± 0.12) 
65 ±9 
(1.52 ± 0.23)  2.5 
113 
N
O
O
N
N Cl
 
1359 ± 315 
(1.78 ± 0.28) 
498 ± 76 
(1.25 ± 0.80)  2.7 
114 
       
N
O
N
 
1376 ± 285 
(1.29 ± 0.86) 
>1.000 
(n.d.)  0.6 
115 
         
N
N
N
N
N
N
N
 
4392 ± 348 
(0.86 ± 0.26) 
2636 ± 349 
(0.77 ± 0.11)  1.7 
 
Additionally, two novel structural elements for aryl residue replacement were noticed: a 
non-aromatic bicycle[2.2.1]heptane and a aryl-thioether moiety. The 4-(2-
methoxyphenyl)piperazine residue of BP 897, the 1,2,3,4-tetrahydroisoquinoline motif 
seen in ST 198 and SB 277011 (cf. 1.2.6), the butyrophenone and dibenzocycloheptadiene 
moieties from marketed antipsychotic drugs has been recognized by virtual screening 
methods. These encouraging results confirm the applicability of the employed 
computational techniques in early stages of the drug discovery process for new lead 
finding.  
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The development of novel drugs targeting GPCRs is of particular interest since modulation 
of subfamilies of this receptor class highly influences neurotransmission in the central 
nervous system. This study has focused on the development of ligands for the dopamine D3 
receptor. The receptor belongs to the dopamine D2-like family among the biogenic amine 
binding GPCRs. The dopamine D3 receptor is involved in neurological and 
neuropsychiatric disorders such as Parkinson’s disease, schizophrenia and drug addiction. 
Due to its close structural similarity to the dopamine D2 receptor subtype, it is still a 
challenge to identify and further optimize new leads. Therefore an in vitro screening assay, 
which also allows elucidating comprehensive structure-affinity relationships, is required.  
In this investigation the implementation and evaluation of radioligand binding assays for 
human dopamine D2S and dopamine D3 receptors and for the related aminergic human 
histamine H1 receptor stably expressed in Chinese hamster ovary (CHO) cells has been 
performed. Saturation binding experiments with [³H]spiperone at dopamine D2S and D3 
receptors and with [³H]mepyramine at histamine H1 receptors were carried out. The 
determined equilibrium dissociation constant of radioligands (Kd) and the total number of 
specific binding sites (Bmax) of the receptor membrane preparations were in good 
agreement with reference data. Inhibition constants (Ki) of reference ligands obtained in 
radioligand competition binding experiments at dopamine hD2S, hD3 and histamine H1 
receptors validated the reliability and reproducibility of the assay. In order to discriminate 
agonists from antagonists, a GTP shift assay has been investigated for dopamine D2S and 
D3 receptors. In competition binding studies at dopamine D2S receptors the high- and low 
affinity state in the absence of the GTP analogue Gpp(NH)p has been recognized for the 
agonists pramipexole and the seleno analogue 54. In the presence of Gpp(NH)p a decrease 
in affinity, referred to as “GTP shift”, has been revealed for agonists at dopamine D2S and 
D3 receptors. An effect of Gpp(NH)p on dopamine D2S receptor binding has not been 
observed for the antagonists ST 198 and BP 897, while a reverse “GTP shift” has been 
noticed at the dopamine D3 receptor. For the development of novel ligands with high 
affinity and selectivity for dopamine D3 receptors, investigation in refined structure-
affinity relationships (SAR) of analogues of the lead BP 897 has been performed. 
Replacement of the naphthalen-2-carboxamide of BP 897 by aryl amide residues (1 - 4) 
had a clear influence on affinity binding and selectivity for dopamine D3 receptors. 
Introduction of the benzo[b]thiophen-2-carboxamide (1) has markedly improved binding 
with subnanomolar affinity and enhanced selectivity for dopamine D3 receptors. 
Exchanging the aryl substituted basic alkanamine residue of 1 by a 1,2,3,4-
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tetrahydroisoquinoline moiety (6) emphasized the benefit of the 4-(2-methoxyphenyl) 
piperazine residue of BP 897 regarding dopamine D2 and D3 receptor affinities. The 
change of particular elements of BP 897 and the rearrangement of the amide functionality 
resulted in inverse amide compounds with new chemical properties. Moderate affinity 
binding data, as obtained for the isoindol-1-carbonyl compound 11, suggest that inverse 
amides provide a worthwhile new lead structure with a novel structural scaffold.  
A hybrid approach combining privileged scaffolds of histamine H1 receptor antagonists 
and fragments of dopamine D3 receptor-preferring ligands, related to BP 897and analogues 
has been investigated. Various benzhydrylpiperazine derivatives and related structures 
have shown moderate to high affinities for dopamine D3 receptors with the impressive 
enhancement of the cinnamide substituted bamipine-related hybrid 39, exhibiting the 
highest affinity and selectivity for dopamine D3 receptors. Improved affinity profiles of 
structural modified histamine H1 receptor antagonists for dopamine D2 and D3 receptors 
and a refined SAR has been achieved. 
A SAR of derivatives of the dopamine agonist pramipexole and the related etrabamine has 
been studied. The propargyl substituted etrabamine derivative 61 demonstrated highest 
affinity and selectivity. The ligand attracts attention since neuroprotective properties have 
been reported for the propargyl functionality. Further development resulted in the most 
promising compound 64, a cinnamide derivative with 4-fluoro substitution on the phenyl 
ring. Subnanomolar affinity and remarkable selectivity for dopamine D3 receptors has 
aroused particular interest in this ligand due to its development potential as a radioligand 
for PET studies.  
Radioligand binding studies in combination with virtual screening and different 
classification techniques of chemoinformatic methods resulted in further elucidation of 
SAR. New leads with novel chemical scaffolds have been found in the 
bicycle[2.2.1]heptane derivative 95 and the benzhydrylidene substituted pyrrolidindione 
112 and can be further optimized by chemical modifications. 
The outcome of the studies provides the development of various novel high affine and 
dopamine D3 receptor selective ligands. Modifications of lead structures or application of 
chemoinformatic tools in combination with radioligand competition binding assays have 
resulted in new leads with different chemical scaffolds. Furthermore, a comprehensive 
insight into structure-affinity relationships of ligands at dopamine D3 receptors has been 
revealed. This refined SAR is valuable to develop more affine and selective drug 
candidates with a designed pharmacological receptor profile. 
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Das Ziel der Arbeit war die Entwicklung von neuen Liganden zur Beeinflussung der 
Neurotransmission im zentralen Nervensystem. Der Fokus lag auf dem Dopamin-D3-Rezeptor, 
der eine wichtige Rolle bei Morbus Parkinson, Schizophrenie und Drogenmissbrauch spielt. 
Aufgrund seiner Strukturähnlichkeit zum Dopamin-D2-Rezeptor ist es eine Herausforderung, 
neue, selektive Leitstrukturen für den Dopamin-D3-Rezeptor zu identifizieren bzw. zu 
optimieren. Ein in vitro Testsystem ist hierfür erforderlich und ermöglicht das Aufstellen von 
Struktur-Wirkungsbeziehungen (SAR) und ein rationales Wirkstoffdesign. 
Die Arbeit umfasste die Etablierung von Radioliganden Bindungsassays an Dopamin-D2S- und 
-D3-Rezeptoren, sowie am verwandten aminergen Histamin-H1-Rezeptor, die stabil in 
Zelllinien von Ovarien des Chinesischen Hamsters exprimiert wurden. Sättigungsstudien 
wurden mit [³H]Spiperon am Dopamin-D2S- und D3-Rezeptor und mit [³H]Mepyramin am 
Histamin-H1-Rezeptor durchgeführt. Die ermittelten Dissoziationskonstanten (Kd) und 
maximale Zahl der Bindungsstellen (Bmax) stimmten mit den Literaturwerten überein. Die in 
Verdrängungsstudien bestimmten Inhibitionskonstanten (Ki) von Referenzsubstanzen am 
Dopamin-D2S- und -D3-Rezeptor sowie am Histamin-H1-Rezeptor bestätigten die 
Zuverlässigkeit und Reproduzierbarkeit der Bindungsassays. Zur Unterscheidung der 
Agonisten von Antagonisten wurden „GTP-Shift“ Assays am Dopamin-D2S- und -D3-Rezeptor 
angewandt. Für Pramipexol und das Selenanaloga  54  wurden zwei Bindungszustände mit 
unterschiedlichen Affinitäten (ein so genannter „high- und low affinity state“) am Dopamin-
D2S-Rezeptor in Abwesenheit von Gpp(NH)p beobachtet. Eine Affinitätsabnahme („GTP-
Shift“) in Anwesenheit von Gpp(NH)p zeigte sich für die Agonisten am Dopamin-D2S- und -
D3-Rezeptor. Dieser Einfluss des Gpp(NH)p konnte nicht für den Antagonisten ST 198 und 
den partiellen Agonisten BP 897 gezeigt werden. Für diese Verbindung wurde ein inverser 
„GTP-Shift“, also eine Affinitätsverbesserung am Dopamin-D3-Rezeptor beobachtet.  
Um neue Liganden mit hoher Affinität und Selektivität für den Dopamin-D3-Rezeptor zu 
entwickeln, wurden ausführliche SAR verschiedener Derivate der Leitstruktur BP 897 und ST 
198 erstellt. Der Austausch des Naphthalen-2-carboxamid-Rests von BP 897 durch 
verschiedene Arylamid-Strukturen (1 – 4) zeigte deren deutlichen Einfluss auf die Dopamin-
D3-Rezeptorbindungsaffinität und -selektivität. Die Einführung eines Benzo[b]thiophen-2-
carboxamid-Rests führte in Verbindung 1 zu herausragender subnanomolarer Affinität am 
Dopamin-D3-Rezeptor sowie zu deutlich erhöhter Selektivität im Vergleich zu BP 897. Die 
Variation des lipophilen basischen Amin-Restes von 1 ergab das 1,2,3,4-
Tetrahydroisochinolin-Derivat  6. Verdrängungsstudien konnten den Vorteil des 4-(2-
Methoxyphenyl)piperazine-Substituenten von BP 897 bezüglich der Affinitäten am Dopamin-
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D2S- und -D3-Rezeptor deutlich zeigen. Modifikationen einzelner Elemente von BP 897 und 
ST 198 und die veränderte Integration der Amid-Funktion in dem lipophilen Aryl-Rest führten 
zur Substanzklasse der inversen Amide mit neuen chemischen Eigenschaften. Moderate 
Bindungsaffinitäten, wie für das Isoindol-1-carbonyl-Derivat 11 gezeigt, legen nahe, dass 
inverse Amide eine lohnenswerte neue Leitstruktur mit andersartigem strukturellem Gerüst 
darstellen. In einer Hybrid-Strategie wurden Strukturelemente von Histamin-H1-
Rezeptorantagonisten mit Substrukturen von Liganden mit ausgeprägter Dopamin-D3-
Rezeptorpräferenz kombiniert. Daraus resultierten Benzhydrylpiperazin-Derivative und 
verwandte Substanzen mit moderater bis hoher Affinität am Dopamin-D3-Rezeptor. Besonders 
hervorzuheben ist das Zimtsäureamid substituierte und zum Bamipin verwandte Hybrid 39, 
welches die besten Ergebnisse in dieser Serie hinsichtlich Affinität und Selektivität am 
Dopamin-D3-Rezeptor erbrachte. Verbesserte pharmakologische Profile der strukturell 
modifizierten Histamine-H1-Rezeptorantagonisten am Dopamin-D2S- und -D3-Rezeptor und 
eine differenzierte SAR wurden erreicht.  
Für Derivate des Dopaminrezeptoragonisten Pramipexol und des strukturähnlichen Etrabamin 
wurden SAR ausgearbeitet. Das Propargyl substituierte Etrabamin-Derivat  61 zeigte 
herausragende Dopamin-D3-Rezeptoraffinität und -selektivität. Der Ligand ist von Interesse, 
da für den Propargyl-Rest neuroprotektive Eigenschaften berichtet wurden. Die 
Weiterentwicklung führte zur Verbindung 64, einem Zimtsäureamid-Derivat mit 4-Fluor-
Substitution am Phenylring. Subnanomolare Affinität und hohe Selektivität am Dopamin-D3-
Rezeptor prädestinieren 64 zur Anwendung als potentiellen PET-Radioliganden. 
Radioliganden Bindungsstudien wurden auf die Ergebnisse von virtuellen Screeningstudien 
angewandt. Sie führten zur Identifizierung neuer Leitstrukturen und zum weiteren Verständnis 
der SAR. Als neue Leitstrukturen mit verschiedenartigen chemischen Gerüsten wurden unter 
anderem das Bicyclo[2.2.1]heptan-Derivat  95 und der Benzhydryliden substituierte 
Pyrrolidindion Ligand 112 gefunden. Diese können nun zur weiteren Optimierung chemisch 
modifiziert werden.  
Die in dieser Arbeit durchgeführten Radioliganden Bindungsstudien führten zur 
Identifizierung, Entwicklung und Optimierung von hoch affinen und selektiven Dopamin-D3-
Rezeptor Liganden. Des Weiteren ermöglichten die Ergebnisse eine ausführliche Vertiefung 
der SAR. Die kombinierte Strategie von chemoinformatischen Methoden und Radioliganden 
Bindungsstudien hat das Finden neuer Leitstrukturen als potentielle Arzneistoffe erlaubt. Die 
Resultate ermöglichen in der Zukunft ein gezieltes Liganden-Design mit einem gerichteten 
pharmakologischen Rezeptorprofil. 
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Das Ziel der Arbeit war die Entwicklung von neuen Liganden zur Beeinflussung der 
Neurotransmission im zentralen Nervensystem. Der Fokus lag auf dem Dopamin-D3-
Rezeptor, der zur Familie der Dopamin-D2-ähnlichen Rezeptoren gehört. Der Dopamin-
D3-Rezeptor spielt eine wichtige Rolle bei neurologischen und psychiatrischen 
Erkrankungen wie Morbus Parkinson, Schizophrenie und Drogenmissbrauch bzw. -
abhängigkeit. Aufgrund seiner Strukturähnlichkeit zum Dopamin-D2-Rezeptor ist es nach 
wie vor eine Herausforderung neue, selektive Leitstrukturen für den Dopamin-D3-Rezeptor 
zu identifizieren bzw. zu optimieren. Ein in vitro Testsystem ist hierfür erforderlich und 
ermöglicht das Aufstellen von Struktur-Wirkungsbeziehungen (SAR) und ein rationales 
Wirkstoffdesign. 
Die Arbeit umfasste die Etablierung von Radioliganden Bindungsassays an Dopamin-D2S- 
und -D3-Rezeptoren, sowie an verwandten aminergen Histamin H1-Rezeptoren, die stabil 
in Zelllinien von Ovarien des Chinesischen Hamsters exprimiert wurden. 115 Liganden 
wurden pharmakologisch an Dopamin-D2S- und -D3-Rezeptoren charakterisiert. 
Die Entwicklung eines Radioliganden Bindungsassays beinhaltete Vorversuche, um 
optimale Testbedingungen zu finden. Hierzu gehörten unter anderem die 
Pufferzusammensetzung, Ionenstärke und pH-Wert Einstellung der Puffer, die 
Inkubationstemperatur, sowie die Herstellung der Zellmembranpräparation. In 
Bindungsexperimenten wurden die benötigte Proteinmenge, die Inkubationszeit und das 
Volumen der Waschschritte ermittelt.  
Sättigungsstudien wurden mit [³H]Spiperon am Dopamin-D2S- und -D3-Rezeptor und mit 
[³H]Mepyramin am Histamin-H1-Rezeptor durchgeführt. Mit steigender Konzentration des 
Radioliganden war die spezifische Bindung für alle Rezeptorsubtypen gesättigt. Scatchard 
Analysen der spezifischen Bindungen der Radioliganden an den verschieden Rezeptoren 
waren linear. Eine einzige Bindungsstelle des jeweiligen Rezeptorsubtyps konnte bestimmt 
werden. Die nicht-spezifische Bindung war nicht gesättigt, stieg linear mit der 
Konzentration des Radioliganden an und zeigte Werte < 20% der Gesamtbindung. Die 
ermittelten Bindungsparameter Kd (Dissoziationskonstante) und Bmax (maximale Zahl der 
Bindungsstellen) stimmten mit den Literaturwerten überein.  
Die in Verdrängungsstudien bestimmten Inhibitionskonstanten (Ki) von 
Referenzsubstanzen am Dopamin-D2S- und -D3-Rezeptor, sowie am Histamin-H1-Rezeptor 
entsprachen den Literaturwerten. Die nicht-spezifische Bindung war < 20% der 
Gesamtbindung und nur 10% des hinzugefügten Radioliganden wurden am jeweiligen 
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Rezeptorsubtyp gebunden. Diese Ergebnisse bestätigten die Zuverlässigkeit und 
Reproduzierbarkeit der etablierten Bindungsassays.  
Für eine funktionelle Charakterisierung und zur Unterscheidung der Agonisten von 
Antagonisten wurden „GTP-Shift“ Assays am Dopamin-D2S-, und -D3-Rezeptor 
angewandt. Für Pramipexol und das Selenanaloga 54 wurden zwei Bindungszustände mit 
unterschiedlichen Affinitäten (ein so genannter „high- und low affinity state“) am 
Dopamin-D2S-Rezeptor in Abwesenheit von Gpp(NH)p, einer GTP analogen Verbindung, 
beobachtet. Eine Affinitätsabnahme („GTP-Shift“) in Anwesenheit von Gpp(NH)p zeigte 
sich für die Agonisten am Dopamin-D2S- und -D3-Rezeptor. Dieser Einfluss des Gpp(NH)p 
konnte nicht für den Antagonisten ST 198 und den partiellen Agonisten BP 897 gezeigt 
werden. Für diese Verbindung wurde ein inverser „GTP-Shift“, also eine 
Affinitätsverbesserung am Dopamin-D3-Rezeptor beobachtet. Die Ergebnisse zeigen, dass 
eine Einteilung in Agonist, partieller Agonist and Antagonist mittels einem „GTP-Shift“ 
Assay durchführbar ist.  
Um neue Liganden mit hoher Affinität und Selektivität für den Dopamin-D3-Rezeptor zu 
entwickeln, wurden ausführliche Struktur-Wirkungsbeziehungen verschiedener Derivate 
der Leitstruktur BP 897 und ST 198 erstellt. Der Austausch des Naphthalen-2-carboxamid-
Rests von BP 897 durch verschiedene Arylamid-Strukturen (1 – 4) zeigte deren deutlichen 
Einfluss auf die Dopamin-D3-Rezeptorbindungsaffinität und -selektivität. Die Einführung 
eines Benzo[b]thiophen-2-carboxamid-Rests führte in Verbindung 1 zu herausragender 
subnanomolarer Affinität am Dopamin-D3-Rezeptor sowie zu deutlich erhöhter Selektivität 
im Vergleich zu BP 897. Der Austausch des lipophilen basischen Aminrestes 4-(2-
Methoxyphenyl)piperazine in 1 durch 1,2,3,4-Tetrahydroisochinolin, der Substruktur von 
ST 198, ergab Derivat 6 mit geringerer Affinität und Selektivität für den Dopamin-D3-
Rezeptor. Verdrängungsstudien konnten den Vorteil des 4-(2-Methoxyphenyl)piperazine-
Substituenten von BP 897 bezüglich der Affinitäten am Dopamin-D2S- und -D3-Rezeptor, 
sowie die Selektivität am Dopamin-D3-Rezeptor deutlich zeigen. 
Modifikationen einzelner Elemente der Leitstruktur BP 897 und ST 198 und die veränderte 
Integration der Amid-Funktion in dem lipophilen Aryl-Rest führte zur Substanzklasse der 
inversen Amide. Diese Moleküle zeigen neuen chemischen Eigenschaften. Die 
Invertierung des Amids führte zu einer umgewandelten Funktionalität, neuen Orientierung 
des Carbonyl Sauerstoffes im Molekül, sowie zu einem veränderten Abstands des 
basischen Stickstoffes zum Amid im Vergleich zu den Leitstrukturen BP 897 und ST 198. 
Moderate Bindungsaffinitäten am Dopamin-D2- und -D3-Rezeptor mit mäßiger Dopamin-
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D3-Rezeptorpräferenz wurden, wie für das Isoindol-1-carbonyl Derivat 11 gezeigt, 
erhalten. Aufgrund dieser Ergebnisse ist die Weiterentwicklung der inversen Amide von 
Interesse, da sie eine lohnenswerte neue Leitstruktur mit andersartigem strukturellem 
Gerüst darstellen. 
Aufgrund von Strukturähnlichkeiten der Antagonisten am Histamin-H1-Rezeptor und an 
Dopamin-D2-ähnlichen Rezeptoren wurde der Einfluss einer Hybridbildung dieser 
Liganden an Dopamin-D2S- und -D3-Rezeptoren, sowie am Histamin-H1-Rezeptor 
untersucht. Substrukturen der Histamin-H1-Rezeptorantagonisten (so genannte 
„Antihistaminika“) Cetirizin, Mianserin, Ketotifen, Loratadin und Bamipin wurden mit 
Strukturelementen der Leitstrukturen BP 897, ST 198 und analogen Verbindungen mit 
ausgeprägter Dopamin-D3-Rezeptorpräferenz kombiniert. Daraus resultierten 
Benzhydrylpiperazin-Derivative, Moleküle mit tri- und tetrazyklischen Ringsystemen, 
sowie Bamipin- Analoga. Die Liganden wiesen moderate bis hohe Affinität am Dopamin-
D3-Rezeptor auf. Besonders hervorzuheben ist das Zimtsäureamid substituierte und zum 
Bamipin verwandte Hybrid 39, welches die besten Ergebnisse in dieser Serie hinsichtlich 
Affinität und Selektivität am Dopamin-D3-Rezeptor zeigte. Der Austausch des Zimtamids 
gegen einen Benzo[b]thiophen-2-carboxamid-Rest (40) erbrachte vergleichbar gute 
Resultate bezüglich Bindungsaffinitäten und Selektivität für den Dopamin-D3-Rezeptor. 
Die Histamin-H1-Rezeptorantagonisten ergaben am Histamin-H1-Rezeptor eine deutliche 
höhere Affinität als an Dopamine-D2- und -D3-Rezeptoren. Die pharmakologischen Profile 
der neuen, strukturell modifizierten Histamine-H1-Rezeptorantagonisten wurden für den 
Dopamin-D2S- und D3-Rezeptor optimiert, während die Affinitäten zum Histamin-H1-
Rezeptor, mit Ausnahme der Loratadin verwandten Substanzen, herabgesetzt wurden. Bis 
auf Molekül 39 zeigten alle Hybridmoleküle einer höhere Affinität zum Histamin-H1-
Rezeptor als zum Dopamin-D2- und -D3-Rezeptor. Die Einführung flexibler Teilstrukturen 
von Histamin-H1-Rezeptorantagonisten wie Phenylaminopiperidin-Reste und Benzhydryl-
Elemente wurden am Dopamin-D3- und -D2-Rezeptor toleriert. Sterisch anspruchsvolle 
und rigide Substanzen wurden in diesem Hybridansatz nur bedingt vertragen. Die 
Hybridstrategie ermöglichte die Entwicklung neuer Liganden mit einem gerichteten 
Rezeptorprofil sowie die Darstellung differenzierte Struktur-Wirkungsbeziehungen an 
verwandten aminergen Rezeptoren.  
In Radioliganden Bindungsstudien wurde der Einfluss struktureller Variationen des 
Dopaminrezeptoragonisten Pramipexol und des strukturähnlichen Etrabamin untersucht. 
Struktur-Wirkungsbeziehungen wurden für die Dopamin-D2- und -D3-Rezeptoren 
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ausgearbeitet. Im Vergleich zu kürzeren Kettenlängen wurde eine N-propyl-Substitution 
am sekundären basischen Stickstoff (43) sowohl am Dopamin-D3-Rezeptor als auch 
Dopamin-D2-Rezeptor bevorzugt. Durch Einführung eines Selen-Atoms in das 
Strukturanalogon des Pramipexols (54) wurden zusätzliche antioxidative und 
Radikalfänger-Eigenschaften integriert. Bindungsaffinitäten im niedrigen nanomolaren 
Bereich und gute Selektivität für den Dopamin-D3-Rezeptor wurden für 54 erhalten.  
Die Kombination eines Dopaminrezeptoragonisten mit einem weiteren Dopamin-D3-
Rezeptor affinen Pharmakophorelement aus BP 897, ST 198 oder verwandten Substanzen 
führte zu Verbindungen mit hoher Affinität und Selektivität am Dopamin-D3-Rezeptor. 
Das Propargyl substituierte Etrabamin-Derivat 61 zeigte herausragende Dopamin-D3-
Rezeptoraffinität und -selektivität. Der Ligand ist von großem Interesse, da für den 
Propargyl-Rest neuroprotektive Eigenschaften berichtet wurden. Die Weiterentwicklung 
führte zur Verbindung 64, ein Zimtsäureamid-Derivate mit 4-Fluor-Substitution am 
Phenylring. Subnanomolare Affinität und hohe Selektivität am Dopamin-D3-Rezeptor 
prädestinieren  64 zur Anwendung als potentiellen PET-Radioliganden. Das 
Benzo[b]thiophen-2-carboxamid substituierte Etrabamin-Derivat 70 zeigte eine hohe 
Affinität am Dopamin-D3-Rezeptor und eine bemerkenswerte Selektivität. Die Einführung 
eines zusätzlichen Dopamin-D3-affinen Pharmakophorelements in Analoga der 
Dopaminrezeptoragonisten Pramipexol und Etrabamin führten zu Verbindungen mit hoher 
Affinität und Selektivität am Dopamin-D3-Rezeptor. Sie stellen eine neue, 
vielversprechende Leitstrukturserie dar. Es wird von großem Interesse sein zu untersuchen, 
ob die Substanzen das selektive Rezeptorbindungsprofil, die vorteilhaften 
pharmakokinetischen Eigenschaften und die neuroprotektiven Effekte des Pramipexols 
aufweisen.  
Um neue Leitstrukturen mit andersartigen chemischen Grundgerüsten für den Dopamin-
D3-Rezeptor zu finden, wurden Radioliganden Bindungsassays mit virtuellen Screening 
Methoden kombiniert. Durch Anwendung von Verfahren, die auf der „Support Vector 
Machine (SVM)“ Methode beruhen, konnten in kurzer Zeit und Kosten sparend neue 
Leitstrukturen gefunden werden. Basierend auf einem Datensatz mit aktiven verwandten 
Substanzen der Leitstruktur BP 897 wurde ein SVM Model generiert und ein 
Substanzkatalog mit kleinen organischen Molekülen durchsucht. 11 Moleküle mit neuen 
Strukturelementen wurden gefunden und Bindungsaffinitäten am Dopamin-D2S- und -D3-
Rezeptor ermittelt. Die Substanzen zeigten Affinitäten im molaren Bereich. Ligand 80 
stellte eine viel versprechende Verbindung mit einem Ki Wert am Dopamin-D3-Rezeptor < 
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2 µM und einem Ki Wert am Dopamin-D2-Rezeptor von 2 - 6 µM dar. Er wurde für eine 
weitere Optimierung verwendet. Eine fokussierte SVM basierte Ähnlichkeitssuche wurde 
mit einem weiteren Substanzkatalog durchgeführt. 5 Moleküle wurden erhalten und im 
Radioliganden Bindungsassay charakterisiert. 4 der 5 Moleküle zeigten nanomolare 
Affinitäten am Dopamin-D3-Rezeptor. Besonders das Benzo[1.4]oxazin-3-on-Derivat 91 
mit Affinität im niedrigen nanomolaren Bereich und Dopamin-D3-Rezeptorpräferenz ist 
hervorzuheben. Die Substanzen 80, 90, 93 und 94 besitzen neue Strukturmerkmale mit 
andersartigen Grundgerüsten, die zur weiteren Optimierung zur Verfügung stehen. 
In weiteren Radioliganden Bindungsstudien wurden Affinitäten am Dopamin-D2S- und -
D3-Rezeptor von Molekülen bestimmt, die aus verschiedenen chemoinformatischen 
Klassifikationstechniken resultierten. Verbindungen mit neuen chemischen 
Strukturelementen konnten in kurzer Zeit gefunden werden und führten zu einem tieferen 
Verständnis der Struktur-Wirkungsbeziehungen. Clustering basiertes virtuelles Screening 
eines Substanzkataloges führten zur Auswahl von 17 Substanzen. Diese wurden am 
Dopamin-D2S- und -D3-Rezeptor pharmakologisch gestestet. Das Derivat 95 zeigte neben 
Bindungsaffinitäten im niedrigen nanomolaren Bereich eine deutliche Präferenz für den 
Dopamin-D3-Rezeptor. Zusätzlich wies 95 mit dem Bicyclo[2.2.1]heptan Gerüst eine 
andersartige Struktur auf. Weitere neue Molekülelemente waren ein Aryl-Thioether-Rest 
(96,  99) sowie Benzamide als Verbindungselement im Molekül (95 – 100). 
Dockingstudien mit einem Homologiemodell des Dopamin-D3-Rezeptors führten zur 
Hypothese zweier alternativer Bindungstaschen. Ein darauf aufgebautes 
Pharmakophormodel identifizierte in einem virtuellen Screening den Benzhydryliden 
substituierten Pyrrolidindion Liganden 112 mit niedriger nanomolarer Affinität am 
Dopamin-D3-Rezeptor. Er unterstützt die Hypothese der zwei Bindungstaschen. Substanz 
112 ist eine neue Leitstruktur und kann nun zur weiteren Optimierung chemisch 
modifiziert werden. 
Die in dieser Arbeit etablierten Radioliganden Bindungsassays führten zur Identifizierung, 
Entwicklung und Optimierung von hoch affinen und selektiven Dopamin-D3-Rezeptor 
Liganden. Des Weiteren ermöglichten die Ergebnisse eine ausführliche Vertiefung von 
Struktur-Wirkungsbeziehungen am Dopamin-D3- und -D2-Rezeptor. Die kombinierte 
Strategie von Radioliganden Bindungsstudien und virtuellen Screening Methoden hat das 
Finden neuer Leitstrukturen als potentielle Arzneistoffe erlaubt. Die Resultate ermöglichen 
in der Zukunft ein gezieltes Liganden-Design mit einem gerichteten pharmakologischen 
Rezeptorprofil. 
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3D       Three-dimensional 
AA     Arachidonic  acid 
AADC       L-amino acid decarboxylase 
AC     Adenylyl  cyclase 
ADHD       Attention deficit hyperactivity disorder 
Asp    Aspartic  acid 
BDNF       Brain-derived neurotrophic factor 
BP 897        N-{4-[4-(2-methoxyphenyl)piperazinyl]butyl}-2-naphtamide 
cAMP       Cyclic adenosine-3’,5’-monophosphate 
CHO-cells    Chinese hamster ovary cells 
CNS        Central nervous system 
COMT       Catechol-O-methyltransferase 
CPM       Counts  per  minute 
CREB       Cyclic AMP response element binding protein 
DA     Dopamine,  2-(3,4-dihydroxyphenyl)ethylamine 
DAC       Diacylglycerol 
DARPP-32    Domain-related phosphoprotein, 32 kDa 
DAT       Dopamine  transporter 
DMSO       Dimethylsulfoxid 
DOPAC     3,4-Dihydroxyphenylacetat 
DOPAL     3,4-Dihydroxyphenylacetaldehyde 
FRET        Fluorescence resonance energy transfer 
ƒmol       Femtomol 
GDP       Guanosine-5’-diphoshate 
Gi    Guanine nucleotide binding protein which regulates inhibition of 
adenylyl cyclase 
GOLD    Genetic optimization for ligand docking 
GPCR       G protein-coupled receptor 
G protein     Guanine nucleotide binding protein 
Gpp(NH)p  5’-Guanylyl-imidodiphosphate 
Gs    Guanine nucleotide binding protein which regulates the stimulation of 
adenylyl cyclase 
GTP      Guanosine-5’-triphosphate 
[
35S] GTPγS   Guanosine-5’-O-(3-[
35S]thiotriphosphate) 
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h Hour,  hours 
H Helix,  helices 
HVA   Homovanilic  acid 
HTS  High throughput screening 
IC50    Concentration  inhibiting 50% of response 
IP3       Inositiol-1,3,5-triphosphate 
IBS    Interbioscreen 
IUPHAR      International Union of Pharmacology 
Kd       Equilibrium  dissociation  constant 
Ki        Dissociation constant of inhibitor, inhibition constant equilibrium 
KH        Inhibition constant of high affinity state 
KL         Inhibition constant of low affinity state 
L-DOPA     L-3,4-dihydroxyphenylalanine,  levodopa 
LID     Levodopa-induced  dyskinesia 
µg      Microgram 
M      Mol/L 
MAO-A      Monoamine oxidase A 
MAO-B      Monoamine oxidase B 
MAPK   Mitogen-activated protein kinase 
min    Minute,  minutes 
mg      Milligram 
mmol     Millimol 
MOE     Molecular  operation  enviroment 
MPTP     1-Methyl-4-phenyl1,2,3,6-tetrahydropyridine 
MT    3-Methoxytyramine 
n        Number of individual experiment 
n.d.     Not  determined 
NIPALS      Non-linear iterative partial least squares 
nM      Nanomol/L 
NMDA     N-methyl-D-aspartate 
NN     Neuronal  networks 
NPA       N-propylnorapomorphine 
PBS     Phosphate-buffered  saline 
PD       Parkinson’s  disease 
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PET        Positron emission tomography 
PKA        Protein kinase A 
PKC        Protein kinase C 
PLC      Phospholipase  C 
PLS    Partial  least  squares 
PP1 or PP2A   Protein phosphatase 1 or 2A 
PPP        Potential pharmacophore points 
3PP    Three-point  pharmacophore 
QSAR       Quantitative structure-activity relationships 
%RH        % of higher affinity sites 
rpm    Rotation  per  minute 
RRA       Retrorubral  area   
SAR      Structure-activity  relationships 
SD       Standard  deviation 
SNc        Substantia nigra pars compacta 
SOM       Self  organising  maps 
SPECT      Single photon emission computed tomography 
SVM        Support vector machine 
TH       Tyrosine  3-hydroxylase 
TM     Transmembrane  domain 
VS       Virtual  screening 
VTA       Ventral  tegmental  area 
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10.1 Radioligand Binding Assays  
10.1.1 Dopamine D2S and D3 Receptor Binding Assays 
CHO-D2S cells, expressing the recombinant human D2(short) dopamine receptor gene,
179 
were grown in Dulbecco’s modified Eagle’s medium/nutrient mixture F12 1:1 mixture 
supplemented with 2 mM glutamine, 10% fetal bovine serum, and 10 µlml
-1 
penicillin/streptomycin in an atmosphere of 5% CO2 at 37 °C (Gibco
TM, Karlsruhe, 
Germany). Human D3 receptors stably expressed in CHO cells as previously described by 
Sokoloff et al.
192 were used. The cell line was cultured in Dulbecco`s modified Eagle’s 
medium supplemented with 2 mM glutamine, and 10% dialyzed fetal bovine serum, and 
were grown in an atmosphere of 5% CO2 at 37 °C (Gibco
TM). Human D2S- and D3 
receptors expressing cell lines were grown to confluence. The medium was removed, and 
the cells were washed with 10 ml PBS buffer (140 mM NaCl, 3 mM KCl, 1.5 mM 
KH2PO4, 8 mM Na2HPO4, pH 7.4) at 4 °C. After removing the wash buffer, the cells were 
scraped from the flasks into 15 ml of ice-cold media, and centrifuged at 3,000 rpm for 10 
min at 4 °C. After centrifugation the medium was removed and the supernatant 
resuspended in ice-cold Tris-HCl buffer containing 5 mM MgCl2, pH 7.4 and disrupted 
with a Polytron and centrifuged at 20,000 rpm, for 30 min at 4 °C. The pellet was 
resuspended by sonication in ice-cold Tris-HCl buffer (containing 5 mM MgCl2, pH 7.4), 
membrane aliquots were stored at -70 °C. Determination of membrane protein was carried 
out by the method of Bradford.
180 Cell membranes containing human D2S and D3 receptors 
from CHO cells were thawed, rehomogenized with sonication at 4 °C in Tris-HCl, pH 7.4 
containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2 and 1 mM MgCl2 (incubation buffer), 
and incubated with 0.2 nM [³H]spiperone (106 Ci·mmol
-1, Amersham Biosciences, 
Freiburg, Germany), and drug diluted in incubation buffer. Nonspecific binding was 
determined in the presence of 10 µM BP 897 (prepared by same of the authors).
248 
Incubations were run at 25 °C for 120 min, and terminated by rapid filtration through 
PerkinElmer GF/B glass fibre filters (PerkinElmer Life Sciences, Rodgau, Germany) 
coated in 0.3% polyethylenimine (Sigma-Aldrich, Taufkirchen, Germany) using an Inotech 
cell harvester (Inotech AG, Dottikon, Switzerland). Unbound radioligand was removed 
with four washes of 1 ml of ice-cold 50 mM Tris-HCl buffer, pH 7.4, containing 120 mM 
NaCl. The filters were soaked in 9 ml Beta plate scint scintillator and counted using a 
PerkinElmer MicroBeta
®Trilux scintillation counter (PerkinElmer Life Sciences). 
Competition binding data were analyzed by the software GraphPad Prism™ (2000, version 
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3.02, San Diego, CA, USA), using non-linear least squares fit. For detailed screening the 
compounds have been tested at seven concentrations in triplicate carrying out three to five 
separate binding experiments for human dopamine D2S and for human dopamine D3 
receptors and expressed as mean ± standard error of the mean (SEM). Ki values were 
calculated from the IC50 values according to Cheng-Prusoff equation.
182 
10.1.2 Preliminary Dopamine D2S and D3 Receptor Binding Screening 
Cell culture was carried out using standard procedures. Human dopamine D2S and D3 
receptors were expressed in stably transfected Human Embryonic Kidney (HEK) and 
Chinese hamster ovary (CHO) cells, respectively. The CHO-D3 cells were cultured at 37°C 
in Dulbecco's Modified Eagle Medium (DMEM, Cambrex Bio Sciences, Rockland Inc) 
supplemented with 10% dialysed fetal calf serum (Invitrogen,Co, Carlsbad, CA), 100 
Units/ml penicillin-streptomycin (Cambrex, Bio Sciences, Rockland Inc), HEPES 20 mM, 
pH = 7.4 and 2 mM glutamine (Cambrex, Bio Sciences, Rockland Inc) in an atmosphere of 
5% CO2.
192 The HEK-D2S cell line was obtained following transfection by pCDNA3.1-
D2S expressing vector. HEK-D2S were cultured at 37°C in Dulbecco's Modified Eagle 
Medium (DMEM-NUT.F-12, Cambrex, Bio Sciences, Rockland Inc) supplemented with 
10% fetal calf serum (Cambrex, Bio Sciences, Rockland Inc), 100 Units/ml penicillin-
steptomycin (Cambrex, Bio Sciences, Rockland Inc), HEPES 20 mM, pH=7.4, 400μg/ml 
geneticin (Cambrex, Bio Sciences, Rockland Inc) and 2 mM glutamine (Cambrex, Bio 
Sciences, Rockland Inc) in an atmosphere of 5% CO2. Incubations containing 2 nM 
[
3H]spiperone (specific activity 15 Ci/mmol, Perkin Elmer Life Sciences, Boston, MA) 
were run in duplicate in 0.1% polyethylenimine (PEI) (Sigma-Aldrich, Inc, St.Louis, MI) 
coated multiscreen GF/B 96 wells microplates (Millipore, Billerica, MA ). Incubations 
were started by adding per well 250 μl membrane suspension diluted to 10 μg protein/ml. 2 
μl of tested compounds diluted in dimethyl sulfoxide (Sigma-Aldrich, Inc, St.Louis, MI) 
were added in increasing final concentrations, at 0.1, 1, 10, 100, 1 000 or 10 000 nM. Non 
specific binding was measured in the presence of 5 μM haloperidol (Sigma-Aldrich, Inc, 
St.Louis, MI). Incubations were run 1 hour at room temperature and stopped by vacuum 
filtration. Filters were washed 4 times by 250 μl of ice-cold binding buffer. Then 50 μl of 
Optiphase Supermix scintillation cocktail (Perkin Elmer, Boston, MA) was added and the 
filters were counted by liquid scintillation on the 14.50 microbeta Trilux counter (Wallac- 
PerkinElmer, Boston, MA). IC50 values representing the concentrations to 50% of maximal 
inhibition were calculated by nonlinear regression using the Origin 6.0 software (microcal 
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software, Inc, Northampton, MA). Ki values were derived from the formula Ki = 
IC50/(1+L/Kd) where L is the concentration of [
3H]spiperone and Kd its dissociation 
constant.
182 
10.1.3 Histamine H1 Receptor Binding Assay  
CHO-H1 cells, stably expressing the recombinant human H1 histamine receptor gene in 
CHO-K1 cells,
181 were grown in Dulbecco’s modified Eagle’s medium supplemented with 
2 mM glutamine, 10% fetal bovine serum, and 100 IU/mL penicillin G, 100 µg/mL 
streptomycin, and 0.1 mM nonessential amino acids in an atmosphere of 5% CO2 at 37 °C 
(Gibco
TM, Karlsruhe, Germany). At confluence , the cells were washed with 10 mL ice-
cold PBS buffer (140 mM NaCl, 3 mM KCl, 1.5 mM KH2PO4, 8 mM NaHPO4, pH 7.4), 
scraped into ice-cold HEPES binding buffer (20 mM HEPES, 10 mM MgCl2, 100 mM 
NaCl, pH 7.4), and homogenized with sonication . Membranes were pelleted at 20,000 rpm 
for 30 minutes at 4 °C, rehomogenized in HEPES buffer using a hand potter, and stored in 
liquid nitrogen. Protein concentrations were determined according to the method of 
Bradford.
180 
Cell membranes were thawed, rehomogenized with sonication at 4 °C into ice-cold HEPES 
binding buffer, and incubated with [³H]mepyramine (1.0 nM; 28 Ci·mmol
-1 , Amersham 
Biosciences, Freiburg, Germany), and drug was diluted in HEPES buffer. Nonspecific 
binding was determined in the presence of 10 µM Chlorphenaminhydrogenmaleat (Sigma-
Aldrich, Taufkirchen, Germany). Incubations were run at 25 °C for 120 min, and 
terminated by rapid filtration through PerkinElmer GF/B glass fibre filters (PerkinElmer 
Life Sciences, Rodgau, Germany) coated in 0.3% polyethylenimine (Sigma-Aldrich, 
Taufkirchen, Germany) using an Inotech cell harvester (Inotech AG, Dottikon, 
Switzerland). Unbound radioligand was removed with four washes of 1 ml of ice-cold 
HEPES buffer. The filters were soaked in 9 ml Beta plate scint scintillator and counted 
using a PerkinElmer MicroBeta
®Trilux scintillation counter (PerkinElmer Life Sciences). 
Competition binding data were analyzed by the software GraphPad Prism™ (2000, version 
3.02, San Diego, CA, USA), using non-linear least squares fit. For detailed screening the 
compounds have been tested at seven concentrations in triplicate carrying out three to five 
separate binding experiments for human histamine H1 receptors and expressed as mean ± 
standard error of the mean (SEM). Ki values were calculated from the IC50 values 
according to Cheng-Prusoff equation.
182 
 
 Pharmacological Experimental Procedures    154 
 
10.1.4 GTP Shift Assay 
GTP shift competition binding experiments for dopamine D2S and D3 receptors are carried 
out under similar assay conditions as competition binding experiments with few 
modifications. Frozen cell membrane preparations with human dopamine D2S or D3 
receptors were thawed, rehomogenized in control buffer (Tris 50 mM, KCl 5 mM, CaCl2 1 
mM, MgCl2 2 mM, HCl ad pH 7.4) using ultrasonic waves (duty cycle constant, 10 sec) at 
4 °C. Final membrane protein concentrations of dopamine D2S receptors was 10 µg/200 µL 
and for D3 receptors 2 µg/200 µL. Test compound and [³H]spiperone were diluted in 
control buffer (final concentration 0.2 nM). Either 50 µL of test compound dilution or 50 
µL of control buffer to determine total binding or 50 µL of 10 µM BP897 in control buffer 
to measure non-specific binding were applied. In the next step, 50 µL GTP-binding buffer 
(NaCl 120 mM (4-fold concentrated), Tris 50 mM, KCl 5 mM, CaCl2 1 mM, MgCl2 2 mM, 
HCl ad pH 7.4), 50 µL control buffer or 50 µL 100 µM Gpp(NH)p in GTP-binding buffer 
were added to the microtiter plate, respectively. Finally, 50 µL 0.2 nM [³H]spiperone (final 
concentration) and 50 µL cell membrane suspension were applied. Samples were incubated 
at 25 °C for 2 h and terminated by rapid filtration through GF/B glass fibre filters, 
presoaked for 30 min and at 4 °C in 0.3% polyethylenimine solution, using a cell harvester. 
Unbound radioligand was removed with four washes of 300 µL ice-cold wash buffer. 
Filters were dried at 55 °C for 50 – 60 min in the oven and afterwards soaked in 9 mL 
scintillant. Bound radioactivity was counted (5 min/well) in a β-counter at 45% counter 
efficiency. Competition binding data were analyzed by the software GraphPad Prism™ 
(2000, version 3.02, San Diego, CA, USA), using non-linear least squares fit. Assays were 
carried out in triplicates and at least 3 independent experiments using 96-well plates. 
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Table 4.1 -logKd values derived from [³H]spiperone saturation experiments.  
Receptor Non-specific  binding  -logKd
a
 
hD2S  10 µM BP897  9.97 ± 0.05 
hD3  10 µM BP897  9.66 ± 0.06 
hD3  10 µM haloperidol  9.66 ± 0.05 
aValues (-logKd) are mean ± SD of at least three independent experiments performed in triplicates. 
 
 
 
 
Table 4.2 -logKd values derived from [³H]mepyramine saturation experiments.  
Receptor  Non-specific binding   -logKd
a 
hH1  10 µM chlorpheniramine  8.89 ± 0.02 
aValues (-logKd) are mean ± SD of at least three independent experiments performed in triplicates. 
 
 
 
 
Table 4.3 -logKi values and Hill coefficients (in parentheses) of determined dopamine reference 
compounds.  
Compound -logKi (hD2S)
a  -logKi (hD3)
a 
BP 897   7.29 ± 0.09 
(1.12 ± 0.30) 
 9.05 ± 0.11 
(0.98 ± 0.28) 
Haloperidol   8.65 ± 0.05 
(0.95 ± 0.05) 
 8.33 ± 0.02 
(1.04 ± 0.15) 
(S)-(-)-Nafadotride   8.19 ± 0.01 
(1.03 ± 0.05)  n.d.
b 
(S)-(-)-Raclopride   8.35 ± 0.01 
(1.07 ± 0.12) 
 8.63 ± 0.17 
(0.85 ± 0.14) 
Spiperone   9.57 ± 0.02 
(0.99 ± 0.15) 
 9.17 ± 0.04 
(1.02 ± 0.22) 
ST 198   5.90 ± 0.03 
(0.95 ± 0.11) 
 8.06 ± 0.01 
(0.76 ± 0.11) 
U 99194A   5.42 ± 0.08 
(0.84 ± 0.16) 
 6.52 ± 0.14 
(0.82 ± 0.06) 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates.
 
bn.d., not determined. 
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Table 4.4 -logKi values and Hill coefficients (in parentheses) of determined histamine reference 
compounds. 
Compound -logKi (hH1)
a 
Bamipine  7.92 ± 0.03 (1.16 ± 0.51) 
Cetirizine  7.56 ± 0.10 (0.79 ± 0.18) 
Chlorpheniramine  7.77 ± 0.07 (1.00 ± 0.19) 
Diphenhydramine  7.46 ± 0.02 (0.86 ± 0.07) 
Fexofenadine  7.48 ± 0.03 (0.86 ± 0.12) 
Ketotifen  9.48 ± 0.08 (1.05 ± 0.13) 
Loratadine  6.91 ± 0.16 (1.00 ± 0.06) 
Mepyramine  8.76 ± 0.03 (0.79 ± 0.02) 
Mianserin  9.10 ± 0.14 (1.18 ± 0.12) 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates. 
 
 
 
 
Figure  4.8, 4.9 Pramipexole binding at dopamine D2S and D3 receptors (Hill coefficients in 
parentheses).  
hD2S 
-logKH
a  % RH
a  -logKL
a  n
b  -logKi Gpp(NH)p
a  n
b 
8.52 ± 0.13 23  ±7  6.49 ± 0.21 3  5.31 ± 0.08 
(0.80 ± 0.12) 
4 
hD3 
-logKi control
a  n
b  -logKi Gpp(NH)p
a  n
b 
8.90 ± 0.02  
(0.72± 0.21)  3   7.93 ± 0.12  
(0.94 ± 0.20)  4 
aValues are mean ± SD of independent experiments.  
bNumber of experiments performed in triplicates. 
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Figure 4.10, 4.11 Compound 54 binding at dopamine D2S and D3 receptors (Hill coefficients in 
parentheses).  
hD2S 
-logKH
a  % RH
a  -logKL
a n
b  -logKi 
Gpp(NH)p
a  n
b 
8.63 ± 0.22  33 ±5  6.74 ± 0.08  3  5.61 ± 0.05 
(0.69 ± 0.09)  4 
hD3 
-logKi control
a  n
b  -logKi Gpp(NH)p
a  n
b 
 8.51 ± 0.10  
(0.78 ± 0.17)  3   7.73 ± 0.08  
(0.89 ± 0.22)  3 
aValues are mean ± SD of independent experiments.  
bNumber of experiments performed in triplicates. 
 
 
Figure 4.12, 4.13 BP 897 binding at dopamine D2S and D3receptors (Hill coefficients in 
parentheses).  
hD2S 
-logKi control
a  n
b  -logKi Gpp(NH)p
a  n
b 
 7.10 ± 0.003  
(1.18 ± 0.27)  3   7.28 ± 0.02 
(1.30 ± 0.20)  3 
hD3 
-logKi control
a  n
b  -logKi Gpp(NH)p
a  n
b 
 8.76 ± 0.04  
(0.80 ± 0.21)  3   9.12 ± 0.07  
(1.10 ± 0.03)  3 
aValues are mean ± SD of independent experiments.  
bNumber of experiments performed in triplicates. 
 
 
 
Figure 4.14, 4.15 ST 198 binding at dopamine D2S and D3receptors (Hill coefficients in 
parentheses).  
hD2S 
-logKi control
a  n
b  -logKi Gpp(NH)p
a  n
b 
 5.74 ± 0.03  
(0.84 ± 0.10)  4   5.97 ± 0.06  
(0.86 ± 0.18)  4 
hD3 
-logKi control
a  n
b  -logKi Gpp(NH)p
a  n
b 
 7.26 ± 0.05  
(0.86 ± 0.06)  3   8.12 ± 0.07  
(0.93 ± 0.16)  4 
aValues are mean ± SD of independent experiments.  
bNumber of experiments performed in triplicates. 
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Table 4.5 -logKi values and Hill coefficients (in parentheses) of 4-(2-methoxyphenyl)piperazine 
and 1,2,3,4-tetrahydroisoquinoline derivatives.  
-logKi
a 
No. 
hD2S hD3 
BP 897   7.29 ± 0.09 
(1.12 ± 0.30) 
 9.05 ± 0.11 
(0.98 ± 0.28 
1   7.36 ± 0.08 
(1.06 ± 0.19) 
 9.39 ± 0.21 
(0.92 ± 0.15) 
2   7.27 ± 0.12 
(1.04 ± 0.18) 
 8.27 ± 0.15 
(0.95 ± 0.33) 
3   7.29 ± 0.05 
(1.09 ± 0.25) 
 8.69 ± 0.04 
(1.02 ± 0.20) 
4   7.23 ± 0.03 
(0.96 ± 0.13) 
 8.51 ± 0.05 
(1.00 ± 0.19) 
ST 198   5.90 ± 0.03 
(0.95 ± 0.11) 
 8.06 ± 0.01 
(0.76 ± 0.11) 
5   6.09 ± 0.03 
(0.85 ± 0.08) 
 7.09 ± 0.08 
(0.87 ± 0.23) 
6   6.11 ± 0.06 
(1.08 ± 0.01) 
 7.62 ± 0.08 
(0.86 ± 0.12) 
aValues (-logKi) are mean ± SD of at least three independent determinations performed in 
triplicates. 
 
 
 
 
Table 4.6 -logKi values and Hill coefficients (in parentheses) of inverse amide compounds.  
-logKi
a 
No. 
hD2S hD3 
7   5.84 ± 0.09 
(0.84 ± 0.07) 
 6.87 ± 0.13 
(0.85 ± 0.09) 
8   6.26 ± 0.11 
(1.04 ± 0.08) 
 6.87 ± 0.06 
(0.92 ± 0.02) 
9   5.98 ± 0.08 
(1.03 ± 0.22) 
 6.92 ± 0.04 
(1.05 ± 0.02) 
10   5.99 ± 0.04 
(0.80 ± 0.11) 
 6.75 ± 0.17 
(1.02 ± 0.20) 
11   6.08 ± 0.09 
(1.02 ± 0.16) 
 7.61 ± 0.05 
(0.98 ± 0.16) 
12   6.72 ± 0.15 
(0.97 ± 0.14) 
 7.34 ± 0.14 
(1.01 ± 0.06) 
13   5.56 ± 0.13 
(0.92 ± 0.11) 
 6.29 ± 0.04 
(0.98 ± 0.10) 
14   6.19 ± 0.09 
(0.93 ± 0.12) 
 7.00 ± 0.03 
(0.89 ± 0.34) 
aValues (-logKi) are mean ± SD of at least three independent determinations performed in 
triplicates. 
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Table 4.7 ClogP value, and preliminary pharmacological screening results for human dopamine D2 
and D3 receptor binding affinities. 
Ki [nM]
a 
Compound ClogP 
hD2S hD3 
15  5.31 559  28.0 
16  5.41 226  42.9 
17  5.93 457  11.1 
18  5.28 652  6.2 
19  6.49 587  2.5 
20  5.84 963  2.5 
21  6.53 1000  17.7 
22  5.38 161  40.9 
23  6.08 633  36.9 
24  5.84 626  3.60 
25  5.68 313  15.2 
26  5.02 972  15.2 
27  5.72 619  22.8 
28  6.33 1324  >1000 
29  5.68 429  50.2 
30  6.37 4925  >1000 
31  4.22 1149  99.1 
32  5.41 >1000  10.9 
33  5.57 n.d.  n.d. 
34  6.46 849  2.7 
35  5.30 128  >1000 
36  6.49 703  0.3 
37  6.53 1570  31.1 
38  5.38 4620  >1000 
39  3.18 >1000  10.8 
aValues (-logKi) received by six-points measurements performed in duplicates in one experiment 
(external tested). ClogP values were provided by Dr. U. Mach. 
 
 
 
 
Table 4.8 -logKi values and Hill coefficients (in parentheses) of cyclizine-based hybrids. 
-logKi
a 
No. 
hD2S hD3 hH1 
15   6.75 ± 0.14 
(0.89 ± 0.01) 
 7.19 ± 0.13 
(1.18 ± 0.26) 
 7.48 ± 0.12 
(1.33 ± 0.50) 
16   6.54 ± 0.21 
(1.70 ± 0.30) 
 6.83 ± 0.01 
(1.04 ± 0.70)  n.d.
b 
17   6.62 ± 0.07 
(1.40 ± 0.14) 
 7.41 ± 0.01 
(1.65 ± 0.42) 
7.69 ± 0.13 
(1.23 ± 0.13) 
18   6.12 ± 0.07 
(1.14 ± 0.17) 
 7.27 ± 0.11 
(0.88 ± 0.15) 
8.16 ± 0.03 
(1.29 ± 0.17) 
19   6.75 ± 0.09 
(1.28 ± 0.09) 
 7.35 ± 0.23 
(1.04 ± 0.06)  n.d.
b 
20   6.54 ± 0.06 
(1.11 ± 0.30) 
 7.24 ± 0.11 
(1.85 ± 0.75)  n.d.
b 
21   6.50 ± 0.09 
(1.33 ± 0.2) 
 7.27 ± 0.09 
(1.20 ± 0.20)  n.d.
b 
22   5.90 ± 0.08 
(1.29 ± 0.78) 
 6.89 ± 0.20 
(1.47 ± 0.61) 
7.60 ± 0.08 
(1.30 ± 0.24) 
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Table 4.8 (continued) 
-logKi
a 
No. 
hD2S hD3 hH1 
23   5.80 ± 0.17 
(2.43 ± 0.21) 
 6.41 ± 0.08 
(1.70 ± 0.61) 
7.32 ± 0.11 
(1.77 ± 0.50) 
24   6.34 ± 0.02 
(1.31 ± 0.05) 
 6.88 ± 0.24 
(1.49 ± 0.17)  n.d.
b 
25   6.86 ± 0.04 
(1.56 ± 0.3) 
 7.46 ± 0.15 
(1.68 ± 0.59)  n.d.
b 
26   6.15 ± 0.13 
(0.95 ± 0.20) 
 7.18 ± 0.08 
(1.25 ± 0.37) 
 7.71 ± 0.12 
(0.92 ± 0.15) 
27   6.29 ± 0.11 
(1.07 ± 0.18) 
 6.97 ± 0.12 
(1.24 ± 0.31)  n.d.
b 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates. 
bn.d., not determined. 
 
 
 
 
Table 4.9 -logKi values and Hill coefficients (in parentheses) of tri- and tetracyclic compounds. 
-logKi
a 
No. 
hD2S hD3 hH1 
28   6.32 ± 0.18 
(1.75 ± 0.05) 
 6.77 ± 0.30 
(1.61 ± 0.27)  n.d.
b 
29   6.33 ± 0.09 
(1.47 ± 0.26) 
 6.65 ± 0.09 
(1.06 ± 0.09) 
 8.19 ± 0.02 
(1.40 ± 0.36) 
30   6.42 ± 0.10 
(1.96 ± 0.03) 
 6.36 ± 0.16 
(2.14 ± 0.36)  n.d.
b 
31   6.28 ± 0.05 
(1.19 ± 0.10) 
 6.86 ± 0.18 
(0.87 ± 0.11) 
 8.08 ± 0.21 
(1.09 ± 0.29) 
32   6.12 ± 0.11 
(1.01 ± 0.22) 
 7.33 ± 0.12 
(1.29 ± 0.59) 
 7.60 ± 0.15 
(1.27 ± 0.44) 
33   6.66 ± 0.17 
(1.61 ± 0.23) 
 7.00 ± 0.15 
(1.29 ± 0.10)  n.d.
b 
34   6.62 ± 0.02 
(1.65 ± 0.38) 
 6.77 ± 0.15 
(1.19 ± 0.32) 
 7.90 ± 0.09 
(1.52 ± 0.53) 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates.
 
bn.d., not determined. 
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Table 4.10 -logKi values and Hill coefficients (in parentheses) of bamipine-based hybrids. 
-logKi
a 
No. 
hD2S hD3 hH1 
35   6.47 ± 0.08 
(1.36 ± 0.67) 
 6.66 ± 0.13 
(1.52 ± 0.36)  n.d.
b 
36   6.25 ± 0.06 
(1.55 ± 0.19) 
 6.88 ± 0.18 
(1.93 ± 0.82)  n.d.
b 
37   6.38 ± 0.11 
(1.30 ± 0.44) 
 7.24 ± 0.15 
(1.20 ± 0.59)  n.d.
b 
38   5.09 ± 0.01 
(0.99 ± 0.18) 
 6.29 ± 0.06 
(1.40 ± 0.47)  n.d.
b 
39   6.02 ± 0.01 
(0.90 ± 0.14) 
 8.15 ± 0.14 
(0.92 ± 0.01) 
 7.78 ± 0.12 
(1.03 ± 0.08) 
40   6.07 ± 0.02 
(0.71 ± 0.05) 
 8.10 ± 0.03 
(0.95 ± 0.19)  n.d.
b 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates. 
bn.d., not determined. 
 
 
 
 
Table 4.11 -logKi values and Hill coefficients (in parentheses) of histamine  H1 receptor 
antagonists. 
-logKi
a 
No. 
hD2S hD3 hH1 
Cetirizine <4  <4.5   7.56 ± 0.10 
(0.79 ± 0.18) 
Mianserin   5.61 ± 0.13 
(0.99 ± 0.27) 
 5.78 ± 0.02 
(1.23 ± 0.25) 
9.10 ± 0.14 
(1.18 ± 0.12) 
Ketotifen   5.33 ± 0.12 
(1.09 ± 0.33) 
 5.93 ± 0.27 
(0.86 ± 0.37) 
 9.48 ± 0.08 
(1.05 ± 0.13) 
Loratadine   4.37 ± 0.02 
(0.82 ± 0.14)  <5   6.91 ± 0.16 
(1.00 ± 0.06) 
Bamipine   5.72 ± 0.10 
(1.01 ± 0.09) 
 5.99 ± 0.05 
(1.07 ± 0.04) 
 7.92 ± 0.03 
(1.16 ± 0.51) 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates. 
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Table 4.12 -logKi values and Hill coefficients (in parentheses) of pramipexole analogues and 
related compounds. 
-logKi
a 
No. 
hD2S hD3 
Pramipexole   5.58 ± 0.04 
(0.66 ± 0.04) 
 8.26 ± 0.31 
(0.72 ± 0.09) 
41   4.67 ± 0.07 
(0.70 ± 0.05) 
 5.97 ± 0.11 
(0.92 ± 0.16) 
42   4.61 ± 0.20 
(n.d.
b) 
 6.68 ± 0.05 
(0.94 ± 0.02) 
43   4.76 ± 0.11 
(0.58 ± 0.09) 
 7.04 ± 0.07 
(0.93 ± 0.07) 
44   4.94 ± 0.05 
(0.73 ± 0.11) 
 7.11 ± 0.01 
(0.89 ± 0.12) 
45   5.14 ± 0.09 
(0.96 ± 0.08) 
 7.04 ± 0.05 
(1.00 ± 0.19) 
46   4.76 ± 0.13 
(0.86 ± 0.12) 
 7.37 ± 0.22 
(0.71 ± 0.05) 
47   4.20 ± 0.03 
(n.d.
b) 
 5.92 ± 0.01 
(0.92) 
48   5.69 ± 0.20 
(0.87 ± 0.11) 
 5.64 ± 0.04 
(1.04 ± 0.06) 
49   4.14 ± 0.21 
(0.94 ± 0.02) 
 5.92 ± 0.13 
(0.82 ± 0.13) 
50 <6  <6 
51   4.38 ± 0.15 
(0.55 ± 0.06) 
 5.92 ± 0.20 
(0.94 ± 0.24) 
52   5.10 ± 0.05 
(0.80 ± 0.05) 
 6.93 ± 0.07 
(1.02 ± 0.06) 
53   4.99 ± 0.10 
(0.63 ± 0.03) 
 6.57 ± 0.10 
(0.90 ± 0.30) 
54   5.77 ± 0.18 
(0.71 ± 0.13) 
 7.83 ± 0.07 
(0.85 ± 0.17) 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates. 
bn.d., not determined. 
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Table 4.13 -logKi values and Hill coefficients (in parentheses) of naphthalen-2-carboxamide 
derivatives.  
-logKi
a 
No. 
hD2S hD3 
55   5.60 ± 0.05 
(0.78 ± 0.01) 
 7.19 ± 0.16 
(0.93 ± 0.15) 
56   4.68 ± 0.05 
(0.75 ± 0.16) 
 6.84 ± 0.09 
(0.99 ± 0.23) 
57   5.43 ± 0.12 
(0.85 ± 0.16) 
 7.62 ± 0.19 
(0.79 ± 0.13) 
58   5.81 ± 0.09 
(0.64 ± 0.09) 
 8.60 ± 0.15 
(1.00 ± 0.29) 
59   6.09 ± 0.19 
(0.89 ± 0.10) 
 8.94 ± 0.07 
(1.23 ± 0.06) 
60   6.34 ± 0.08 
(0.89 ± 0.18) 
 9.03 ± 0.09 
(1.12 ± 0.05) 
61   5.04 ± 0.03 
(0.69 ± 0.04) 
 8.11 ± 0.08 
(1.06 ± 0.36) 
aValues (-logKi) are mean ± SD of at least three independent determinations performed in 
triplicates. 
 
 
 
 
Table 4.14 -logKi values and Hill coefficients (in parentheses) of cinnamoyl derivatives. 
-logKi
a 
No. 
hD2S hD3 
62   5.40 ± 0.04 
(0.47 ± 0.08) 
 8.09 ± 0.07 
(1.00 ± 0.23) 
63   6.35 ± 0.05 
(0.81 ± 0.05) 
 8.65 ± 0.23 
(1.02 ± 0.27) 
64   6.08 ± 0.02 
(0.67 ± 0.02) 
 9.25 ± 0.03 
(0.90 ± 0.22) 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates. 
 
 
 
Table 4.15 -logKi values and Hill coefficients (in parentheses) of 4-(2-methoxyphenyl)piperazine 
derivatives. 
-logKi
a 
No. 
hD2S hD3 
65   6.83 ± 0.07 
(1.00 ± 0.06) 
 7.87 ± 0.04 
(0.92 ± 0.22) 
66   6.86 ± 0.07 
(1.03 ± 0.1) 
 7.05 ± 0.01 
(0.92 ± 0.09) 
67   6.32 ± 0.05 
(0.86 ± 0.18) 
 7.27 ± 0.14 
(0.84 ± 0.13) 
aValues (-logKi) are mean ± SD of at least three independent determinations performed in 
triplicates. 
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Table 4.16 -logKi values and Hill coefficients (in parentheses) of heteroaryl amide derivatives. 
-logKi
a 
No. 
hD2S hD3 
68   4.63 ± 0.02 
(1.02 ± 0.23) 
 6.54 ± 0.06 
(0.92 ± 0.18) 
69   5.47 ± 0.05 
(1.13 ± 0.20) 
 7.28 ± 0.04 
(1.06 ± 0.22) 
70   5.61 ± 0.08 
(0.58 ± 0.06) 
 8.54 ± 0.07 
(0.96 ± 0.15) 
71   5.64 ± 0.02 
(0.88 ± 0.12) 
 7.82 ± 0.16 
(0.93 ± 0.17) 
72   4.62 ± 0.14 
(0.81) 
 5.73 ± 0.13 
(0.73 ± 0.21) 
73   5.79 ± 0.16 
(0.55 ± 0.04) 
 8.35 ± 0.09 
(1.04 ± 0.37) 
74   5.68 ± 0.07 
(0.76 ± 0.13) 
 8.25 ± 0.02 
(0.92 ± 0.24) 
75   6.48 ± 0.16 
(0.78 ± 0.19) 
 9.19 ± 0.06 
(0.82 ± 0.08) 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates. 
 
 
 
 
Table 4.17 -logKi values and Hill coefficients (in parentheses) of diverse structural elements. 
-logKi
a 
No 
hD2S hD3 
76   5.60 ± 0.02 
(1.08 ± 0.10) 
 7.08 ± 0.01 
(1.16 ± 0.24) 
77   5.07 ± 0.01 
(0.87 ± 0.21) 
 5.88 ± 0.19 
(1.06 ± 0.21) 
78 <5  <5 
aValues (-logKi) are mean ± SD of at least three independent experiments performed in triplicates. 
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Table 4.18 Dopamine receptor affinities of compounds from the first virtual screening cycle. 
-logKi
a 
No. 
hD2S hD3 
79  > 5.7 >  5.7 
80  5.2 – 5.7 >  5.7 
81  5.2 – 5.7   5.2 – 5.7 
82  < 5.2  5.2 – 5.7 
83  < 5.2  5.2 – 5.7 
84  < 5.2  5.2 – 5.7 
85  < 5.2 <  5.2 
86  < 5.2 <  5.2 
87  < 5.2 <  5.2 
88  < 5.2 <  5.2 
89  < 5.2 <  5.2 
aValues (-logKi) are mean ± SD of two independent experiments performed in triplicates. 
 
 
 
 
Table 4.19 Dopamine receptor affinities of compounds from the second virtual screening cycle. 
-logKi
a 
No. 
hD2S n
b  hD3 n
b 
90   5.88 ± 0.17 
(1.35 ± 0.43)  2   6.04 ± 0.43 
(1.38 ± 0.5)  2 
91   6.26 ± 0.08 
(1.13 ± 0.22)  4   7.41 ± 0.07 
(1.06 ± 0.15)  4 
92   6.36 ± 0.06 
(1.12 ± 0.13)  8   6.86 ± 0.06 
(1.18 ±0.15)   5 
93   6.71 ± 0.11 
(1.03 ± 0.13)  8   7.03 ± 0.09 
(1.09 ± 0.30)  7 
94   5.36 ± 0.05 
(0.87 ± 0.08)  6   6.07 ± 0.18 
(1.10 ± 0.17)  6 
aValues (-logKi) are mean ± SD. 
bNumber of experiments performed in triplicates. 
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Table 4.20 Dopamine receptor affinities of compounds from clustering-based virtual screening. 
-logKi
a 
No. 
hD2S n
b  hD3 n
b 
95  6.05, 6.14  
(0.88 ± 0.11)  2  7.19 ± 0.05 
(0.95 ± 0.23)  3 
96  6.05, 6.18 
(0.93 ± 0.14)  2  6..54, 6.61  
(1.11 ± 0.79)  2 
97  5.11, 5.31 
(0.83 ± 0.43)  2  5.86, 6.21 
(0.88 ± 0.34)  2 
98  4.97 ± 0.22 
(0.54 ± 0.06)  3  5.49, 5.71  
(0.66 ± 0.34)  2 
99  5.47, 5.32 
(1.28 ± 0.46)  2  6.67, 6.53 
(0.88 ± 0.25)  2 
100  5.55, 5.63  
(1.14 ± 0.15)  2  6.24, 6.24  
(0.91 ± 0.05)  2 
101  5.96, 6.11  
(1.26 ± 0.18)  2  6.01, 6.03  
(0.63 ± 0.02)  2 
102  <5.00  
(n.d.)
c  2  5.34, 5.37  
(0.91 ± 0.28)  2 
103  6.10, 6.13 
(1.13 ± 0.26)  2  6.65 ± 0.31 
(0.93 ± 0.20)  4 
104  <5.00  
 (n.d.)
c  2  5.70, 5.69  
(0.69 ± 0.18)  2 
105  5.15, 5.36  
(0.97 ± 0.51)  2  5.64, 5.64  
(0.80 ± 0.23)  2 
106  4.67 ± 0.27 
(0.76 ± 0.06)  3  5.46, 4.99 
(0.72 ± 0.27)  2 
107  <5.00  
 (n.d.)
c  2  5.52, 5.18  
(1.15, n.d.))  2 
108  5.49, 5.26 
(0.61 ± 0.28)  2  6.74 ± 0.13 
(0.99 ± 0.26)  3 
109  <5.00  
(n.d.)
c  2  5.18, 5.36  
(n.d.)
c  2 
110  6.67, 6.55  
(0.90 ± 0.19)  2  5.57, 5.61  
(1.24 ± 0.18)  2 
111  6.31, 6.24  
(0.78 ± 0.16)  2  5.96, 6.21 
(0.77 ± 0.16)  2 
aValues (-logKi) are mean ± SD. 
bNumber of experiments performed in triplicates. 
cn.d., not determined. 
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Table 4.21 Dopamine receptor affinities of compounds from pharmacophore based virtual 
screening. 
-logKi
a 
No 
hD2S n
b  hD3 n
b 
112   6.80 ± 0.07 
(1.20 ± 0.12)  4   7.19 ± 0.06 
(1.52 ± 0.23)  3 
113   5.87 ± 0.10 
(1.78 ± 0.28)  3   6.31 ± 0.07 
(1.25 ± 0.80  4 
114   5.87 ± 0.09 
(1.29 ± 0.86)  3  5.50, 5.39 
(n.d.)
c  2 
115   5.36 ± 0.03 
(0.86 ± 0.26)  3  5.54, 5.62 
(0.77 ± 0.11)  2 
aValues (-logKi) are mean ± SD. 
bNumber of experiments performed in triplicates. 
cn.d., not determined. 
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